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Abstract 
 
The focus of this thesis is to investigate the intracellular protein-peptide complex 
3-hydroxyacyl-CoA dehydrogenase (HADH), also known as ABAD (amyloid-
binding alcohol dehydrogenase) and amyloid-beta peptide (Aβ).  This complex 
has been identified in the development of Alzheimer's disease (AD), and this 
study tries to identify if ABAD is a useful biomarker for genetic risk profiling 
strategies for the early diagnosis of Alzheimer’s disease, or a suitable target for 
disease-modifying drug development. The major aim of this project is to explore 
the biochemical and cellular processes activated as a result of the interaction of 
ABAD and Aβ.  Understanding the cellular responses to these interactions could 
help identify important biomarkers and/or drug targets for the diagnosis or 
treatment of Alzheimer’s disease. This study assesses the cytotoxic effects of Aβ 
in tissue culture and in animal models overexpressing ABAD. 
 
An in vitro cell system using SK-N-SH cells was developed for investigating the 
effects of ABAD expression in cells when incubated with synthetic Aβ peptide.  
In vitro studies confirmed ABAD to be a mitochondrial protein.  There were 
problems with the efficiency of the synthetic Aβ peptide used, which was found 
to aggregate excessively.   Trial of a soluble oligomeric Aβ peptide proved to be 
more efficient. 
 
A cell system was also developed, culturing neurospheres from murine stem cells. 
This proved to be a reliable system for culturing primary cells and keeping them 
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in culture for up to 8 weeks.  Cells were grown from a wild type strain and then 
differentiated and stained for endogenous expression of  proteins. 
 
Proteomic studies were carried out with novel transgenic mouse models for AD.  
Seven proteins were identified with changed expression in the 2x Tg mouse 
model.  Further immunocytochemistry of human AD brain tissue confirmed the 
upregulation of peroxiredoxin II and endophilin I.  Both proteins could be 
returned to normal expression in the mouse models by peritoneal injection for two 
weeks of a novel peptide inhibitor to ABAD, confirming the involvement of the 
ABAD/Aβ complex in the increased expression of these proteins.  
 
Finally ABAD/Aβ was investigated as a possible target for AD therapy by 
screening with a small molecule fragment library.  Only an initial screen was 
carried out, but several small molecule compounds were found to bind to ABAD.  
Further screening may produce lead compounds for a synthetic drug to inhibit the 
enhanced Aβ toxicity associated with the ABAD/Aβ complex 
 
! v!
Acknowledgements 
 
I would like to thank my supervisor Dr Frank Gunn-Moore for giving me the 
opportunity to work on this project and submit it as a PhD thesis.  He has been 
very generous in support and encouragement and patient with my unconventional 
approach to research.  I would also like to thank Dr Jim Aiton for his support.  
Other people who worked on Floor E in the Medical Bute building who need a 
mention are Tina Briscoe, Dr Michelle McRobbie and Dr Lindsey Gray who 
made life fun and interesting.  Also thanks to Sarah Lynch, who started as a 
disgruntled project student and has become a friend. It has been exciting watching 
her progress to a PhD graduate and go on to develop her scientific career. 
 
Thanks also to several people whose help along the way was invaluable: Tony 
Vaughan for help with fluorescent microscopy who helped me develop a passion 
for the technique; Huanting Liu, the most patient, helpful and knowledgable 
molecular biologist I know, Peter Coote for help with 2D gel proteomic analysis 
and Catherine Botting, Robin Antrobus and Alex Houston for their invaluable 
help with Mass Spec analysis data. 
 
No PhD would be complete without visits to exotic places. For me, that included 
working in Prof. Shi Du Yan’s laboratory in Columbia University, New York, 
where the Tg mouse brain samples were prepared, in Prof. Sandra D’Azzo’s 
laboratory in St Jude Children’s Research Hospital, Memphis where I learned 
much, including the Neurosphere culture and Prof. Sue Wonnacott’s laboratory in 
Bath, UK.  Thanks for all their help and advice. 
! vi!
I am grateful for all the funding that I have received for the project from SHERT 
(Scottish Hospital Endowment Research Trust) and the Cunningham Trust.  Also 
thanks for travel grants from BRAIN (now ‘guarantors of Brain’) and the 
Minshull trust. 
 
Finally to the present.  Thanks to all who I work with in the Biomolecular Science 
building, especially the Taylor group lab 3.10 and everyone in the 2nd floor labs.  
Thanks especially to my current PI, Dr Rupert Russell who has encouraged me to 
write up my thesis and generously allowed me time to do this.  Thanks to my 
colleagues Dr Phil Kerry and Dr Claudia Haas who have steered the ship while I 
have been writing. (Cupcakes on return please).   
Thank you to my friends in USA, for encouragement, laughs and support: Allen 
and Mary in Memphis; Nancy, Bob, Paulette, Marie and Ron, Frank and Rob, 
Kathy, Alex et al in Salt Lake City.  And many thanks to friends Tina, Annie and 
Nicola for much encouragement and lubrication to keep me going and Dr Milton 
Kiefel who provided a wonderful meal when Garry abandoned me to travel to 
Australia. And thanks to Nicola for initial reading of the thesis while 
simultaneously moving home. And of course thanks to Garry who has watched, 
listened and helped during the whole process.  Many thanks for his patience at the 
end of the writing, which was more stressful for him than me, as he hates being 
late! 
 
! vii!
Abbreviations 
17β-HSD10   17β-hydroxysteroid dehydrogenase type 10 
4HNE    4-hydroxynonenal 
ABAD    amyloid-binding alcohol dehydrogenase 
Aβ    beta amyloid peptide 
Aβ40    beta amyloid peptide 
Aβ42    beta amyloid peptide 
AD    Alzheimer’s disease 
ADAM10   a disintegrin and metalloprotease 10 
ADP    adenosine diphosphate 
AMPA    α-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid 
ApoE    apolipoprotein E 
ApoJ    apolipoprotein J 
APP    amyloid precursor protein 
APS    ammonium persulfate 
ATP    adenosine triphosphate 
BACE1   βeta site APP cleaving enzyme 
BSA    bovine serum albumin 
CAT    computerized axial tomography 
CFP    cyan fluorescent protein 
CK    creatine kinase 
CNS    central nervous system 
CSF    cerebrospinal fluid 
CypD    cyclophilin D 
DAB    diaminobenzidine 
DAPI    4’, 6’- diamidino-2-phenylindole 
DMEM   Dulbecco's modified Eagle's medium 
DMSO    dimethyl sulfoxide 
DTT    dithiothreitol 
dUTP    deoxyuridine triphosphate 
ECE1    endothelin-converting enzyme 
! viii!
EDTA    ethylenediaminetetraacetic acid 
EGCG    epigallocatechin gallate 
EGF    epidermal growth factor 
ELISA    enzyme-linked immunosorbent assay 
ER    endoplasmic reticulum 
ERAB    endoplasmic reticulum binding amyloid beta 
FBS    fragment based screening 
FCS    foetal calf serum 
FITC    Fluorescein isothiocyanate 
GAB2    GRB2-asscoiated binding protein 2 
GAPDH   glyceraldehyde 3-phosphate dehydrogenase 
GFAP    glial fibrillary acidic protein 
GFP    green fluorescent protein 
HADH    3-hydroxyacyl-CoA dehydrogenase 
HBSS    Hanks buffered salt solution 
4HNE    4 hydroxynonenal 
HRP    horseradish-peroxidase 
17βHSD10   17β hydroxysreroid dehydrogenase type 10 
Hsp60    heat shock protein 60 
HTS    high throughput screening 
IDE    insulin degrading enzyme 
IEF    isoelectric focusing 
KPI    Kunitz protease inhibitor 
LCHADD   long-chain hydroxyacyl-CoA dehydrogenase  
deficiency 
MAP    microtubule associated protein 
MALDI-TOF   matrix-assisted laser desorption/ionization  
time-of-flight 
mAPP    mutant amyloid precursor protein 
MARK   microtubule affinity regulating kinase 
MCADD   medium-chain acyl dehydrogenase deficiency 
MRI    magnetic resonance imaging 
MTC    methylthioninium chloride 
! ix!
MTS    mitochondrial targeting sequence 
MTT 3-(4,5-dimethylthiazol-2-yl)- 
2,5 diphenyltetrazolium bromide 
NEP    neprilysin 
NMDA   N-methyl D-aspartate 
NSAID   non-steroidal anti-inflammatory drugs 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PET    positron emission tomography 
PFA    paraformaldehyde 
PIB    Pittsburg compound B 
Pin1    peptidyl prolyl cis-trans isomerise 
PKA    protein kinase A 
PKN    protein kinase 
PICALM   phosphattidyllinositol-binding clathrin  
assembly lymphoid-myeloid leukaemia gene 
PRB    plasma retinol binding protein 
PrxI    peroxiredoxin I 
PrxII    peroxiredoxin II 
PS1    presenilin 1 
PS2    presenilin 2 
ROS    reactive oxygen species 
R/T    room temperature 
SCHAD   short chain L-3-hydroxyacyl-CoA dehydrogenase 
SDH    succinate dehydrogenase 
SDS    sodium dodecyl sulphate  
SORL 1   sortilin-related receptor 1 
SPR    surface plasmon resonance 
TACE    TNFα converting enzyme 
TEMED   tetramethylethylenediamine 
Tg    transgenic 
TNF    tumour necrosis factor 
! x!
Tris    tris(hydroxymethyl)aminomethane 
TUNEL   TdT-mediated dUTP nick-end labelling 
UCH-L1   ubiquitin carboxy-terminal hydrolase L-1 
WT    wild type !
 
! xi!
Contents 
 
--------------------------------------------------------------------------------------------------- 
Declarations                                                                                                            i 
Abstract                                                                                                                  iii 
Acknowledgements                                                                                                 v 
Abbreviations                                                                                                       vii 
Contents page                                                                                                        xi
List of Figures                                                                                                      xvi 
List of Tables                                                                                                       xix 
--------------------------------------------------------------------------------------------------- 
 !!
Chapter 1: Introduction   1 
  
1.1 History and epidemiology of Alzheimer’s disease  1 
1.2 Neuropathology of AD  3 
1.2.1 Extracellular amyloid plaques and APP processing  5 
1.2.1.1 Aβ discovery and links with Down’s syndrome 6 
1.2.1.2 APP processing 6 
1.2.1.3 Protein sequence of human AP770 8 
1.2.1.4 Aβ42 the toxic peptide in AD 11 
1.2.1.5 Aβ42 and mitochondrial dysfunction 15 
1.2.2 Intracellular neurofibrillary tau tangles (NFTs) 17 
1.3 Genetics of AD 19 
1.3.1 Early onset AD 19 
1.3.1.1 APP point mutations 20 
1.3.1.2 Presenilins in AD 22 
1.3.2 Late onset Alzheimer’s disease (LOAD) 23 
1.3.2.1 ApoE 23 
1.3.2.2 Other genes associated with LOAD 24 
1.3.3 Risk factors for sporadic, late onset AD (LOAD) 25 
! xii!
1.4 The amyloid cascade hypothesis 28 
1.5 Proteomic analysis in AD 30 
1.6 Diagnosis of AD 31 
1.7 Treatment for AD 33 
1.7.1 Current drug treatment specific for AD 32 
1.7.2 Other drug treatments 34 
1.8 Current therapeutic and vaccine developments for AD 35 
1.8.1 Drugs involved with APP processing 36 
1.8.2 Drugs used for preventing and reversing tau aggregation 37 
1.8.3 Other treatments 39 
1.8.4 Vaccines  40 
11.9 Mitochondrial dysfunction in AD 40 
1.9.1 3-hydroxyacyl-CoA dehydrogenase (HADH/ABAD) 42 
1.9.2 ABAD/Aβ interaction 44 
1.9.3 The function of ABAD 45 
1.9.4 Fatty acids and β-fatty acid oxidation 46 
1.9.5 Crystal structures of ABAD 48 
1.9.6 Structure of ABAD – mutations and activity 49 
1.9.7 Aβ and ABAD expression 52 
1.9.8 Toxicity of ABAD plus Aβ 52 
1.9.9 Localisation of ABAD 54 
1.9.10 In vivo ABAD/Aβ 54 
1.9.11 ABAD deficiency 55 
1.10 Mouse models in Alzheimer’s disease 55 
1.11 Aims of this thesis 58 
  
Chapter 2: Materials and Methods 61 
  
2.1 Mammalian cells and tissue culture 61 
2.1.1 Cell lines 61 
2.1.2 Cell culture 61 
2.1.3 Cryopreservation and resuscitation of cells 62 
! xiii!
2.2 Transfection of cells 63 
2.2.1 Liposomal transfection of DNA into cells 63 
2.2.2 Making stable expressing mammalian cell lines 63 
2.2.3 Cloning out stable cell lines 64 
2.2.4 Culture of multipotent neurospheres and immunocytochemistry 64 
2.2.4.1 Differentiation of neurospheres 65 
2.2.5 Fixing cells and mounting for microscopy 65 
2.2.6 Preparation of Mowiol mounting medium 66 
2.2.7 Preparation of 4% PFA  (paraformaldehyde) 67 
2.2.8 Permeabilising and immunostaining fixed cells 67 
2.2.9 Transfection using the Chariot® protein delivery reagent 67 
2.3 Protein analysis 68 
2.3.1 Protein concentration microassay 68 
2.3.2 SDS PAGE 69 
2.3.3 Coomassie blue staining of SDS-PAGE gels 70 
2.3.4 Western immunoblotting 70 
2.3.5 Stripping primary and secondary antibodies from a 
nitrocellulose  
         membrane 
72 
2.4 Cell viability assays 72 
2.4.1 The MTT Assay 72 
2.4.2 Mitochondrial fractionation 73 
2.5 Plasmid production and cloning procedures 75 
2.5.1 Polymerase chain reaction (PCR) 75 
2.5.2 Agarose gel electrophoresis 75 
2.5.3 Purification of DNA fragments from agarose gels 76 
2.5.4 Restriction enzyme digests 76 
2.5.5 Plasmid construct production 77 
2.5.6 Preparation of competent E. coli cells (DH5α)  77 
2.5.7 Transformation of competent E. coli cells and clonal isolation 78 
2.5.8 Preparation of glycerol stocks of transformed E. coli   78 
2.5.9 Bacterial culture 78 
2.5.10 Preparation of plasmid DNA (‘mini’ and ‘midi’ preps) 79 
! xiv!
2.6 Proteomics 79 
2.6.1 2D gel Electrophoresis 79 
2.6.2 1st Dimension IEF 79 
2.6.3 2nd Dimension SDS-PAGE 80 
  
Chapter 3: Investigation of Aβ  toxicity on SK-N-SH cells  
                    transfected with ABAD 
83 
  
3.1 Background and aims 83 
3.2 Cellular localisation of ABAD in SK-N-SH, a human neuroblastoma cell  
                    line 
85 
3.2.1 Previous studies on the cellular location of ABAD 86 
3.2.2 Cellular localisation of ABAD by fluorescent microscopy in  
         SK-N-SH cells 
87 
3.2.3 Transient transfection of SK-N-SH cell line with ABAD-EGFP 88 
3.2.4 Further subcellular localisation by fluorescence microscopy 90 
3.2.5 Stable expression of ABAD-EGFP in SK-N-SH cells 93 
3.2.6 Creation of new construct by cloning of a mitochondrial 
targeting 
                         sequence (MTS) into ABAD-EGFP plasmid 
94 
3.2.6.1 Plasmid design 95 
3.3 Developing an in vitro model for AD 99 
3.3.1 MTT cell viability assays with Aβ42 99 
3.3.2 Fluorescence imaging studies of Aβ42 toxicity 102 
3.4 Assays to assess apoptosis 106 
3.4.1 Toxic effects of actinomycin D, PBS and Aβ42 on SK-N-SH  
         (ABAD-EGFP) cells 
106 
3.4.2 Subcellular fractionation and western blots 108 
3.4.3 Investigation of apoptotic pathways induced in SK-N-SH 
(ABAD- 
         EGFP) cells 
112 
3.4.3.1 Investigation of caspase inhibition of apoptosis 112 
3.4.3.2 Investigation of inhibition of apoptois by the novel  
            inhibitor TAT24 
114 
3.5 Investigating the Aβ42 peptide 116 
3.5.1 Investigating the oligomeric and fibrillar forms of the Aβ42 
                 peptide 
117 
3.5.2 Immunostaining of Aβ added topically to growth medium 118 
! xv!
3.5.3 Electron microscopy of Aβ peptide 119 
3.5.4 Introducing synthetic Aβ to cells using a carrier peptide 120 
3.5.5 Transfection with mAPP plasmid 123 
3.5.6 MTT assays using soluble oligomeric Aβ 125 
3.6 Primary neurons from murine embryonic cells 127 
3.7 Culture of multipotent neurospheres from murine neuronal stem cells 128 
3.7.1 Immunostaining neurospheres 129 
3.8 Discussion 132 
  
Chapter 4: Proteomic analysis of brain tissue from novel transgenic 
mouse  
                   models for Alzheimer’s disease 
139 
  
4.1 Background and aims 139 
4.2 Protein expression in vivo using novel AD transgenic mouse models 141 
4.3 Mouse brain protein identification by 2D electrophoresis from mature  
                     (8-12 months) transgenic AD models 
143 
4.3.1 Choice of method for identification of proteins 147 
4.3.2 Mass Spectrometry analysis 148 
4.3.3 Results from mass spectrometry analysis 152 
4.3.4 Characterisation of the four proteins chosen for further study 153 
4.3.4.1 Peroxiredoxin II 153 
4.3.4.2 Endophilin 1 154 
4.3.4.3 ATP synthase β subunit 155 
4.3.4.4 Creatine kinase β subunit 155 
4.3.4.5 ApoE 156 
4.4 Protein identification in immature (4-8 months) mouse model by Western  
                     immunoblotting 
157 
4.4.1 Peroxiredoxin – hippocampal samples 158 
4.4.2 Peroxiredoxin – cortex samples 159 
4.4.3 Endophilin – hippocampal samples 160 
4.4.4. Endophilin – cortex samples 161 
4.4.5 ATP synthase - hippocampus samples 162 
4.4.6 ATP synthase  – cortex samples 163 
4.4.7 Creatine kinase β subunit  - hippocampus samples 164 
! xvi!
4.4.8 Creatine kinase β subunit  - cortex samples 165 
4.5 Protein identification in isolated mitochondria 166 
4.6 Protein changes seen in transgenic mice and Alzheimer’s patients 170 
4.7 Discussion 172 
  
Chapter 5: Identifying small molecule inhibitors to the ABAD/Aβ  
complex 
                   using fragment based screening 
179 
  
5.1 Background and aims 179 
5.2 Fragment based screening for drug discovery and design 179 
5.2.1 Conventional high-throughput screening (HTS) 179 
5.2.2 Lipinski’s ‘rule of 5’ 181 
5.2.3 Fragment based screening 182 
5.2.4 FBS improvements over conventional HTS 184 
5.3 Overall rationale of FBS 186 
5.3.1 Benefits of the thermal shift assay 186 
5.3.2 Principle of the thermal shift assay 187 
5.4 Determination of the dissociation temperature for ABAD 190 
5.4.1 Initial optimisation of ABAD concentration with Sypro Orange 190 
5.5 FBS of ABAD with Maybridge compounds 1-96  193 
5.6 FBS of ABAD with NAD+ cofactor 198 
5.6.1 FBS of ABAD with NAD+ against compounds 289-300, 337-
348 
199 
5.7 Discussion 201 
  
Chapter 6. Thesis summary and discussion 207 
  
Bibliography 217 
  
Appendix 255 
  
Publications 257 
  
! xvii!
List of figures  
  
Fig. 1.1 Amino acid sequence of human APP isoform 770 8 
Fig. 1.2 APP processing of APP770.  Non amyloidogenic pathway. 10 
Fig. 1.3 APP processing of APP770. Amyloidogenic pathway 11 
Fig. 1.4 Amino acid sequences of Aβ40 and Aβ42 12 
Fig. 1.5 Amino acid sequence 669-718 of human APP isoform 770 20 
Fig. 1.6.  The amyloid cascade hypothesis 28 
Fig. 1.7 Four step fatty-acid β-oxidation pathway 48 
Fig. 1.8 Amino acid sequence of ABAD 49 
Fig. 1.9 3D crystal structure of ABAD 51 
Fig. 3.1 The human ABAD protein sequence 87 
Fig. 3.2 The ABAD-EGFP plasmid 88 
Fig. 3.3 A fluorescent microscope image of paraformaldehyde fixed SK-N-
SH 
              cells after transient transfection with ABAD-EGFP 
89 
Fig. 3.4. Fluorescent microscope images of two SK-N-SH cells, co-
transfected 
               with ABAD-EGFP and pDsRed2-Mito 
91 
Fig. 3.5. Fluorescent microscope images of one SK-NS-H cell dividing, co-  
               transfected with ERCFP and pDsRed2-Mito 
91 
Fig. 3.6. A 0.1µm section through SK-N-SH cells co-transfected with ABAD- 
               GFP and ER-Red 
92 
Fig. 3.7. Fluorescent microscope image of a group of SK-N-SH cells stably 
               transfected and expressing ABAD-EGFP 
94 
Fig. 3.8. Cloning strategy for pMTS-ABAD-EGFP 96 
Fig. 3.9.  Fluorescent microscope images of transient transfections of cells 
with 
                MTS-ABAD-EGFP 
98 
Fig 3.10 Microscope phase contrast images of the cultivation of PC12 cells 
and 
                SK-N-SH cells  
98 
Fig. 3.11. The template of the 96 well plate showing different concentrations 
of 
                  Aβ42 peptide added 
100 
Fig. 3.12. Results from the MTT readings of SK-N-SH (ABAD-EGFP) cells 
                 incubated for 16hr with Aβ42 
101 
Fig. 3.13. Live imaging of stably transfected SK-N-SH (ABAD-EGFP) cells 103 
Fig. 3.14. Live imaging of stable SK-N-SH (ABAD-EGFP) cells, co 
transfected 
                 with pDsRed2-Mito and incubated with 1µM Aβ over 17hr 
105 
! xviii!
Fig. 3.15. Results of MTT assay with actinomycin D or Aβ 107 
Fig. 3.16. Western blot of fractionated SK-N-SH (ABAD-EGFP) cells  
                 incubated for 24hr with 100µM actinomycin D or 2µM Aβ42 
109 
Fig. 3.17.  Western blot of fractionated SK-N-SH (ABAD-EGFP) cells 
                  incubated for 16hr 
110 
Fig. 3.18. Western blot of fractionated SK-N-SH (ABAD-EGFP) cells 
                 incubated for up to 48hr with 2µM Aβ42 
111 
Fig. 3.19. Results of the MTT assay with actinomycin D or Aβ 113 
Fig. 3.20. Results of the MTT assay with 1µM Aβ 114 
Fig. 3.21. Results of the MTT assay with 50µM actinomycin D 115 
Fig. 3.22. Results of the MTT assay with staurosporin or Aβ.   117 
Fig. 3.23. SK-N-SH (ABAD-EGFP) cells incubated with Aβ peptide, fixed  
                 and stained 
119 
Fig. 3.24. Electron microscope images of synthetic Aβ. 120 
Fig. 3.25. SK-N-SH cells transiently transfected with MTS-ABAD-EGFP 122 
Fig. 3.26. Two example images of SK-N-SH (ABAD-EGFP) cells transfected 
                 with mutant APP 
123 
Fig. 3.27. SK-N-SH cells transfected with mutant APP  124 
Fig. 3.28. Results of the MTT assay with oligomeric Aβ +/- inhibitor TAT24 126 
Fig. 3.29. Primary cortical cells co-transfected with ABAD-EGFP and with  
                 pDsRedmito2 
127 
Fig. 3.30. Phase Contrast microscope images of neurospheres from murine 
                neural stem cells 
128 
Fig 3.31. An example of stained neurospheres 129 
Fig. 3.32.  Endogenous expressed ABAD in WT murine neurospheres 130 
Fig. 3.33.  Immunostaining showing co-localisation of endogenous expressed 
                 ABAD and TOM40 
131 
Fig. 3.34. Differentiated neurospheres from Tg mAPP mouse 132 
Fig. 4.1. Demonstration of ABAD-Aβ complex in brains of Tg mAPP/ABAD 
mice 
144 
Fig. 4.2. 2D gels from tissue samples of each genotype 146 
Fig. 4.3.  Magnified detail from 2D gels with tissue samples from each 
genotype 
147 
Fig. 4.4. Protein sequences of the three isoforms of mouse endophilin 150 
Fig. 4.5. Peptide sequences expected from the tryptic digest of endophilin I 151 
Fig. 4.4. Western blots using 0.5µg/ml rabbit anti-PrxII antibody (Alexis CA) 
               on hippocampus tissue samples 
158   
Fig. 4.5. Western blots using 0.5µg/ml rabbit anti-PrxII antibody (Alexis CA) 
               on cortex tissue samples 
159 
Fig. 4.6. Western blots using 0.5µg/ml anti-endophilin I antibody (Zymed  
               laboratories) on hippocampus tissue samples 
160 
! xix!
Fig. 4.7. Western blots using 0.5µg/ml anti-endophilin I antibody (Zymed  
               laboratories) on cortex tissue samples 
161 
Fig. 4.8. Western blots using 1.0µg/ml anti-ATP synthase antibody (Pierce) 
on 
               hippocampus tissue samples 
162 
Fig. 4.9. Western blots using 1.0µg/ml anti-ATP synthase antibody (Pierce) 
on 
               cortex tissue samples 
163 
Fig. 4.10. Western blots using 0.5µg/ml anti-CKβ antibody (Santa Cruz) on 
                 hippocampus tissue samples 
164 
Fig. 4.11. Western blots using 0.5µg/ml anti-CKβ antibody (Santa Cruz) on 
                 cortex tissue samples 
165 
Fig. 4.12. A 2D gel of mitochondrial tissue from WT mouse 8 months of age 167 
Fig. 4.13. Two 2D gels of mitochondrial samples comparing WT with  
                2 xTg mAPP/ABAD samples 
168 
Fig. 4.14. Magnified detail from 2D gels shown in Figure 4.12 169 
Fig. 4.15. Staining of excess PrxII in the 2 x Tg mAPP/ABAD tissue in mice 
                 and in human AD brain tissue 
170 
Fig. 4.16. Staining of excess endophilin I in the 2 x Tg mAPP/ABAD tissue 
in 
                 mice and in human AD brain tissue 
171 
Fig. 5.1. Comparison of HTS with FBS 185 
Fig 5.2. Examples of dissociation curves from a 96 well microplate thermal  
              shift assay 
188 
Fig 5.3. Data shown as dissociation temperature peaks of native protein 189 
Fig. 5.4. The thermal dissociation assay for native ABAD 192 
Fig. 5.5. Dissociation peak of ABAD 195 
Fig. 5.6.  Dissociation curves of ABAD control and four examples of  
                compounds binding 
195 
Fig. 5.7. Dissociation peak temperatures of ABAD and mixes of ABAD in the 
               presence of NAD+.   
198 
Fig. 5.8. Thermal shift assay from 250 C to 900C for ABAD with NAD+  
               cofactor and compounds 337 – 348 
200 
Fig. 5.11. Chemical structure of Pfizer compound AG18501 203 
Fig. 5.12. Chemical structure of frentizole 204 
  
  
List of tables  
  
Table 1.1 Examples of well-known APP mutations  21 
Table 1.2 The substrates of ABAD 43 
! xx!
Table 2.1. Antibodies used in the western blotting experiments 70 
Table 3.1 Student t test p values of the readings giving the results of the MTT  
                assay 
 101 
Table 4.1 Details of the five proteins identified from mass spectrometry 153 
Table 4.2 Cellular locations of peroxiredoxin subgroups  154 
Table 4.3 Protein expression in samples as shown by the western blots 166 
Table 5.1. Experimental setup for optimisation of Sypro Orange concentration 191 
Table 5.2. Wells charged with Sypro Orange optimisation 191 
Table 5.3a. A 96-well microplate template showing wells containing chemical  
                   fragment compounds 
193 
Table 5.3b. Distribution of fragments among the 96 wells for Plate 1 194 
Table 5.4. Chemical details of the fragments giving ≥ 3°C thermal shift 197 
Table 5.5. Compounds selected from plate 4 199 
Table 5.6. Chemical details of compounds 340 and 345 201 
 !
 1 
Chapter 1 
Introduction 
 
1.1 History and epidemiology of Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 
approximately 65% of all dementia cases in the elderly (Henderson and Jorm, 
1997; Luengo-Fernandez et al., 2010).  There is a lack of consistent data on the 
prevalence of AD around the world, but the percentage of all dementia in the 
elderly has increased since studies published in the 1990’s.  In 2009 it was 
estimated that there would be over 35 million cases of AD worldwide (2009 
World Alzheimer Report; Alzheimer’s Disease International), with numbers 
increasing especially in heavily populated regions e.g. Asia, Africa and South 
America.  The disease affects all cultures worldwide, although there are three 
cited examples where AD is rare: in Japan, Kashmir and in Cree native American 
Indians (Graves et al., 1996; Hendrie et al., 1993; Raina et al., 2009; Razdan et 
al., 1994; White et al., 1996). However, from the Honolulu-Asia Ageing Study, 
Japanese immigrants living in Hawaii and King County, Washington State USA, 
have the same incidence of AD as others in the USA or Europe (White et al., 
1996), adding evidence to there being an environmental influence on the disease, 
although no single factor has been identified. According to the 2009 World 
Alzheimer Report, predictions for 2010 show ‘57.7% of individuals with 
dementia worldwide live in low- and middle-income countries, but this percentage 
will rise to 70.5% by 2050’. Forecasted growth figures for East Asia are 117%, 
107% for South Asia, 134% to 146% in parts of Latin America, and 125% in 
North Africa and the Middle East. The report also forecasts an increase of 40% in 
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the number of people with dementia in Europe, 63% in North America, 77% in 
southern Latin America, and 89% in the developed Asia Pacific countries. 
 
A report in 2003 for the UK has shown that the incidence of AD is increasing 
worldwide, estimating an increase of 37% in developed countries over 10 years 
(Comas-Herrera et al., 2003).  This report, by Prof. Martin Knapp of the London 
School of Economics (LSE), estimates that there will be a 66% increase of cases 
in the UK from 1998 - 2031. This will create a serious financial burden to 
governments for the future care of Alzheimer patients.  However the LSE report 
concludes that if there were a treatment available that could reduce the rate of 
cases of cognitive impairment by 1% per year, this would offset the long-term 
costs.  
 
AD was first described as a medical condition in 1906 by the German medical 
researcher Alois Alzheimer (1864-1915) as ‘an unusual disease of the cerebral 
cortex’.  He had identified this in a woman, Auguste Deter, in her fifties with 
symptoms of ‘memory loss, disorientation, hallucinations and an untimely death 
in 1906 aged 55yrs’.  At post mortem he found ‘abnormal clumps’ (now called 
amyloid plaques) and ‘tangled bundles of fibres’ (neurofibrillary tangles of the tau 
protein).  These are now recognised as the two classic hallmarks of AD seen at 
post mortem (Selkoe and Abraham, 1986).  However this was an unusual case, as 
most AD is found in the elderly, the incidence doubling every 5 years over 65yr of 
age, with 20-25% affected over 80yrs age (Yesavage et al., 2002).  It is estimated 
that early onset AD, which occurs below 65 years of age, affects about 5% of the 
AD population (Campion et al., 1999).  
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It is possible that symptoms of AD were first described in a non-professional, but 
accurate way, in 1726 by Jonathon Swift, in his novel Gulliver’s Travels in his 
‘struldbrugs’ (the people who never died). Ironically Swift probably suffered from 
the disease himself (Lewis, 1993). Early signs of AD are short-term memory loss 
that disrupts daily life, this progresses to an inability to recognise and use 
everyday objects and loss of verbal and communication skills such as forgetting 
words and problems with speaking and writing. As the disease develops, 
spreading to more areas within the brain, the AD sufferer becomes more 
withdrawn due to an inability to make decisions or join in with social situations as 
their mood and personality changes, becoming confused, suspicious, depressed or 
anxious. AD is a progressive neurodegenerative disorder with survival following 
the onset of symptoms being variable but shortened. The main predictor of life 
expectancy is the age of onset. The expected life span can be as long as 7 to 10 
years for patients whose conditions are diagnosed when they are in their 60s and 
early 70s, to only about 3 years or less for patients whose conditions are 
diagnosed when they are in their 90s (Zanetti et al., 2009).  AD is a complex 
disease and all the research indicates that it is probably caused by the interaction 
of more than one factor including genetic, environmental and life-style. 
 
1.2 Neuropathology of AD 
AD is a progressive neurodegenerative disease for which there is no cure. There is 
no absolute diagnosis except at post mortem when the two characteristic 
hallmarks are seen, extracellular amyloid plaques and intraneuronal fibrillary 
tangles (NFTs). Several types of neurons are involved: glutamatergic, cholinergic, 
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serotonergic and noradrenergic. The location and type of neuron involved will 
influence the symptoms (Perl, 2010). 
 
The extracellular plaques consist mainly of beta amyloid peptide (Aβ).  These 
plaques are also found in the cerebral cortex of non-demented elderly persons, so 
alone are not significant in AD.  Neuroimaging, using 11C Pittsburgh compound-B 
positron emission tomography (11C-PiB PET) is able to discriminate between 
frontotemporal dementia and AD, showing significantly higher PiB retention in 
the grey matter of AD patients.  PET scanning matches histopathological reports 
in aging and dementia, reflecting the true regional density of Aβ plaques in 
cortical areas.   However there is no correlation with analyses of cognitive decline 
and cognition in AD, as ∼30% of healthy older people, and ∼60% with mild 
cognitive impairment, show cortical retention of 11C-PiB retention, consistent with 
a high concentrations of plaques.  Aβ plaques correlate with the rate of memory 
decline and episodic memory, suggesting that Aβ deposition is not a normal event 
in ageing. This supports the idea that Αβ deposition is an early event, occurring 
before the start of symptoms, possibly representing preclinical AD (Fodero-
Tavoletti et al., 2009).   
 
However the gradual accumulation of hyperphosphorylated tau protein within 
neurons correlates well with the progression of AD, as seen by worsening clinical 
symptoms. Levels of tau in cerebrospinal fluid (CSF), taken from patients with 
and without AD, show a very high correlation with the cognitive results from the 
Mini Mental State Examination (MMSE). Six stages of increasingly severe 
cortical destruction have been described (Braak and Braak, 1996).  Stages I and II 
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are characterized by NFTs in the trans-entorhinal region, and stages III and IV are 
marked by severe involvement of both the entorhinal and transentorhinal regions. 
Isocortical destruction occurs during stages V and VI. NFTs alone are not 
diagnostic of AD as they are also found in frontotemporal dementia and other 
neurodegenerative diseases (Perl, 2000).  Other pathological abnormalities seen in 
AD are a profound loss of neurons and synapses, reactive gliosis, microglial 
activation and inflammatory changes (Aisen, 2002).   
 
1.2.1 Extracellular amyloid plaques and amyloid precursor protein (APP) 
         processing 
Extracellular amyloid plaques are solid insoluble lesions composed mainly of the 
beta amyloid peptide Aβ42, deposited in the brain.  A proteomic analysis of over 
2000 plaques from two AD post mortem brains identified 168 proteins in plaques 
that were not identified in non-plaque controls (Liao et al., 2004).  From these, 26 
proteins were identified as enriched by a minimum of 2-fold in the plaques, by 
quantitative comparison with surrounding non-plaque tissues.  These included the 
classic components: Aβ42, α1-antichymotrypsin, α-synuclein, apolipoprotein E 
(ApoE), collagen type XXV, cystatin C, proteoglycans and clusterin.  This study 
used laser capture microdissection (LCM) to collect the tissue samples, which 
allows cutting a microscopic region as small as 3-5 μm in diameter, followed by 
analysis using liquid chromatography combined with tandem mass spectrometry 
(LC-MS/MS).  This study shows the complexity and diversity of cellular 
processes involved in Aβ plaque formation (Liao et al., 2004). The beta amyloid 
peptide Aβ42 is a product from the metabolism of the amyloid precursor protein 
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(APP), by proteolytic cleavage by β- and γ-secretases.  Aβ42 is the toxic peptide 
and is found at the core of the amyloid plaques.   
 
1.2.1.1 Aβ  discovery and links with Down’s syndrome 
Aβ was first sequenced 20 years ago from meningeal blood vessels of AD patients 
and also individuals with Down’s syndrome (Glenner and Wong, 1984).  In 1985 
Aβ was identified as the main component of senile neuritic plaques of AD brain 
tissue (Masters et al., 1985). As the most common of the neurodegenerative 
diseases, these discoveries marked the beginning of extensive research into AD.  
Cloning of the APP gene and its localisation to chromosome 21, linked with the 
knowledge that individuals with Down’s syndrome, which possess a trisomy of 
chromosome 21, invariably develop AD, led to the hypothesis that excessive Aβ 
accumulation in the brain was the primary event in the development of AD (Tanzi 
et al., 1987).   
 
1.2.1.2 APP processing 
APP is a transmembrane glycoprotein with a 590-680 amino acid extracellular 
amino terminal domain, a single membrane-spanning region, and an 
approximately 55 amino acid cytoplasmic tail, which contains intracellular 
trafficking signals. Human APP contains a neural-specific promoter element, the 
physiological significance of which is still unclear (Collin and Martens, 2006).  
The APP gene is located on chromosome 21, spans 291 kilobases and contains at 
least 18 exons. APP can produce eight possible isoforms, three of which (the 695, 
751 and 770 amino acid isoforms) predominate in the brain (Kang et al., 1987). 
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The APP695 isoform is expressed mainly in neurons (Thakur and Mani, 2005).  
The APP751 and APP770 isoforms, which contain a Kunitz-protease inhibitor 
(KPI) domain, are found mostly in non-neuronal glial cells. All three isoforms 
share the same Aβ, transmembrane and intracellular domains and are thus all 
potentially amyloidogenic. APP has been found in the cytoplasm of rat brain cells 
and is present in most neurons but in different amounts depending on the neuron 
size, the larger the neuron, the greater amount of APP.  This would indicate that 
APP may play a specific role in the function of several different classes of 
neurons (Ouimet et al., 2004).  The complete function of APP is still unclear, 
although it has been demonstrated that APP localizes in the synapses of neurons 
where it may play a role in neurite growth and synaptic formation and repair 
(Priller et al., 2006).  APP knock-out mice are viable with only minor effects in 
their phenotype, demonstrating evidence of memory loss and some impaired long-
term potentiation but without general neuron loss (Phinney et al., 1999). 
However, APP expression in neurons increases with age in non-demented 
individuals, but APP expression in neuronal somata decreases in AD patients in 
direct correlation with the mature amyloid plaque aggregation (Barger et al., 
2008). Interestingly ApoE expression correlates with the mature amyloid plaque 
aggregation and excess ApoE was detected in plaques. It is probable that in vivo, 
over expression of ApoE and APP are linked during cellular stress but this link is 
disrupted during AD pathogenesis. 
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1.2.1.3 Protein sequence of human APP770 
The protein sequence for human APP 770 isoform is shown in Figure 1.1. 
 
   10         20         30         40         50         60  
MLPGLALLLL AAWTARALEV PTDGNAGLLA EPQIAMFCGR LNMHMNVQNG KWDSDPSGTK  
 
        70         80         90        100        110        120  
TCIDTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHPH FVIPYRCLVG  
 
       130        140        150        160        170        180  
EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR  
 
       190        200        210        220        230        240  
GVEFVCCPLA EESDNVDSAD AEEDDSDVWW GGADTDYADG SEDKVVEVAE EEEVAEVEEE  
 
       250        260        270        280        290        300  
EADDDEDDED GDEVEEEAEE PYEEATERTT SIATTTTTTT ESVEEVVREV CSEQAETGPC  
 
       310        320        330        340        350        360  
RAMISRWYFD VTEGKCAPFF YGGCGGNRNN FDTEEYCMAV CGSAMSQSLL KTTQEPLARD  
 
       370        380        390        400        410        420  
PVKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA  
 
       430        440        450        460        470        480  
KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL  
 
       490        500        510        520        530        540  
QAVPPRPRHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER  
 
       550        560        570        580        590        600  
MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET  
 
       610        620        630        640        650        660  
KTTVELLPVN GEFSLDDLQP WHSFGADSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN  
 
       670        680        690        700        710        720  
IKTEEISEVK MDAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL  
 
       730        740        750        760        770  
VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN 
 
Fig. 1.1 Amino acid sequence of human APP isoform 770 (UniprotKB P05067). The 
residues in red (672-713) show the sequence of Aβ42.  The residues in green (1-35) show 
an ER targeting sequence. The residues in blue (40-51) show a mitochondrial targeting 
sequence (section 1.2.15) (Anandatheerthavarada et al., 2003).  
 
APP is cleaved by three secretases in specific, successive sequences: α-secretase 
is member of the ADAM (A Disintegrin And Metalloprotease) family that are 
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expressed on the surface of cells, are zinc dependent and are anchored to the cell 
membrane. ADAM10, ADAM17, ADAM9 and tumour necrosis factor α (TNFα) 
or TNFα converting enzyme (TACE) show α-secretase activity (Postina, 2008).  
α-secretase cleaves within the Aβ domain initiating the non-amyloiogenic 
pathway.  ß-secretase, also known as beta-site APP cleaving enzyme 1 (BACE1) 
is a transmembrane aspartic acid protease and cleaves at the N terminus of the Aβ 
domain, and this initiates the amyloidogenic pathway.  γ-secretase is a protease 
complex of at least four proteins: presenilin, nicastrin, anterior pharynx-defective 
1 (APH-1), and presenilin enhancer 2 (PEN-2), and cleaves residues in the 
intramembrane space, around the C terminus of the Aβ domain.  The sequence of 
cleavages promotes proteolytic processing via two pathways: non-amyloidogenic 
and amyloidogenic (Figures 1.2 and 1.3).   
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Fig. 1.2. APP processing of APP770 promoting the non amyloidogenic pathway.  
Cleavage by the α-secretase at amino acid 692(A), splitting the Aβ domain (green), 
creates a non-amyloidogenic soluble N-terminal fragment APPα. Further cleavage by γ-
secretase at residue 713(A), in the intramembranous space, forms a non-toxic peptide P3 
and non-amyloidogenic C-terminal fragment. 
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Fig. 1.3. APP processing of APP770 promoting the amyloidogenic pathway. The Aβ 
peptides are produced by proteolytic cleavage, first by the ß-secretase at the extracellular 
residue 672(D) which creates a shorter N-terminal soluble peptide APPβ.   Further 
cleavage by the γ-secretase at residue 711 or 713, in the intramembranous space, forms 
the insoluble peptides Aβ40 or Aβ42. 
 
 
1.2.1.4 Aβ42 the toxic peptide in AD 
Aβ40 and Aβ42 are the two most common Aβ species containing 40 and 42 
amino acids, respectively, but Aβ42 is the toxic peptide found in excess in the 
brains of AD patients, with Aβ40 being found mainly in blood vessels (Tekirian et 
al., 1996).  Other smaller Aβ peptides (38 or 39 amino acids) can be formed if the 
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γ-secretase cuts before residue 711. Both α- and β-secretase cleave the 
extracellular domain of APP.  The γ-secretase cleaves the transmembranous 
domain, and it is suggested that this may be why the Aβ peptides still retain their 
affinity for membrane binding (Williams and Serpell, 2011).  
 
The two extra amino acids in Aβ42, isoleucine and alanine, are hydrophobic 
(Figure 1.4). This increases its affinity to bind to itself and aggregate in aqueous 
solutions, more than Aβ40. It is thought that this tendency to cluster is responsible 
for its toxicity.  Evidence for this has been shown by substitution of the two 
residues with hydrophilic amino acids that results in a decrease in aggregation 
(Kim and Hecht, 2005). 
 
Aβ40 
672    680     690  700       710    
  DAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV V 
  10     20     30  40 
 
Aβ42 
 
672    680     690  700       710    
  DAEFRHDSG YEVHHQKLVF FAEDVGSNKG AIIGLMVGGV VIA 
  10     20     30  40 
 
Fig. 1.4. Amino acid sequences of Aβ40, residues 672-711 of APP and Aβ42, residues 
672 to 713 of APP. The residue numbers of the peptides 1-40 and 1-42 are shown in blue. 
The two residues at the C terminus of the Aβ42, shown in red, are the hydrophobic 
residues isoleucine and alanine. 
 
Certain other residues also play a key role in aggregation.  Two hydrophobic 
regions of Aβ42 at residues 17–21(LVFFA) and 31–42 (IIGLMVGGVVIA) are 
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considered to be important for fibril structure (Luhrs et al., 2005).  Substitution at 
residue 20 for the hydrophilic glutamic acid, F20E, in the Aβ sequence also 
reduces aggregation (Fraser et al., 1992).   There is much research aimed at 
reducing the toxic effect of Aβ by inhibiting its expression and/or its aggregation 
thus reducing its direct interaction with neuronal cellular mechanisms. 
 
Aβ can disrupt membrane integrity by direct or indirect effects.  Aβ binds to 
phospholipid membranes with a high affinity and it is suggested that the head-
group charge of the phospholipids contributes to the association between Aβ and 
the membrane via electrostatic interactions (Kremer and Murphy, 2003).  Aβ 
interacts with several cell surface receptors inducing membrane permeation or cell 
death.  The formation of stable pores and ion channels is a model proposed for 
amyloid-induced toxicity. The disruption of Ca2+ homeostasis has been recognized 
as a potential mechanism associated with AD, and was shown to be involved in 
the amyloid cascade hypothesis, where elevated Ca2+ was suggested to be a 
consequence of both tau phosphorylation and cell death (Hardy and Higgins, 
1992).   
 
There is considerable evidence of Aβ binding at neuronal surfaces and at synapses 
(Lambert et al., 1998).  Interaction of Aβ42 with cell surface receptors triggers 
cell signal transduction leading to changes in intracellular protein expression with 
toxic effects (Irvine et al., 2008).  Several examples of cell surface receptors have 
been postulated to be affected by Aβ42, including the insulin receptor, amylin 
receptor, receptor for glycation end products (RAGE) (Patel and Jhamandas, 
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2012), α7- nicotinic acetylcholine receptor (Parri et al., 2011), p75 neurotrophin 
receptor (p75NTR), NMDA glutamate receptors and monosialoganglioside 
(GM1).  Aβ42 peptides compete with insulin for the insulin receptor and this may 
be the cause of impaired glucose metabolism in AD (Xie et al., 2002).  A study 
using primary cultures of rat cholinergic forebrain neurons showed that an amylin 
receptor antagonist blocked Aβ induced neurotoxicity (Jhamandas and 
MacTavish, 2004). Inhibition of the RAGE-Aβ interaction suppresses 
accumulation of Aβ in the brain (Deane et al., 2003).  The α7-nicotinic 
acetylcholine receptor mediates survival pathways via the PI3-AKT pathway 
leading to up-regulation of anti-apoptotic proteins BCL2 and BCL-X and initiates 
jak2/stat3 survival pathway.  This receptor is highly expressed on cholinergic 
basal forebrain neurons (Patel and Jhamandas, 2012).  Aβ binding to α7-nicotinic 
acetylcholine receptors triggers endocytosis of glutamate receptor subunits and 
the insulin receptor and alters trafficking of metabotropic glutamate receptors 
(Patel and Jhamandas, 2012). 
 
Aβ binding to NMDA receptors causes abnormal Ca2+ mobilization and there is 
an overall reduction of NMDA receptors in the presence of Aβ causing a loss of 
memory and reduced learning capacity.  RAGE controls the entry of Aβ into the 
blood–brain barrier (BBB), by binding soluble Aβ in a dose-dependent manner at 
nanomolar concentrations and mediating Aβ transcytosis across the BBB in a 
time- and temperature-dependent manner (Chen et al., 2007; Deane et al., 2003; 
Mackic et al., 2002).  Aβ binding to GM1 enables Aβ to cross the blood-brain 
barrier.  These interactions could all be useful as therapeutic targets for AD.    
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1.2.1.5 Aβ42 and mitochondrial dysfunction 
Aβ has also been shown to insert into the cell membrane, with a short section 
associating with lysosomal membranes, causing lysosomal destabilization leading 
to toxic effects in the cell (Liu et al., 2010).  There is now evidence that Aβ42 
enters mitochondria, binding to mitochondrial proteins, causing mitochondrial 
dysfunction and eventually cell death.  Evidence suggests that Aβ42 interferes 
with the mitochondria permeability transition pore, which disrupts normal protein 
functions, leading to cell homeostasis and cell death, reviewed in (Muirhead et al., 
2010).  Mitochondrial Aβ was first described in 2004 (Lustbader et al., 2004).  
This study showed, using immunoelectron microscopy, that Aβ binds to 3-
hydroxyacetylCoAdehydrogenase (HADH2), also known as amyloid binding 
alcohol dehydrogenase (ABAD), an enzyme which is expressed in the matrix of 
mitochondria.  This was shown to occur only in AD affected brains (Lustbader et 
al., 2004), and this was confirmed and also shown in a Tg mAPP mouse model 
(Caspersen et al., 2005). The Caspersen study showed that Aβ40 and Aβ42 
colocalised with the mitochondrial matrix chaperone heat shock protein 60 
(HSP60) but a protease-protection assay could not discriminate between the 
matrix compartment and the intermembrane space or the inner mitochondrial 
membrane.  The ability of Aβ to enter the cell is a matter of debate. As shown in 
Figure 1.3, the Aβ peptides are assumed to be cleaved outside the cell.  However 
studies have shown Aβ present within the mitochondrial membrane in 
mitochondrial preparations from non-demented brain biopsies (Hansson Petersen 
et al., 2008).  Subsequent studies on a human neuroblastoma cell line revealed Aβ 
was imported, independent of the mitochondrial membrane potential, and 
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dependent on the outer mitochondrial membrane (TOM) translocase pathway, 
using TOM20, TOM40 and TOM70 (Hansson Petersen et al., 2008).  Other 
studies have shown indirect import of Aβ into mitochodria can also occur by 
localised APP processing followed by Aβ synthesis.  It is reported that APP has a 
chimeric N-terminal targeting sequence (Figure 1.1), causing the peptide to 
translocate to the ER and the mitochondria (Anandatheerthavarada et al., 2003).  
The APP is seen in a transmembrane arrested form, in an N- in C- out orientation, 
with a 73kDa C-terminal domain in the cytosol.  Anandatheeravarada proposed 
that the acidic domains 220-290 of APP 695 hindered the transfer and the 
transmembrane arrested form is associated with mitochondrial dysfunction.  
Anandatheeravarada colocalised APP with mitochondrial translocase proteins 
TOM 40, TIM 23 and TIM44, indicating that APP translocating to the 
mitochondria is dependent on the translocase pathway.  APP accumulates in the 
protein import channels of mitochondria in AD brains but not in age matched 
controls (Devi et al., 2006).  Devi showed APP formed a 480kDa complex with 
TOM40 and a 620kDa complex both with TOM40 and the translocase of the inner 
mitochondrial membrane 23 (TIM23).  This was shown to inhibit the import of 
cytochrome C oxidase subunits IV and Vb proteins, which was associated with 
decreased cytochrome C oxidase activity and increased H2O2 production.  This 
mitochondrial APP was found to be concentrated in areas of the brain vulnerable 
to AD toxicity, such as the frontal cortex, hippocampus, and amygdala and the 
levels of APP correlated directly with mitochondrial dysfunction.  It is still 
unclear whether Aβ accumulates in the mitochondria matrix or in the membrane 
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compartment of AD affected brain. But it has been shown that it is possible that 
the translocase system is a direct method of importing APP and Aβ into the cell. 
 
1.2.2 Intracellular neurofibrillary tau tangles (NFTs) 
 
Intracellular NFTs are formed from aggregates of the hyperphosphorylated tau 
protein that is deposited inside neurons. Tau is a very soluble microtubule-
associated protein (MAPT) and is expressed in six isoforms ranging from 352 to 
441 amino acid residues.  It contains 3 or 4 binding domains at the C terminus, 
depending on the isoform. The tau gene is located on chromosome 17, locus 
17q21 and contains 16 exons. In the cell, MAPT reacts with tubulin to stabilise 
microtubules in the cytoskeleton, and in humans MAPT stabilises the axons of 
neurons.  Post-translational modification of MAPT is caused by glycation, 
glycosylation, phosphorylation, ubiquitination and proteolytic processing that may 
disrupt its normal function (Gong et al., 2005).  In AD the stability of 
microtubules may be disrupted by phosphorylation of MAPT, which is controlled 
by certain kinases e.g. protein kinase N (PKN), glycogen synthase kinase 3 
(GSK3) and cyclin-dependent kinase 5 (cdk5) (Schneider et al., 1999). 
Phosphorylation by microtubule affinity regulating kinase (MARK) and protein 
kinase A (PKA) at sites that interfere with microtuble binding, interfere with tau 
tangle production (Schneider et al., 1999).  In AD, MAPT becomes 
hyperphosphorylated and aggregated when paired helical filaments join to become 
‘tau tangles’, the hyperphosphorylated tau being insoluble.  Recent studies have 
also identified the involvement of prolyl isomerase (PIN1) a protein that protects 
neurons (Butterfield et al., 2006).  PIN1 acts on proteins after phosphorylation at 
certain sites, changing the structural conformation. This change in conformation 
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promotes cellular health in AD by untwisting APP and tau to return them to a 
functional state. Loss of PIN1 leads to over production of Aβ and accumulation of 
abnormal tau (Butterfield et al., 2006; Driver and Lu, 2010).  There is still some 
debate as to whether NFTs appear before amyloid plaques in the progression of 
AD as the dementia symptoms correlate more with the production of NFTs in the 
brain than with amyloid plaque formation (Gomez-Isla et al., 1997) and NFT 
formation follows a specific pattern of distribution in AD, starting in the 
entorhinal cortex which is not age related (Braak and Braak, 1991).  However, it 
is more generally accepted that NFTs appear after Aβ production, as explained by 
the amyloid cascade hypothesis (Hardy and Higgins, 1992).  Interestingly 
mutations in the MAPT gene do not result in AD but are related to frontotemporal 
dementia like Pick’s disease also called frontotemporal dementia with 
Parkinsonism linked to chromosome 17  (FTDP-17), cortico-basal degeneration 
and progressive supranuclear palsy (Hutton et al., 1998; Spillantini and Goedert, 
2000).  These dementias do not have amyloid plaques indicating that tau 
aggregation is downstream from Aβ effects. 
 
Similar to Aβ, it is now thought that MAPT may be present as a toxic, soluble, 
oligomeric, phosphorylated form, before aggregating into the insoluble tangles 
(Haass and Selkoe, 2007). The progression of soluble to insoluble tau is now most 
likely the important physiological/pathological change in AD.  However there is 
little agreement as to whether tau is a good target for drug treatment for AD.  
Some pharmaceutical companies are looking at inhibiting the phosphorylation, 
while other research concentrates on preventing tau aggregation and expression 
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(Roberson et al., 2007) and improving microtubule function (Schneider and 
Mandelkow, 2008). 
 
1.3 Genetics of AD 
Genetic studies have identified four genes associated with AD.  Three are 
associated with early onset familial AD (FAD): APP, presenilin 1 (PS1) and 
presenilin 2 (PS2) and one with sporadic late onset AD (LOAD): ApoE.   
(1) APP located on chromosome 21 which produces the Aβ peptides.  
(2) PS1 located on chromosome 14 which interacts with the Aβ peptide.  
(3)  PS2 located on chromosome 1 which also interacts with the Aβ peptide.    
(4) ApoE  is located on chromosome 19 and binds lipoproteins and cholesterol. 
 
FAD is rarer than sporadic AD and is caused by mis-sense mutations that account 
for less than 5% of all cases of AD (Campion et al., 1999). Autosomal dominant 
mutations of APP, PS1 and PS2 genes increase the risk of early onset familial 
FAD, i.e. before 60yrs age.  
 
1.3.1 Early onset AD 
Research on Down’s syndrome, a genetic abnormality where there are three 
copies of chromosome 21, found genetic mutations causing AD (Goate et al., 
1991).  This was significant as the APP gene is located on chromosome 21 and 
therefore the protein is expressed in excess, giving rise to a higher probability of 
AD because of excess Aβ being produced.   
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1.3.1.1 APP point mutations 
In the Goate study, two families with early onset AD and symptoms occurring 
before 60 years of age, were identified with a point mutation at residue 717 
(V717I) in APP770.  This APP mutation was found to produce Aβ deposits and 
was recognised as a marker for early onset familial AD (FAD).  Prior to this, Aβ 
deposits had been found in individuals with a history of hereditary cerebral 
haemorrhage with amyloidosis–Dutch (HCHWA-D) (Levy et al., 1990).  A point 
mutation at codon 693 (E693Q) in APP770 was identified in these patients, and 
was named the Dutch mutation.  Twenty five other APP point mutations have 
since been found (Hardy J 2010 Alzheimer Research Forum).  The most well 
known disease associated with intra-Aβ mutations, include Flemish A692G, 
Italian E693K, Arctic E693G, Dutch E693Q, Iowa D694N, and London V717I.  A 
double missense mutation in a Swedish family occurs at residues K670N/M671L 
(Figure 1.5 and Table 1.1). 
 
 β-cleavage             α-cleavage          γ-cleavage 
    |      |      | 
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         G           F 
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                   L 
Fig. 1.5 Amino acid sequence 669-718 of human APP isoform 770, showing the secretase 
cleavage sites. The residues in red show the sequence of Aβ42. The residues in blue show 
the point mutations found in APP causing FAD and in purple the point mutation for 
HCHWA-D. 
Most of the mutations are at, or very near, the sites within APP that are normally 
cleaved by the α-, β- and γ-secretases.  APP mutations within the Aβ sequence 
increase the aggregation of Aβ into amyloid fibrils.  Mutations at or near the γ-
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secretase cleavage site appear to increase the Aβ42/Aβ40 ratio without altering 
the overall quantity of Aβ. This can only happen when the mutations exert an 
effect on γ-secretase (Bentahir et al., 2006; Citron et al., 1997).  Mutations near 
the α-secretase cleavage site are thought to create more vascular amyloidosis or a 
mixed vascular/AD pathology (De Strooper and Annaert, 2000).  
 
NAME CODON MUTATION CLOSE TO 
SECRETASE 
CLEAVAGE 
SITE 
Aβ  
PRODUCTION 
ARCTIC 693 E-G α-secretase Decreased Aβ40 and 
Aβ42 production in 
plasma, but increased 
protofibril formation. 
 
DUTCH 693 E-Q α-secretase HCHWA-D and 
increased Aβ and p3 
production. 
FLEMISH 692 A-G α-secretase HCHWA & increased 
Aβ and p3 production. 
IOWA 694 D-N α-secretase  
ITALIAN 693 E-K α-secretase  
  V-G   
LONDON 717 V-I β-secretase increased Aβ42 
production. 
  V-L   
SWEDISH 670/671 K-N/M-L γ-secretase increased Aβ40 and 
Aβ42 production due to 
increased affinity for 
BACE for the cleavage 
site. 
 
Table 1.1   Examples of well-known APP mutations showing the codon and mutation, 
common nomenclature and effect on Aβ peptide production. 
All of the mutations in Table 1.1 (except the Flemish) alter the charge properties 
of Aβ, which probably increases the likelihood of Aβ aggregation. Recently it has 
been suggested that the Flemish mutation causes an increase in γ-secretase 
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cleavage by preventing an inhibitory influence by the middle region of Aβ on γ-
secretase activity. 
 
1.3.1.2 Presenilins in AD 
Both presenilins are highly homologous at the DNA sequence, protein sequence 
and gene structure levels (Alzheimer’s Collaborative Group 1995).  The proteins 
are large multi-pass transmembrane proteins (PS1 contains 467 amino acid 
residues, and PS2 contains 448) and they each contain 6 or 8 transmembrane 
domains. Several studies indicated that the functions of PS1 and PS2 are the 
catalytic components of γ-secretase (De Strooper et al., 1999; Haass and De 
Strooper, 1999), γ secretase being a protein complex composed of at least four 
proteins: presenilin, nicastrin, anterior pharynx-defective 1(APH-1), and 
presenilin enhancer 2 (PEN-2).  Presenilins are also involved with Notch 
signalling (Baumeister et al., 1997; Levitan et al., 1996) and presenilins have been 
found to play a key role in the modulation of intracellular Ca2+ involved in 
presynaptic neurotransmitter release and long-term potentiation induction (Zhang 
et al., 2006).  More recently, presenilin has been identified in having a 
fundamental role in autophagy, the process by which cells dispose of unwanted 
proteins which is essential for neuronal survival (Nixon and Yang, 2011).  
 
Mutations in PS1 or PS2 lead to amyloidogenic processing of APP with an 
increasing ratio of toxic Aβ42 to Aβ40.   Their role in AD was noted after 
observations that presenilins lead to altered APP processing in the same way as 
APP717 mutations (Scheuner et al., 1996). Approximately 20 point-mutations 
have been identified in PS1 and over 10 in PS2. Most of the pathogenic mutations 
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are missense mutations in residues conserved in the two proteins. They are not 
randomly distributed, but cluster in exon 8 and along faces of the transmembrane 
alpha-helices (Crook et al., 1997; Perez-Tur et al., 1996).  Most single and double 
transgenic mouse models for AD have been developed based on mutations in APP 
and presenilins.  Some triple transgenic models have been developed recently 
including tau or a tau mutation (Oddo et al., 2003). 
 
1.3.2 Late onset Alzheimer’s disease (LOAD) 
Most AD is sporadic, of uncertain cause and occurs in the elderly.  Tau, located 
on chromosome 17, is thought to be activated later in the progression of both 
early onset and late onset disease. Apolipoprotein E allele 4 (ApoE4) located on 
chromosome 19 is associated with LOAD. 
 
1.3.2.1 ApoE 
The ApoE gene is associated with late onset AD and is known as the late onset 
susceptibility gene.  The ApoE gene contains four variants (alleles). Allele 3 is the 
most common.  Allele E2 reduces the risk of getting AD, but allele E4 increases 
the risk of getting the disease.  It is suggested that ApoE4 promotes excess 
deposition of Aβ42 in a similar manner to the mutations of the other genes 
associated with AD (Esler et al., 2002; Golabek et al., 1996).  Importantly, E3 and 
E4 bind to different lipoprotein particles.  E3 and E2 bind preferentially to high-
density lipoproteins (HDL).  E4 preferentially binds very low lipoproteins 
(VLDL).  There is an increased prevalence of ApoE E4 in late onset AD (Corder 
et al., 1998) but it is unclear how it perturbs the cellular activity; however, the 
ApoE E4 allele is without a cysteine that will affect its ability to crosslink with 
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other molecules by disulphide bridging.  It is also suggested that E4 preferentially 
binds very low lipoproteins (VLDL) because its structure is different from E3 
(Ruiz et al., 2005).   The amino acid substitution R112C, causes a hidden arginine 
at position 61 to point outwards and this then forms a salt-bridge between with 
glutamic acid at position 255. This completely changes the conformation of the 
structure and causes this isoform to bind preferentially to VLDL instead of HDL. 
In addition the cysteine in apoE2 and apoE3 means that they form dimers (via a 
disulphide bond) whereas apoE4 does not. This affects lipid binding, the dimers 
reducing LDL binding. ApoE4 also has a greater tendency to form a molten 
globule state being more unstable. ApoE2 is most stable at the N-terminal region 
and this may contribute to its reported protective effect in AD. 
 
1.3.2.2 Other genes associated with LOAD 
Other genes have also recently been identified with LOAD: clusterin (CLU), also 
known as ApoJ (apolipoprotein J) and PICALM (phosphatidyl-inositol-binding 
clathrin assembly lymphoid-myeloid leukaemia gene) an intracellular signalling 
protein (Harold et al., 2009).   ApoJ has previously been linked with expression of 
cholesterol (Gelissen et al., 1998) and ischaemic heart disease. ApoJ is known to 
be induced in myocarditis and numerous other inflammatory injuries (McLaughlin 
et al., 2000).  Clusterin is now identified with Aβ clearance due to its action in 
removing cellular debris. Angiotensin-converting enzyme (ACE) has significantly 
increased levels in the AD brain (Miners et al., 2009b). 
 
Other mutations and genes have also been identified with AD but they present a 
lower risk. These include on chromosome 12 (Scott et al., 2000), an 
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antichymotrypsin gene, serotonin transporter gene, butyryl cholinesterase E gene 
and various ApoE receptor genes.  More recently two more genes associated with 
AD have been identified.  Sortilin-related receptor (SORL 1) protein protects 
neurons but varients in the gene increase Aβ production (Lee et al., 2008). GRB2-
associated binding protein 2 (GAB2) is a modifying factor of ApoE epsilon 4 
allele (Williamson et al., 2009) but another group found no link with GAB2 when 
genotyping 1116 individuals (521 AD patients and 475 normal controls) from a 
national population in Spain  (Ramirez-Lorca et al., 2009).    
 
1.3.3 Risk factors for sporadic, late onset AD (LOAD) 
 
AD is a complex disease and its pathogenesis is probably multifactorial but can be 
influenced by genetic factors.  Studies consistently identify the main risk factors 
as increasing age, genetic susceptibility especially the presence of the apoE4 
polymorphism, obesity and diabetes.   
 
ApoE is the best established genetic risk factor for LOAD. The presence of the 
ApoE4 polymorphism increases the chance of developing sporadic AD.   ApoE 
has 3 main polymorphisms, with E2 and E4 differing each from E3 by only one 
amino acid: 
ApoE2 – C158 & C112 
ApoE3 – R158 & C112 
ApoE4 – R158 & R112 
 
ApoE4 may be such a robust risk factor for AD for a number of reasons. One of 
these is that it is poorly lipidated. The E4 form, because of its constrained 
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structure, compared with other isoforms, is not able to bind HDL but binds VLDL 
instead. Lipidated ApoE3 is able to bind Aβ  and  thus to clear it from the brain. 
ApoE4, being less lapidated, binds to Aβ and fibrillises it rather than clears it. 
However all the polymorphisms are associated with NFTs and Aβ plaques in the 
brain.  In the transgenic model of a cross of the knockout ApoE mouse with a 
mutant APP (mAPP) over-expressing mouse has shown reduced amyloid plaques 
without changing the total amount of Aβ produced.  ApoE receptors mediate 
several intracellular signalling kinases including PI3K, CDK-5, JnK and MAPK, 
some of which are involved with phosphorylation of tau.  ApoE receptor binding 
APP and Reelin also influence cell signalling.  Reelin increases neurite outgrowth 
possibly by keeping APP at the cell surface and not allowing its endocytosis (Hoe 
and Rebeck, 2008).  
 
In the search for environmental factors, diet has been investigated.   In a three-
centre study in France, between 1999 and 2004, the conclusion was that ‘frequent 
consumption of fruits and vegetables, fish, and omega-3 rich oils may decrease 
the risk of dementia and AD, especially among ApoE4 non-carriers’ (Barberger-
Gateau et al., 2007).  Antioxidants and certain naturally occurring dietary 
polyphenolic phytochemicals have all been investigated, in particular, curcumin 
from turmeric, resveratrol from grapes and wine, and green tea catechins, 
epigallocatechin gallate (EGCG) because of their anti-amyloidogenic, anti-
oxidative, and anti-inflammatory properties (Kim et al., 2010).  It is claimed that 
protection against Aβ-induced cytotoxicity can be shown for some antioxidants.  
In addition, increased activities of superoxide dismutase and catalase have been 
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shown to inhibit neuronal cell death induced by Aβ (Behl et al., 1994; Qin et al., 
2002).  Studies have also suggested a link between dietary intake of antioxidants 
and a reduced risk for AD (Gonzalez-Gross et al., 2001; McDaniel et al., 2003).   
 
In the early stages of AD, aerobic exercise slows the progression, ‘showing a 
positive effect on cognition, glucose metabolism, and hypothalamic-pituitary-
adrenal axis and trophic activity’, particularly in women (Baker et al., 2010).  
 28 
1.4 The amyloid cascade hypothesis 
It was first proposed that the neurodegeneration in AD may be caused by the 
accumulation of Aβ in extracellular plaques in brain tissue.  This became known 
as ‘the amyloid cascade hypothesis’, showing that accumulation of extracellular 
Aβ in the brain is the primary event in the development of AD (Hardy and 
Higgins, 1992) (Figure 1.6).  
 
 
 
 
Fig. 1.6.  The amyloid cascade hypothesis.  
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Other processes of the disease occur later, including formation of NFTs.  NFTs 
are thought to result from an imbalance between Aβ production and clearance. 
 
 
There has been recent evidence that intracellular soluble oligomeric Aβ 
accumulation is more likely the cause of a pathological cascade (Wirths et al., 
2004), leading to the clinical signs of AD and the amyloid cascade hypothesis has 
subsequently been modified (Hardy, 2009; Wirths et al., 2004).  The observation 
of intermediary toxic soluble oligomers of Aβ initiating AD (2a in Figure 1.6), 
would help explain why amyloid plaque deposits have also been found in 
cognitively normal elderly patients.   There is evidence to support the effects of 
intracellular Aβ, for when Aβ42 fibrils were injected into the brains of P301I 
mutant tau transgenic mice, the intracellular Aβ was able to influence NFT 
formation (Gotz et al., 2010). 
 
In AD, Aβ accumulates as a result of an imbalance between the production of Aβ 
and its removal from the brain, with increasing evidence that in the majority of 
sporadic forms of AD, the accumulation of Aβ is a result of defects in its removal 
(Miners et al., 2008). The secretases influence the production of Aβ.  BACE1 is 
recognised as a rate-limiting enzyme affecting the production of the peptide from 
APP.  A recent publication suggests regulation also occurs by ADAM10 
suppressing the α-secretase cleavage, allowing the β-secretase to cleave 
preferentially, thereby increasing Aβ production (Kuhn et al., 2010).  There are 
several enzymes identified in the degradation of Aβ, most of which are expressed 
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in neurons or glia, but some are found in the cerebral vasculature.  These include 
including plasmin, insulin degrading enzyme (IDE), endothelin-converting 
enzymes (ECE1 and ECE2) and neprilysin (NEP) and angiotensin converting 
enzyme (ACE).  NEP is a zinc metalloendopeptidase localised to the plasma 
membrane where it functions to degrade extracellular peptides.  Findings suggest 
that reduction in NEP and IDE activity is not the primary cause of Aβ 
accumulation in AD but rather a late-stage phenomenon secondary to 
neurodegeneration (Miners et al., 2009a). 
 
 
1.5 Proteomic analysis in AD 
Proteomic studies of cerebrospinal fluid (CSF), blood and AD brain tissue have 
identified numerous proteins linked to the development of AD (Korolainen et al., 
2010).  However it is unusual for different proteins to be replicated in different 
studies.  Korolainen’s recent review noted only seven proteins showing similar 
changes in at least two studies performed by independent laboratories where the 
same brain regions were analysed. These seven proteins were: aldolase A in the 
frontal cortex, heart specific fatty acid binding protein (H-FABP) in the temporal 
cortex, peptidyl prolyl cis-trans isomerise (Pin1) and ubiquitin carboxy-terminal 
hydrolase L-1 (UCH-L1) in the frontal cortex as well as increased levels of α-
enolase in hippocampus, glial fibrillary acidic protein (GFAP) in the frontal 
cortex, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampus. 
For this thesis, a proteomic approach was taken to identify proteins up-regulated 
in the brain tissue of two novel AD mouse models.  The tissue was examined 
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from mice at 4 months and 8 months of age to imitate closely early and late stage 
AD pathology.  All additional factors contributing to the onset and progression of 
the disease is of great importance in order to develop both preventive and 
therapeutic intervention. 
 
1.6 Diagnosis of AD 
Criteria for clinical diagnosis of AD relies on a diagnosis of dementia using the 
mini-mental state examination (MMSE) (Folstein et al., 1975) combined with 
deficits in two or more areas of cognition.   Other systemic orders that could give 
rise to similar symptoms, such as a brain tumour, need to be excluded.  Other 
forms of dementia also need to be excluded. The MMSE results need to be 
supported by progressive deterioration of memory, cognition and other 
neuropsychological aspects such as language (aphasia), motor skills (apraxia) or 
perception (agnosia) (McKhann et al., 1984). 
 
At present there is no a simple biochemical diagnostic test for AD.  Diagnostic 
tests include cerebrospinal fluid (CSF) analysis after an invasive spinal tap, 
showing concentrations of tau and phosphorylated tau proteins and a change in the 
ratio of Aβ40:Aβ42 over a period of time (De Meyer et al., 2010).  This study 
examined CSF in 102 Alzheimer's patients, 200 people with mild cognitive 
impairment and 114 individuals with no cognitive impairment. They found low 
amyloid levels and high phosphorylated tau levels present in 90% of the AD 
patients, 72% with mild cognitive impairment (MCI) and 36% in individuals with 
no cognitive impairment. High phosphorylated-tau levels and low amyloid levels 
identified patients with MCI who progressed to Alzheimer's with 100% accuracy.   
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Brain imaging has become very useful in identifying markers early in the 
progression of the disease. Magnetic resonance imaging (MRI) and computerized 
axial tomography (CAT) scanning can show gross anatomical and structural 
changes in the brain.  This is useful in differentiating AD from frontotemporal 
dementia.  AD is usually characterized by global atrophy with prominent atrophy 
of the medial temporal lobe.  MRI can help in establishing clinical progression by 
monitoring atrophy of the amygdala or hippocampus by measuring its size and 
shape.  The amygdala, an area of the brain, anterior and superior to the 
hippocampus, atrophies in a comparable manner to the hippocampus.  Amygdala 
atrophy is strongly related to MMSE results (Poulin et al., 2011).  Brain imaging 
using radioisotope labelled compounds can show brain function and metabolism. 
A change in brain metabolism normally precedes any structural change 
(Scheltens, 2009).  Positron emission tomography (PET), using 2-[18F] fluoro-2-
deoxy-D-glucose, (18F-FDG PET) enables glucose metabolism in the brain to be 
assessed.  The 18F-FDG is located in the brain where there is the most glucose 
metabolism. The gamma radiation from 18F is detected using a gamma camera, a 
series of photomultiplier tubes targeted onto a large flat crystal plate of sodium 
iodide that scintillates when hit by the gamma photons.  Increased levels of 
metabolism are shown by a greater incidence of radiation. Studies have shown 
that individuals with normal cognitive functions, but who have a mother with late 
onset AD, show reduced glucose metabolism, similar to patients with AD 
(Mosconi et al., 2010) indicating a predisposition to AD later in life.  It is possible 
to identify Aβ deposits in the brain with PET using 11C Pittsburgh compound-B 
(11C-PIB) in a similar way.  PIB binds to extracellular fibrillar deposits and is a 
sensitive marker for cognitively normal, MCI and individuals with AD.  PIB-PET 
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imaging confirms the early accumulation of Aβ in cognitively normal elderly 
patients, progressing to greater accumulation in AD.  PIB-PET may help select 
suitable anti-amyloid treatment when used with clinical assessment (Rabinovici et 
al., 2010). However to date the only absolute confirmation of the disease is at post 
mortem.   
 
 
1.7 Treatment for AD 
1.7.1 Current drug treatment specific for AD 
Drug treatments currently available are used to stabilise symptoms, but do not 
affect the pathological progression.  These are cholinesterase inhibitors, 
galantamine, rivastigmine and donepezil, drugs which reduce the breakdown of 
the neurotransmitter acetylcholine at the synapses in the brain.  Alzheimer patients 
have low levels of acetylcholine and these drugs are used in the early to mid 
stages of the disease.  One other drug, memantine, is a glutamate receptor 
antagonist of AMPA/NMDA receptors, protecting neurons against excess of 
glutamate and inhibiting prolonged influx of Ca2+.    The receptor function is not 
disrupted and is still activated by high concentrations of glutamate released after 
presynaptic neuron depolarisation. Reviews have shown it has a small positive 
effect on cognition, mood, behaviour and the ability to perform daily activities in 
moderate to severe AD (Herrmann et al., 2011b).  This is the first drug designed 
to act on the glutamergic system.  In the UK memantine is licensed for use in 
moderate to severe cases of AD but is not routinely provided by the NHS.   
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1.7.2 Other drug treatments 
Both oxidative damage and inflammation are elevated in AD.  A reduced AD risk 
has been associated with a high intake of both non-steroidal anti-inflammatory 
drugs (NSAIDs) and antioxidants.  Studies with transgenic APP mice with the 
Swedish mutations (TgAPPsw) (see Table 1.1.) showed ibuprofen reduces 
amyloid accumulation without suppressing many inflammatory markers (Cole et 
al., 2004). The anti-inflammatory omega-3 fatty acid docosahexaenoic acid 
(DHA) had a very significant impact on pathogenesis but did not significantly 
reduce inflammation, while surprisingly vitamin E was not effective in reducing 
oxidative damage or amyloid in the aged APPsw mouse (Amtul et al., 2011). In 
contrast, the NSAID/antioxidant curcumin lowered oxidative damage, cognitive 
deficits, synaptic marker loss, and amyloid deposition. Curcurmin 
(diferuloylmethane) is a polyphenol similar to green tea, epigallcatechin 3-gallate 
(EGCG).  In a neuronal cell culture study, both curcumin and EGCG suppressed 
Aβ induced BACE-1 upregulation and both significantly reduced amyloid 
induced reactive oxygen species (ROS) production (Shimmyo et al., 2008).  Other 
studies have shown that NSAID, taken for other medical reasons, afford some 
protection from AD (Gasparini et al., 2004).  It has also been reported that taking 
statins, normally prescribed to reduce cholesterol levels have beneficial 
neuroprotective effects.  Statins, which lower neuronal cholesterol, have been 
shown to decrease the amount of Aβ secreted by neurons (Ostrowski et al., 2007).  
One study shows that use of statins in cell cultures result in a large increase of 
secreted soluble APPα and ADAM 10 was responsible for the α-secretase activity 
(Kojro et al., 2001).  However a recent report from the Cochrane Database 
Systematic Review, identified two trials with over 20,000 participants, which 
 35 
concludes ‘There is good evidence that statins given in late life to individuals at 
risk of vascular disease have no effect in preventing AD or dementia’ 
(McGuinness et al., 2009). 
 
A tumour necrosis factor (TNF) antagonist, Etanacept, developed as an anti-
inflammatory for arthritis, has shown temporary cognitive reprieve with perispinal 
administration (Tobinick, 2009). This study reported a rapid improvement in 
verbal abilities, within 20 minutes of administration, in a patient with severe 
primary progressive aphasia. With repeated weekly dosing, sustained 
improvement at one month was documented.  It is unclear how this works, but the 
study hypothesises that this may be related to TNF's role as a gliotransmitter and 
modulator of synaptic communication, although the rapidity of the change 
observed in cognition, mood, memory, motor function and attention suggest they 
are mediated by non-synaptic signalling mechanisms.  The study states that there 
are populations of cells, including CSF-contacting neurons and modified 
ependymal cells, called tanycytes, which have receptive surfaces in direct contact 
with the CSF.  Tobinick hypothesises that CSF-contacting cells may constitute a 
therapeutic target for a diverse group of brain, psychiatric and spinal disorders 
(Tobinick, 2009). 
 
1.8 Current therapeutic and vaccine developments for AD 
      
Development of more suitable drugs for AD is an urgent medical need.  In recent 
years, several approaches aimed at inhibiting AD progression have advanced to 
clinical trials, with those targeting the production and clearance of Aβ being the 
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most advanced. Disease modifying drugs such as α-secretase activators (Kuhn et 
al., 2010), β- and γ-secretase inhibitors, inhibitors of Aβ aggregation and 
enhancers of Aβ degradation, are being developed. Some of these drugs are in 
phase III clinical trials and are expected to be available for clinical use in the near 
future (Tabira, 2010). Approaches aimed at modulating the abnormal aggregation 
of tau filaments and targeting neuronal metabolic dysfunction, are also being 
evaluated such as  ‘Rember’ (methylthioninium chloride or MTC) that is in phase 
II clinical trials (Deiana et al., 2009). 
 
1.8.1  Drugs involved with APP processing 
• BACE1 inhibitors – e.g. CTS-21166 (CoMentis Inc.). Phase II studies 
were due to begin in 2008 but limited information has been released so far.  
Unfortunately, finding suitable BACE inhibitors has been slow (Panza et 
al., 2009). 
• Modulating γ-secretase activity – e.g. (R)-flurbiprofen (Myriad Genetics 
Inc.). Phase III clinical trials, in 2008, showed no benefit when the R-
racemate of flurbiprofen was used (Barrett et al., 2011; Green et al., 
2009). 
• γ-secretase inhibitors- e.g. Semagacestat LY45013 (Eli Lilly). In a 
multicentre Phase II trial, plasma Aβ40 decreased by 58-65% in 100-140 
mg/day groups (Carlson et al., 2011). There are over forty endogenous 
substrates for γ-secretase inhibitors that play critical roles in the adult 
human, most notably Notch which is essential for differentiation of T and 
B lymphocytes.  Phase III trials in 2010 showed a decline in cognitive 
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function compared to the placebo group but was associated with a greater 
risk of skin cancer. Eli Lilly has halted development and Bristol-Myers 
Squibb now have a competitor drug named BMS708163. 
• Prevention of peptide accumulation – e.g. Alzhemed (tramiprosate, also 
called homotaurine) (Neurochem Inc.) is a small molecule designed to 
stop aggregation of Aβ (Aisen et al., 2007). It is similar in structure to 
GABA. Alzhemed is safe and well tolerated, but a North American Phase 
III trial did not meet its 18-month endpoints. 1,052 mild-to-moderate 
Alzheimer's patients received a placebo, or a 100 or 150 mg dose of 
Alzhemed given along with conventional treatments. 
Although not significant, cognitive tests did improve with Alzhemed and 
data suggested an effect on CSF levels of Aβ and tau, and a difference in 
hippocampal volume approached statistical significance. However more 
than 50% of patients on placebo did not show cognitive decline, and some 
who were declining for many months, suddenly started to improve.   The 
FDA is open to Neurochem Inc. adjusting its ongoing European Phase III 
trial to increase the likelihood of success based on knowledge gained in 
the North American trial. 
  
1.8.2 Drugs used for preventing and reversing tau aggregation  
• Methylene blue, methylthioninium chloride (MTC), tradename REMBER 
(TauRx Therapeutics).  This compound was first used by Paul Ehrlich in 
1890. The formulation used by TauRx is different from that commonly 
available and caution has been expressed about the presence of heavy 
metals. It is thought that methylene blue has an effect on tau aggregation 
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and probably aids clearance of tau aggregates. This is orally available and 
has been successful in Phase II clinical trials.  It was given to patients with 
MMSE scores of 10 to 25 (top score = 30).  Overall there was no effect 
because mild AD showed no decline of MMSE. Moderate AD patients did 
decline and MTC showed dose related improvement. There was no effect 
with 100mg, due to cross-linking of protein to the gelatin capsule. This is 
going to a Phase III trial at a cost of $80M.  Using mouse models, SS295-
390 mice (overexpressing tau fragment) that show Braak staging, perform 
badly in T-maze and Morris water maze experiments.  However, this is 
reversed by MTC. Similarly in FTDP-tau mice (P301S/G335D).  
• GSK3 inhibitors - NP031112 (Neuropharma), is a non-ATP GSK3 
inhibitor, down-regulating the phosphorylation of tau and  preventing tau 
phosphorylation (Luna-Medina et al., 2007).  This compound has passed 
Phase I trials. 
• Cdk5 inhibitors. -  The cyclin-dependent kinase Cdk5 is implicated in the 
phosphorylation of tau.  Kosik tested ~58,000 small molecules in a high-
throughput screen of tau phosphorylation and discovered inhibitors that 
block Cdk5 phosphorylation of tau (Glicksman et al., 2007).  Crystal 
structures of inhibitor-enzyme complexes show that two of the 
compounds occupy Cdk5’s ATP pocket. More recently Kosik delivered a 
Cdk5 RNAi that reduced the phosphorylation of tau and decreased the 
number of neurofibrillary tangles in the hippocampi of 3XTg-AD mice. 
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1.8.3 Other treatments 
• Nerve growth factor (NGF) maintains cholinergic neurons and prevents 
their death via the TrkA receptor. In a Phase I clinical trial in Alzheimer’s 
patients, fibroblasts engineered to produce human NGF were implanted 
into the brain near the cholinergic nucleus. Improvements were seen in 
cognition and brain glucose utilization.  Ceregene Inc. (San Diego) 
successfully carried out a Phase I study to assess adeno-associated virus 
(AAV) mediated delivery of NGF (CERE-110).  CERE-110 is an AAV 
serotype 2-based vector producing human NGF administered by 
stereotactic injection to the nucleus basalis.  A USA-based multicentre 
Phase II clinical trial has now begun recruiting patients for a randomized, 
controlled study in up to fifty subjects with mild to moderate Alzheimer's 
disease, with half of the patients due to undergo a placebo surgery with no 
medication injected (Mandel, 2010). 
 
• Folic acid, DHA and increased exercise have been examined in trials or 
epidemiologically.  
 
 
Folic acid and folate (vitamin B9).  Folic acid controls blood levels of the 
amino acid homocysteine, and elevated levels of homocysteine are linked 
to depression and AD.  A few clinical trials with folic acid, e.g. 579 people 
aged ≥60 were followed for 7 years.  Those who consumed ≥ 400 μg of 
folic acid had a 55% less risk of AD (Dangour et al., 2010).   
In a study of 815 people >65 years, eating fish gave a 60% reduction in the 
risk of developing AD. Docosahexaenoic acid (DHA) is an omega 3 fat 
(Oster and Pillot, 2010). 
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Exercise and mental activity.  An exercise programme of 1hr, twice a 
week in 134 AD patients in 5 nursing homes showed reduced decline in 
activities of daily living after 1 year. >800 elderly patients in Chicago 
followed over four years showed that AD was more than double in lonely 
persons. This confirms behavioural studies that show enriched 
surroundings improve mental function. DHA on its own did not improve 
AD symptoms. 
 
 
1.8.4 Vaccines 
Active and passive forms of immunotherapy against Aβ have shown lowering of 
its cerebral levels and improved cognitive function in animal mouse models.  An 
active, immunotherapeutic treatment was developed following positive results in 
transgenic mice (PDAPP V717F). The mice developed fewer plaques after 
immunisation with full length Aβ42 peptide both before and after onset of AD 
pathology (Vehmas et al., 2001).  An Aβ vaccine, produced by Elan Corporation, 
reached phase II clinical trials in 2002 but had to be withdrawn when 6% of 
patients developed encephalitis.  However some of the results from this trial 
demonstrated some cerebral clearance of Aβ and a moderate improvement in 
cognitive function (Schenk, 2002).  Following this, there are at least seven passive 
Aβ immunotherapies in clinical trials in patients with mild to moderate symptoms.  
The Aβ42 peptide has been shortened.  At least two examples use only the N 
terminal residues 1-6.  Several active Aβ vaccines are also in clinical trials.  From 
the pre-clinical data, these vaccines appear to be the most effective in slowing the 
disease when given at an early stage in the disease (Lemere and Masliah, 2010).   
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Passive vaccination injects antibodies directly into the patients, crossing the blood 
brain barrier and stimulating a microglial response, without involving T cells.  Eli 
Lilly have a phase III clinical trial running, using Solanezumab.  So far this has 
shown Aβ40 and Aβ42 serum levels increasing, indicating reduced levels in the 
brain.  Other phase II trials are being run by Pfizer Inc., Elan Corp., and Johnson 
& Johnson with Bapineuzumab.  Results have been mixed so far and the 
companies are having difficulties getting patients to volunteer for Phase III trials. 
 
1.9 Mitochondrial dysfunction in AD 
Mitochondrially-generated and age-dependent reactive oxygen species (ROS) are 
important factors responsible for cell death and disease progression, particularly 
in late-onset diseases, where genetic mutations are not causal factors (Reddy, 
2009a, b).  Mitochondrial dysfunction and oxidative stress have been proposed as 
important mechanisms in the development of AD.  Important cellular functions of 
the mitochondria include ATP production by phosphorylation of ADP, generation 
of ROS, regulation of calcium homeostasis and initiation of the apoptotic 
pathway.  The mitochondrial electron transport system is the major source of free 
oxygen radicals and hydrogen peroxide.  ROS also cause damage to mitochondria 
(Polidori et al., 2007).  The brain is particularly vulnerable to ROS damage due to 
lack of antioxidant enzymes compared to other organs.  It is thought that 
impairment of mitochondrial function leads to reduction of ATP and an increase 
in free radicals leading to neurodegeneration in AD (Polidori et al., 2007).  
Positron emission tomography showed a decline in cerebral metabolic activity in 
parietal and temporal lobes in AD patients (Kessler et al., 1991).  This indicated 
possible mitochondrial dysfunction. 
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Studies have shown that Aβ plaques do not significantly affect neuronal survival 
(Carpenter et al., 1993).  But transient intraneuronal accumulation of Aβ, in the 
early to middle stages of AD, cause neuronal damage and death (Christensen et 
al., 2008a; Christensen et al., 2008b; LaFerla et al., 2007).  Intracellular Aβ has 
been found to affect cellular function by disturbing mitochondrial respiration (Yan 
and Stern, 2005).  There is growing evidence for the role of soluble intracellular 
Aβ in the progression of AD (Muirhead et al., 2010).  Three proteins in the 
mitochondria have been identified as binding Aβ: ABAD, cyclophilin D (CypD) 
and heat shock protein 60 (Hsp60) (Caspersen et al., 2005; Du et al., 2008; 
Lustbader et al., 2004). The interactions of Aβ with these proteins interfere with 
their normal functions, resulting in damage and eventually death to the cell. Aβ 
binding to ABAD and CypD results in increased levels of ROS leading to 
neuronal death. 
 
1.9.1 3-hydroxyacyl-CoA dehydrogenase (HADH2/ABAD) 
There are two fatty-acid beta-oxidation systems in most eukaryotic cells, one 
located in the mitochondria and one in the peroxisomes (Birktoft et al., 1987). 
HADH2/ABAD is a member of the short-chain dehydrogenases/reductases (SDR) 
family and is a multifunctional mitochondrial enzyme acting as an 
oxidoreductase.  The human HADH2 gene is mapped to the chromosome X, 
(Location: Xp11.2), coding for a 261-residue protein (Q99714- UniprotKB) with a 
molecular weight of 27kDa.  HADH2 is expressed in all tissues and is also found 
to be over-expressed in neurons of patients with AD at post mortem (Yan et al., 
1997a) suggesting a role in the neuronal dysfunction associated with this disease.   
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From a yeast two hybrid screen using a murine brain library, HADH2 was the 
only protein identified to bind Aβ (Yan et al., 1997a). From this observation 
HADH2 became known as amyloid-binding alcohol dehydrogenase (ABAD), and 
this name is now used when associated with AD.  The first eleven amino acids at 
the N terminal are thought to be a mitochondrial targeting sequence, but HADH2 
has also been identified in the endoplasmic reticulum (ER) (Yan et al., 1997a).  
Because of this link, in the literature HADH2 is also known as ERAB, 
Endoplasmic Reticulum binding Amyloid Beta.  ABAD has since been identified 
within the mitochondria, but it is suggested that its distribution may be cell-line 
dependent (Frackowiak et al., 2001). Other names have also been allocated; 
SCHAD, Short Chain L-3Hydroxyacyl-CoA Dehydrogenase; and 17β-HSD10, 
17β- Hydroxysteroid Dehydrogenase Type 10, as it also oxidises simple alcohols 
and hydroxysteroids, in particular 17β-estradiol.  As an enzyme, ABAD catalyses 
a broad spectrum of substrates (Table 1.2). 
 
 
Table 1.2. The substrates of ABAD, taken from (Muirhead et al., 2010).  
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1.9.2 ABAD/Aβ  interaction 
The first report of an interaction between ABAD and Aβ reported a Kd of 88nM 
(Yan et al., 1997a).  Confirmation of ABAD binding Aβ has since been reported 
by a number of different techniques. Including X-ray crystallography (Lustbader 
et al., 2004), SPR (Yan et al., 2007b), ELISA based studies (Xie et al., 2006), co-
immunoprecipitation (Frackowiak et al., 2001; Yan et al., 2007b) and 
immunocytochemistry followed by confocal microscopy (Lustbader et al., 2004).   
Aβ40 and Aβ42 both inhibit the activity of ABAD with Ki  values of 1.2-1.6 µM 
for the reduction of acetoacetyl-CoA (Oppermann et al., 1999; Yan et al., 1999), 
2.6 µM for the oxidation of octanol and 3.2 µM for the reduction of 17β-
oestradiol (Yan et al., 1999).  These concentrations are higher than the nanomolar 
binding constants of ABAD to Aβ.  This implies that Aβ monomers are not 
enough to cause ABAD inhibition and that Aβ aggregation may be required to 
alter the ABAD structural conformation.  The Opperman study showed that 
residues 13-22 of Aβ were critical for inhibiting ABAD activity.  This region, 
residues 16-20, is also characterised by its fibril forming properties. 
 
Recently, several studies have shown that Aβ is found in the mitochondria 
(Caspersen et al., 2005; Lustbader et al., 2004), which supports the hypothesis 
that the ABAD/Aβ complex is involved in the pathogenesis of AD. The Aβ 
peptide is generated  in cells before extracellular amyloid plaques have formed, 
suggesting a possible early interaction with ABAD, possibly initiating neuronal 
dysfunction.  There is still much interest in the exact mechanism of Aβ toxicity 
and the ABAD/Aβ complex is therefore of interest for its possible role in neuronal 
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damage during the early stages of AD.  In neuronal cell culture studies, Aβ is 
independently cytotoxic, but the ABAD/Aβ complex enhances this toxicity, 
coincidentally generating the toxic aldehydes, malondialdehyde and 4-
hydroxynonenal (4HNE), leading to oxidative stress (Yan et al., 1997a).  The 
enzymatic activity of ABAD is essential for this toxicity, as mutations at the 
catalytic binding site have been shown to inhibit the cytotoxic effects (Yan et al., 
1999).  
 
1.9.3 The function of ABAD 
The primary function of ABAD as a mitochondrial enzyme, is to catalyse the third 
stage of β fatty acid metabolism.   It catalyses the oxidation of 3-hydroxyacyl-
CoA to 3-ketoacyl-CoA by reduction of NAD+ (Figure 1.7).  As this is its main 
function, ABAD is involved in energy production and may be important in 
glucose-deficient environments, where other energy sources become more 
significant e.g. in situations of neuronal stress.   An example is the increased 
ability of cells to use ketones as an energy source, when ABAD was 
overexpressed in COS cells (Yan 2000).   Overexpression of ABAD can have a 
positive effect with regard to cellular stresses and probably plays a cytoprotective 
role during stress.   For example, in mouse stroke models, following transient 
middle cerebral artery occlusion, ABAD expression was increased in both 
transgenic ABAD overexpressing and wild type mice.  However the transgenic 
animals showed fewer effects of the stroke, and fewer neurological deficits (Yan 
et al., 2000b). Conversely, ABAD levels were shown to be decreased in the 
ventral midbrain of PD (Parkinson’s disease) patients, and in the ventral midbrain 
of 1-methyl-4-phenyl-1,2,3,6,tetrahydrapyridine (MPTP) mice.  MPTP-treated 
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mice overexpressing HADH2/ABAD were protected against apoptosis and the 
loss of dopaminergic neurons in this brain region (Tieu et al., 2004). 
 
Other functions of HADH2/ABAD have been identified, such as oxidation of 
alcohols and hydroxysteroids eg. 17β-estradiol (He et al., 1998), and with the 
degradation of isoleucine (Ofman et al., 2003).  Ofman identified the molecular 
basis for clinical cases of (2-methyl-3-hydroxybutyryl-CoA dehydrogenase) 
MHBD deficiency.  Mass spectrometry identified the MHBD protein to be 
identical to HADH2.  Sequence analysis of the HADH2 gene from patients with 
MHBD deficiency revealed two missense mutations (R130C and L122V) (see 
1.9.11). 
 
1.9.4  Fatty acids and β-fatty acid oxidation 
Fatty acids are long hydrocarbon chains, typically 14 - 24 carbons, terminated 
with a carboxylate group.  They have four major physiological roles: 
1. They are building blocks of phospholipids and glycolipids.  
2. They modify proteins by covalent attachment, which targets them to cell 
membranes. 
 3. They are an important source of energy and ATP for cells.  They produce more 
energy than carbohydrates and are stored as triacylglycerols in adipose cells until 
required.   
4. Fatty acid derivatives act as hormones or intracellular messengers.  The 
triacylglcerols are degraded in the cells by lipases and released into the blood 
plasma as insoluble free fatty acids and glycerol.  The fatty acids are bound by 
serum albumin and are transported to the tissue requiring fuel.  They are released 
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by the serum albumin to cross the cell membrane into the cytosol. They are then 
activated on the outer mitochondrial membrane to produce Acyl CoA.  
 
 The Acyl CoA is transported across the outer mitochondrial membrane 
conjugated to carnitine, to produce Acyl carnitine, catalysed by carnitine-
palmitoyl transferase1 (CPT-1) that is bound to the outer mitochondrial 
membrane.  Acyl carnitine is further transferred across the inner mitochondrial 
membrane by a carnitine-acylcarnitine translocase. Once on the matrix side the 
acyl group is transferred back to CoA.  Once in the mitochondrial matrix, Acyl 
CoA undergoes β-oxidation, which is a recurring sequence of a four-stage 
process: 1. oxidation by flavin adenine dinucleotide (FAD) to FADH2, 2. 
hydration, 3. oxidation by NAD+, and 4. thiolysis by CoA.  
 
During the four stage process two carbon molecules are repeatedly cleaved from 
the Acyl-CoA.  At the  end of the process Acetyl-CoA is produced which enters 
the citric acid cycle which eventually produces ATP, the energy required by the 
cell (Figure 1.7). 
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Fig. 1.7. Four step fatty-acid β-oxidation pathway. HADH2/ABAD is highlighted in the 
black box. 
 
 
1.9.5  Crystal structures of ABAD 
The 3D protein structures from rat and human ABAD have been determined by 
crystallography (Barycki et al., 2000; Birktoft et al., 1987; Engel et al., 1996; 
Lustbader et al., 2004; Powell et al., 2000) .  These include a structure of ABAD 
with its cofactor NAD+ (Birktoft et al., 1987; Powell et al., 2000), human ABAD 
binding Aβ (Lustbader et al., 2004), and human ABAD with a small molecule 
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inhibitor (Kissinger et al., 2004).  All show it to exist as a tetramer and identify 
residues Ser155, Tyr168 and Lys172 as key conserved residues in the catalytic 
binding site (Figures 1.8, 1.9). Mutation at these residues to glycine, inactivate the 
enzyme activity (Yan et al., 1999).   The crystal structure with Aβ was unable to 
see electron density for the Aβ but the active site and NAD+ binding sites were 
distorted as evidence of its presence, with no co-factor present. SDS-PAGE of the 
crystal confirmed the ABAD/Aβ complex. Further studies of ABAD binding to 
Aβ using SPR confirmed binding at nanomolar concentrations (Yan et al., 2007a).  
Saturation-transfer difference NMR showed competitive binding of ABAD with 
Aβ inhibiting the binding of NAD+ in a concentration dependent manner.  
Conversely the ability of Aβ to bind to ABAD was reduced in the presence of 
NAD+ (Lustbader et al., 2004). 
 
10         20         30         40         50         60  
MAAACRSVKG LVAVITGGAS GLGLATAERL VGQGASAVLL DLPNSGGEAQ AKKLGNNCVF  
        70         80         90        100        110        120  
APADVTSEKD VQTALALAKG KFGRVDVAVN CAGIAVASKT YNLKKGQTHT LEDFQRVLDV  
       130        140        150        160        170        180  
NLMGTFNVIR LVAGEMGQNE PDQGGQRGVI INTASVAAFE GQVGQAAYSA SKGGIVGMTL  
       190        200        210        220        230        240  
PIARDLAPIG IRVMTIAPGL FGTPLLTSLP EKVCNFLASQ VPFPSRLGDP AEYAHLVQAI  
       250        260  
IENPFLNGEV IRLDGAIRMQ P 
Fig. 1.8 Amino acid sequence of ABAD: highlighted in yellow are residues (S155, Y168, 
K172) which on mutation inactivate the enzyme activity. Underlined 93-116 (loop D) 
found in TAT-ABAD 24aa inhibitor (see Chapter 3). Highlighted in blue are the two 
mutations (L122V and R130C) seen in MHBD deficiency. 
 
 
1.9.6  Structure of ABAD - mutations and activity 
Structures of rat ABAD indicated the presence of an active site loop, from 
residues 200-220 in the rat ABAD and from the conformation indicated that Thr 
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208 of this loop would form a strong hydrogen bond with the substrate (Powell et 
al., 2000).   The same study showed that binding with either 3-ketobutyrate or 
17β-oestiadol as substrates bound in the same position within the active site. 
These structures showed the close proximity of the substrate-binding site to the 
catalytic site.   Molecular modelling (Marques et al., 2008) suggests that without a 
substrate the loop is in an open conformation but closed in the presence of NAD+.   
Rat and human ABAD have two significant insertions between 100-110 and 140-
150 compared with other HAD type I short chain enzymes.  A model of CoA 
binding in the active site has suggested that CoA linked substrates are more 
efficiently oxidised when bound to the positively charged residues in the 100-110 
region and this would indicate that the sex steroids are not the main substrates for 
ABAD (Kissinger et al., 2004; Powell et al., 2000).  The region comprising 
residues 100-110 was a disordered loop in the crystal structure of ABAD binding 
Aβ (Lustbader et al., 2004).  Point mutations with alanine at residues within this 
loop region prevented the binding of Aβ to ABAD.  Two groups of residues were 
highlighted as important: Ser98, Lys99, Thr100, Tyr101 and Thr108, His109, 
Thr110.  This region is thought to be Aβ binding specific as similar bacterial 
enzymes 3β/17β dehydrogenase and HADH1 are unaffected by Aβ and do not 
contain this loop (Figure 1.9) (Lustbader et al., 2004). The lack of order in the Aβ 
component of the complex is either due to high levels of flexibility within the 
amino acid chain of Aβ or due to a disordered aggregation of the peptide, which 
would fit with the aggregation hypothesis. Figure 1.9 also shows the tetrameric 
structure of human ABAD in complex with NAD and a small molecule inhibitor.  
 
 51 
 
 
 
 
 
 
 
 
Fig. 1.9. 3D crystal structure of ABAD. (A) Monomer of rat ABAD in presence of Aβ 
showing active site residues S155, Y168 and K172 (Protein Data Bank (PDB) code 
1so8). (B) Monomer of rat ABAD in complex with NADH (PDB code 1e3s). (C) 
Superposition of rat ABAD shown in A and B, with the loop (residues 94-114) that is 
disordered in the presence of Aβ highlighted in darker blue. (D) Tetrameric structure of 
human ABAD (PDB code 1u7t) with NAD in atom colours in one monomer, and the 
covalent complex formed between NAD and an inhibitor shown in grey in the other three 
monomers. All pictures drawn with PyMol (Schrödinger Inc.) 
 
 
A 
B 
C D 
 52 
1.9.7 Aβ and ABAD expression 
Aβ influences ABAD expression. Transgenic mAPP mice show increased ABAD 
expression in the hippocampus (Yan et al., 1997a). This increased expression has 
also been observed in neurons in the temporal lobes of AD brains. Overexpressing 
a catalytically inactive form of ABAD in the presence of Aβ does not enhance 
cytotoxicity in cell cultures compared with Aβ alone. Therefore cellular effects 
are not simply based on the inactivation of ABAD, but are due to other 
downstream effects mediated by the active enzyme once bound with Aβ. This is 
supported by the observed discrepancies in the binding constants of Aβ and 
ABAD (in the nanomolar range) and the Ki values determined for the inhibition 
of ABAD by Aβ (in the micromolar range).  
 
1.9.8 Toxicity of ABAD plus Aβ  
Aβ was found to increase DNA fragmentation and apoptosis in SK-N-SH cells 
and reduce cell viability as detected by MTT assay; 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a yellow tetrazole, that is reduced to purple 
formazan in living cells. These effects were reduced in the presence of anti-
ABAD antibodies, indicating the interaction ABAD and Aβ was important for the 
toxicity (Yan et al., 1997a). Apoptosis and DNA fragmentation were also greatly 
enhanced in COS cells co-transfected with plasmids expressing Aβ and ABAD, or 
mAPP and ABAD, compared with those transfected with Aβ or ABAD alone 
(Yan et al., 1999). The toxicity was not seen in cells transfected with a mutant 
ABAD that made it inactive, in the presence of Aβ, despite Aβ having a similar 
binding affinity for the mutant and wild-type forms (Kd of 64.5 nM and 38.9 nM 
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respectively). This indicates that the toxicity is due to a combination of increased 
ABAD activity and Aβ expression (Yan et al., 1999).   
Increase of toxic aldehydes HNE and MDA are found in AD (Delibas et al., 2002; 
Sayre et al., 1997).  SH-SY5Y or HeLa cells transfected with ABAD and then 
treated with HNE for 24 hours have improved survival (Murakami et al., 2009).  
However cells overexpressing both ABAD and APP (either wild-type or mAPP 
forms) showed increased production of MDA and HNE, compared with those 
expressing ABAD or APPm alone. Transfection with mutant ABAD, that made it 
inactive and mAPP together did not produce this response (Yan et al., 1999). 
Although the ABAD/Aβ interaction induces the production of toxic aldehydes, it 
is possible that ABAD alone is able to remove them.  This suggests that ABAD 
protects against toxic aldehydes such as HNE and MDA and it is proposed that a 
main function of ABAD may be to remove toxic aldehydes but that Aβ inhibits 
this function (Murakami et al., 2009). 
 
 
The toxic effects of overexpressing ABAD, together with Aβ, has also been 
confirmed in an AD mouse model. E18 cortical neurons cultured from double 
transgenic mAPP and ABAD (2 x Tg mAPP/ABAD) mice produced higher levels 
of hydrogen peroxide, decreased mitochondrial function and increased cell death 
(Takuma et al., 2005b).  Mitochondrial dysfunction was observed in vivo in 2 x 
Tg mAPP/ABAD mice, which had decreased glucose utilization and ATP 
production and deficits in spatial and temporal memory as early as 4–5 months 
(Takuma et al., 2005a). These results again emphasize that it is the combination of 
ABAD and Aβ that is necessary for effects to be seen and that these effects occur 
early in the disease. 
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1.9.9 Localisation of ABAD  
Localization of ABAD has been reported to change in the presence of Aβ.   The 
study reported ABAD redistribution from the ER and mitochondria to the inner 
surface of the plasma membrane in the presence of Aβ (applied externally or 
produced from a transfected APP plasmid) (Yan et al., 1997a).  
 
1.9.10 In vivo ABAD/Aβ  
 
The in vitro evidence does not necessarily mean that the enzyme will behave in 
the same way in vivo.  But in vivo binding of ABAD and Aβ has been 
demonstrated by a variety of techniques.  Immunoprecipitation of tissue samples 
of human cerebral cortex identified the ABAD/Aβ complex in AD brains.  Similar 
results were seen in mitochondria isolated from the cerebral cortex of single 
transgenic Tg mAPP and double transgenic 2 x Tg mAPP/ABAD mice (Lustbader 
et al., 2004).  Co-localisation of ABAD and Aβ was shown by 
immunocytochemistry in mitochondria both co-localised with voltage-dependent 
anion channel (VDAC) a mitochondrial membrane protein (Lustbader et al., 
2004).  Aβ influence on ABAD has been shown in Tg mAPP mice and a triple 
transgenic AD model (expressing mAPP, mPS1 and tau) where both showed 
increased ABAD expression in the hippocampus compared to non-transgenic litter 
mates (He et al., 2002; Yao et al., 2009).  Increased ABAD expression in the 
neurons of the temporal lobe has also been seen in human AD brains compared 
with normal age-matched controls (Yan et al., 1997a).  The binding of Aβ to 
ABAD inhibits ABAD activity.  This was shown when Aβ was added to cells 
overexpressing a catalytically inactive ABAD.  The cytotoxicity was not 
enhanced compared to the effects of Aβ alone.  This indicated that the cytoxic 
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effects on cells was not due to ABAD activity alone but must induce some 
downstream effects. This is supported by the discrepancies in the binding 
constants of ABAD and Aβ, which are nanomolar and the ki values determined for 
inhibition of ABAD by Aβ in the micromolar range (Yan et al., 1999).    
 
1.9.11 ABAD deficiency 
Deficiency of this enzyme has been identified and studied in drosophila and 
humans.  In drosophila, deficiency of this enzyme known as Scully, produces 
numerous gross abnormalities and is a lethal phenotype (Torroja et al., 1998).  In 
humans the deficiency is due to two missense mutations, R130C and L122V and 
symptoms in infancy are hyperinsulinaemia, hypoglycaemia and hyperammonia 
syndrome (Filling et al., 2008; Ofman et al., 2003) with a report of sudden infant 
death (Treacy et al., 2000). Other mutations in ABAD (HSD17B10) have been 
identified in males with mental retardation where an imbalance in neurosteroid 
and isoleucine metabolism could be the cause. (Yang et al., 2009). The evidence 
of neuronal involvement with ABAD provides evidence that ABAD may be 
involved in the neuronal damage in AD. 
 
1.10 Mouse models in Alzheimer’s disease 
Mice have been used as animal models in research due to their genetic similarity 
to humans and the ease with which they can be kept in laboratory conditions.  
Transgenic mice were developed in the 1980’s, allowing genetically altered 
animal models to be produced for research into specific diseases.  Animal models 
of disease aim to reproduce the symptoms, the lesions and/or the cause of the 
disease (Duyckaerts et al., 2008).  Due to their rapid rate of reproduction, effects 
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of specific diseases can be monitored over a lifetime of the animal. 
 
Mice have a remarkable genetic similarity to humans, with approximately 85% 
similarity between human and mouse genes.  However the proteins expressed can 
vary considerably in the two species due to post-translational modifications or 
alternative splicing (US Human Genome Project 2011; (Carver and Stubbs, 
1997)).  A study by Strand and colleagues examined if mouse models were a good 
representation for human CNS gene expression.  They reported that expression 
patterns across comparable regions of human and mouse brains have mainly been 
conserved since divergence of the two lineages.  This correlates with the general 
conservation of gross mammalian brain structure, and the conservation of cell 
types within comparable regions of the brain that have long been known from 
classical comparative neuroanatomy. The use of model organisms, or species, is 
also supported by the conserved patterns of gene expression in the mammalian 
brain. Finally, the three brain regions examined in mouse and human brain 
(cerebellum, motor cortex and striatum) are more alike between the two species 
than to different regions of the brain within a species (Strand et al., 2007).  
 
Several genetically modified mice have been bred as models for AD using the 
genes or mutations of genes associated with the onset of the disease.  These are 
APP, PS1, PS2, ApoE4 and Tau protein. Double transgenic (2xTg) mice available 
as models for investigating AD include: Tau + PS1(M146L), tau + APP(swe), APP(V717) 
+ ApoE, APP + AlphaSynuclein   (recently implicated in mitochondrial 
dysfunction in AD (Devi and Anandatheerthavarada, 2010).  A novel triple 
transgenic mouse was developed in 2003, APP(Swe) + PS1(M146V) + tau(P301L) (Oddo et 
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al., 2003). This model exhibits Aβ plaques by 6 months of age as well as 
neurofibrillary tangles by 10-12 months of age, showing both AD phenotypes in 
one model and consistent with the amyloid cascade hypothesis. 
 
Over expressing wild type APP alone does not cause Aβ plaques in most mouse 
lines.  Double transgenic 2xTg APP/mPS1 develop lesions but much earlier than 
expected.  The Tg APP mouse lines have provided information on the kinetics 
involved with cellular changes. But the relationships between behaviour, increase 
in Aβ and the lesions produced are still not completely in synchronisation with the 
human pathology (Duyckaerts et al., 2008).  Other transgenic mice have been 
developed where BACE1 has been knocked out or overexpressed.  Also mouse 
lines with altered expression of neprilysin, the main degrading enzyme of Aβ, 
have been bred. 
 
This project has had access to two novel transgenic mice, Tg ABAD and 2 x Tg 
mAPP/ABAD, which overexpress either ABAD alone or mAPP and ABAD 
which produces an over-production of Aβ.  These mice were specifically bred as 
models for AD for our collaborator, Professor Shi Du Yan at Columbia 
University, New York.   The 2 x Tg mAPP/ABAD mice express high levels of 
ABAD and produce high concentrations of Aβ peptide (Lustbader et al., 2004) 
and their behaviour shows cognitive decline from 5 months but they do not 
develop the tau phenotype. Neurons from the double transgenic mice show 
evidence of free radical-induced stress.   These models have been useful in 
analysing the Aβ toxicity in AD including showing evidence of mitochondrial 
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dysfunction by identifying ABAD and Aβ in the mitochondria (Lustbader et al., 
2004). 
 
 
1.11 Aims of this thesis 
Chapter 3 describes in vitro experiments that were designed to identify the toxic 
effects of the ABAD/Aβ complex and further experiments were then designed to 
identify the type of toxicity induced in the cells.  Fluorescent microscopy was 
used to identify the involvement of the mitochondria by studying the localisation 
of ABAD and Aβ in a neuroblastoma cell line, and MTT assays together with 
western blots were used to analyse the toxicity within the cells.   These 
experiments were planned to evaluate the ABAD/Aβ model in the pathogenesis of 
AD.  Another in vitro cell culture system was developed from murine neuronal 
stem cells to produce neurospheres, and this allowed primary cells to be cultured 
for a minimum of 8 weeks.  Cells could be differentiated to neuronal cells by 
removal of the growth factors.  Cell culture and differentiation of mouse brain 
stem cells was carried out and immunostaining of endogenous mitochondrial 
proteins showed this to be a useful model to develop further. 
 
Chapter 4 describes a proteomic study that was undertaken to identify proteins 
upregulated in a novel AD mouse model.  Proteomic studies are providing 
increasingly detailed information on cellular pathways activated during the 
pathogenesis in AD.  For this thesis two novel transgenic mouse models for AD, 
expressing ABAD (Tg ABAD) or mAPP and ABAD (2 x Tg mAPP/ABAD) were 
used to explore pathways activated by the ABAD/Aβ complex, in particular to 
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identify cellular pathways activated early in AD. 2D gel proteomic analysis and 
MALDI-TOF mass spectrometry identified proteins upregulated in the 2x Tg or 
single Tg genotypes compared with non transgenic littermates.  Further analysis 
by western blot was carried out on 4 month old mice to identify how early protein 
expression changes.   
 
Chapter 5 describes the use of fragment based screening to identify compounds 
that bind to ABAD alone or ABAD in the presence of its NAD+ co-factor.  
Several compounds were identified as potential small molecule binding partners 
to ABAD.   This has been useful as a proof of concept experiment allowing for 
further compounds to be examined.  Finding an inhibitor of the ABAD/Aβ 
complex without disrupting ABAD’s normal function in the mitochondria could 
be another useful therapeutic approach in the treatment of AD. 
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Chapter 2 
Materials and Methods 
 
Most chemicals were supplied by Sigma Aldrich unless stated otherwise.  
Solutions were made with ultrapure distilled water (18 MΩ resistance).  Most 
plastic tissue culture dishes and flasks were sourced from Nunc unless stated 
otherwise.   
 
2.1 Mammalian cells and tissue culture  
All work with mammalian cells was carried out under standard aseptic procedures 
in a class II safety cabinet. Cells were counted using a Beckman Coulter Z1 cell 
and particle counter.  
 
2.1.1 Cell lines 
Two cell lines were used in the work presented in this thesis: SK-N-SH, human 
neuroblastoma (ECACC 86012802); and PC12, rat pheochromocytoma.  Cells 
were obtained from ECACC (The European Collection of Cell Cultures, United 
Kingdom). 
 
2.1.2 Cell culture 
Cell cultures were maintained in 75cm2 vented tissue culture flasks  in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum 
(FCS) (Cambrex, United Kingdom), 2 mM L-glutamine, 100 units/ml of penicillin 
and 0.1 mg/ml streptomycin. Cells were incubated in a humidified incubator, at 
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37°C under 5% CO2.  Cells were routinely passaged when 80-90% confluent (8 x 
106 cells).  They were detached using 1ml trypsin-EDTA in either PBS 
(Phosphate Buffered Saline) or HBSS (Hanks Buffered Salt Solution).  
Immediately after the cells were detached, the trypsin was neutralised by the 
addition of 10% FCS in DMEM and cells were diluted and split 1:6.  Flasks were 
reused for 4 passages. 
 
2.1.3 Cryopreservation and resuscitation of SK-N-SH and PC12 cells 
For cryopreservation, cells were detached with trypsin EDTA and neutralised as 
described in 2.1.2.   The cells were collected into 15ml Falcon centrifuge tube and 
pelleted at 800g for 5min.  The cells were resuspended gently in 4ml 
cryopreservation medium: DMEM, FCS, and 10% DMSO.  1ml cell suspension 
was aliquoted into 1.5ml cryotubes (Corning).  The cells were frozen slowly by 
placing the cryotubes into an isopropanol freezing container (Nalgene) at room 
temperature.  This container was then put into a -70°C freezer for a minimum of 
5hrs.  The gradual freezing of the isopropanol reduces the cell temperature by 1°C 
per hour.  The slow freezing process is optimal for preservation of mammalian 
cells.  The cryotubes were transferred to liquid nitrogen for long term storage.  
For resuscitation, cells were thawed quickly.  After removal from liquid nitrogen, 
the cells were heated by placing in a water bath at 37°C until thawed.  The cell 
suspension was diluted slowly with 10ml pre-warmed DMEM with supplements.  
The cells were then placed in a 75cm2 flask and incubated for 24hrs.  The medium 
was then replaced with DMEM 10% FCS, to remove all DMSO, as this can 
inhibit cell growth.  Cells were grown to 80% confluence and passaged twice 
before use in experiments. 
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2.2 Transfection of cells 
 
2.2.1 Liposomal transfection of DNA into cells 
Twenty four hours before transfection, cells were seeded onto tissue culture 
dishes, at a density of 1 x 104 cells/cm2.  If required for microscopy, the cells were 
seeded onto 22mm2 glass coverslips.  The cells were transfected when 50% 
confluent as a monolayer, using Lipofectamine Reagent (Invitrogen UK) at a ratio 
of 1µg DNA to 4µg Lipofectamine.  Lipofectamine and DNA were mixed in 
serum free OptiMEM (Gibco) and incubated together at room temperature, light 
protected, for 30min.  The cells to be transfected were washed and covered in 
serum free OptiMEM.  The DNA Lipofectamine mix was added dropwise to the 
cells and then incubated for 5-8hrs.  The medium was then replaced with DMEM 
10% FCS plus supplements as required, and the cells incubated for a further 18-
24hrs.  For live imaging, Willco 35mm, glass bottom tissue culture dishes with 
lids were used. 
 
2.2.2 Making stable expressing mammalian cell lines. 
Stable cell lines were made by transfecting 75cm2 vented tissue culture flasks, 
when 50% confluent, with 10µg of the relevant DNA (with G418 resistance) per 
flask, using the Lipofectamine protocol described above and in accordance with 
the manufacturer’s instructions.  Cells were grown for 48hrs after transfection in 
their normal growth medium.  Medium was then supplemented with 1mg/ml 
G418-sulfate and the cells were maintained in this medium thereafter. 
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2.2.3 Cloning out stable cell lines expressing ABAD-EGFP. 
Stable cell lines were cloned out by plating cells at low seeding densities 
(typically 10 to 50 cells) onto 60mm tissue culture plates.  After 10-14 days, 
plates were imaged and plates with individual colonies were chosen.  Selected 
colonies were enclosed and separated from the rest of the plate by placing a sterile 
stainless steel cloning ring around the colony.  The individual colonies were 
trypsinised (as described above) and grown in individual wells in a 96 well tissue 
culture plate to 80-90 % confluency. Transfection was checked by 
immunofluorescent imaging for 95% cells expressing ABAD-EGFP and western 
blot for confirmation using anti ABAD antibody. 
 
2.2.4 Culture of multipotent neurospheres and immunocytochemistry 
(Carried out in the laboratory of Professor Alessandra D’Azzo, St Jude Children’s 
Research Hospital, Memphis, USA.) 
Cerebella and subependymal zones were isolated from brains of 3- to 6-day-old 
newborn mice and dissociated into a single-cell suspension by 5 min incubation in 
0.25% trypsin-EDTA (GIBCO) and trituration with glass pipettes. Single-cell 
dissociates were resuspended in growth medium containing DMEM/F12 
supplemented with N2 growth supplement (GIBCO), 5% FBS, 20ng ml-1 
epidermal growth factor (EGF), and 10 ng ml-1 basic fibroblast growth factor 
(bFGF). The cells were then plated on ultra low attachment polystyrene 6-well 
dishes (Corning Costar) at a density of 100,000 cells ml-1. Cultures were 
supplemented with fresh growth factors every other day. To analyze their cell 
composition, the neurospheres were transferred onto glass coverslips, coated 
sequentially with poly- L-ornithine (10 g ml-1) and laminin (5 g ml-1). The cells 
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quickly attached and began to differentiate. After an additional 48 hr, attached 
neurospheres were fixed in PBS containing 4% PFA, washed well, and processed 
for immunocytochemical analysis with polyclonal antibodies against the 
astrocyte-specific intermediate filament protein, glial fibrillary acid protein 
(GFAP), and the mAb against the neuronal marker β-III tubulin. Images were 
analyzed with the confocal laser scanning microscope (Leica, TCS-NTSP). 
 
2.2.4.1 Differentiation of neurospheres 
Wild-type neurospheres were trituration with glass pipettes to a single cell 
suspension and transferred onto Petri dishes coated sequentially with poly-L-
ornithine (10g ml-1) and laminin (5g ml-1) and grown in DMEM/F12 
supplemented with only N2; FBS or EGF was not added to promote neuronal 
differentiation. Cells were maintained for 2 days in serum-free DMEM and then 
fixed in PBS containing 4% PFA and processed for immunocytochemical analysis 
with polyclonal antibodies. Images were analyzed with the confocal laser 
scanning microscope (Leica, TCS-NTSP). 
 
2.2.5 Fixing cells and mounting for microscopy 
The media was removed from the cells.  The cells were then washed 3 times with 
ice-cold PBS, incubating for 5mins for each wash.   The PBS was removed and 
replaced with ice-cold 4% PFA (paraformaldehyde) to cover the cells.  The cells 
were incubated for 20mins and the PFA removed and discarded in accordance 
with local rules for toxic waste.  Next the cells were rinsed 4 times with ice-cold 
PBS, incubating for 5mins for each rinse. To mount coverslips, the PBS was 
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removed and the cells air-dried for 5mins.  10 - 20µl mounting fluid was pipetted 
onto a microscope slide and the coverslips were placed carefully onto the slide.  
Several mounting fluids were used including Vectashield (Vector Laboratories), 
and Mowiol (Calbiochem).  Mowiol with added anti-fade was the most successful 
and provided a hard set.  DAPI (4’, 6’- diamidino-2-phenylindole), a DNA-
binding fluorochrome, was added for nuclear staining, at a concentration of 0.5 
µg/ml.   Coverslips mounted with Vectashield were sealed at the edges with nail-
varnish. 
 
2.2.6 Preparation of Mowiol mounting medium 
Mowiol is a high quality mounting medium with good anti-fade characteristics.  It 
hardens and matches the refractive index of immersion oil and is particularly 
suited for immunofluorescent microscopy.  Anti-fade DABCO is added to further 
retard photobleaching.   
 
Preparation protocol: 2.4g Mowiol 4-88 (Calbiochem) was added to 6g glycerol 
and stirred briefly with a pipette.  12ml dH2O was added and stirred at room 
temperature for 1-2 hrs.  Then 12ml 0.2M Tris pH 8.5, was added and heated to 
50°C for 1-2hr while stirring.  When the Mowiol had dissolved, it was clarified by 
centrifugation at 55g for 15min.  DABCO was added to 2.5% (0.72g).  DAPI was 
added at 0.5ug/ml.  Bubbles were removed by centrifugation.  1.5ml aliquots were 
stored up to 2 weeks at 4°C or frozen at -20°C for long-term storage. 
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2.2.7 Preparation of 4% PFA (paraformaldehyde)  
4g PFA was added to 100ml PBS.  In a fume hood, it was mixed and heated to 
approximately 60°C and then 6-7 drops of 10M NaOH was added until dissolved.  
It was left to cool and then the pH was adjusted to 7.4 with concentrated HCl.  
The solution was aliquoted and frozen at -20°C. 
 
2.2.8 Permeabilising and immunostaining fixed cells 
After fixing the cells, the PBS was discarded.  0.2%Triton X100 in PBS was 
added to each dish and incubated for 10min at R/T.  Each dish was rinsed 4 times 
with PBS, incubating for 5 mins for each rinse. 
 
The antibodies were diluted in 3% BSA in PBS.  The coverslips were placed into 
a humidified 90mm tissue culture dish, containing a damp tissue and parafilm.  
The cells were incubated with the primary antibody, by pipetting 100µl onto the 
coverslip and incubating for 1hr at R/T.  The cells were then rinsed 4 times with 
5ml PBS, incubating for 5 mins for each rinse.  Then the coverslip was returned to 
the humidified dish.  The cells were incubated with the secondary 
immunofluorescent-antibody, by pipetting 100µl onto the coverslip and 
incubating for 1hr at R/T. Each dish was rinsed 4 times with PBS, incubating for 5 
mins for each rinse.  The coverslips were mounted onto slides as above. 
 
2.2.9 Transfection of cells using the Chariot® protein delivery reagent 
Chariot (Actif Motif) is provided as a lyophilized powder and reconstituted in 
sterile PBS at a concentration of 2mg ml-1.  Cells were seeded at 2.5-5.0 x 104  
cells cm2 and incubated at 370C with 5% CO2 for 16hr until 40-50% confluent.  
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The Aβ peptide (4kDa) was diluted in PBS to achieve 100-500ng per transfection 
reaction and 200µl was needed per 60mm tissue culture dish giving a final 
concentration of ~ 1.0ng µl-1).  The Chariot was further diluted 1:10 in sterile 
H2O and 20µl was needed per 60mm tissue culture dish.  The diluted Aβ peptide 
was added to the diluted Chariot and incubated at room temperature for 30min for 
the complex to form. 
 
To transfect the cells, the medium was aspirated from cells and the cells were 
washed once with PBS. The Chariot-Aβ complex was added to the cells and the 
appropriate amount of serum-free medium added to the plate and  rocked gently to 
ensure even delivery. The cells were incubated at 370C with 5% CO2 for 60min. 
To prevent the cells deteriorating due to being in a serum starved environment, 
complete growth medium was added to the cells without removing the Chariot- 
Aβ complex. No more than 25% v/v of complete growth medium was added to 
the cells, as the presence of serum can interfere with the Chariot transfection 
efficiency.  The cells were incubated for a further 30-60min.  Cells were fixed and 
immunostained. 
 
 
2.3 Protein analysis  
2.3.1 Protein concentration microassay (1-10 µg). 
The protein concentration was determined using Bradford’s reagent.  Samples to 
be assayed were diluted to a final volume of 500µl and added to 500µl of 
Bradford reagent.  Absorbance was measured at λ595 nm with a 
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spectrophotometer, and the protein concentrations were calculated from a standard 
curve created using known concentrations of BSA, between 2 and 10µg. 
 
2.3.2 SDS PAGE (sodium dodecyl sulphate polyacrylamide gel 
electrophoresis) 
SDS-PAGE was performed using Invitrogen’s NuPAGE polyacrylamide gel 
system as per the manufacturer’s instructions.  When necessary SDS-PAGE gels 
were also prepared manually as follows.  The resolving gel was prepared (8-10% 
(v/v) acrylamide, 0.37M Tris-HCl pH 8.8, 0.1% w/v SDS) and polymerised by 
adding 20µl APS (ammonium persulfate 10% w/v) and 20µl (TEMED) NNN’N’-
tetramethylethylenediamine.  The acrylamide mixture was poured gently into a 
gel-casting rig and covered with water-saturated butanol.  When the gel was set 
the butanol was removed and the gel rinsed with 20mM Tris pH 6.8.  The stacking 
gel was prepared (acrylamide 4.7% (v/v), 0.121M Tris-HCl pH 6.8, 0.46% (v/v) 
SDS), and again polymerised with 10% w/v APS and 20µl TEMED.  The 
polymerised mixture was poured gently onto the resolving gel, and a comb was 
placed into the stacking gel.  The gel was allowed to set at room temperature.  
Samples were prepared for equal loading, normally 20-40µg protein per lane, by 
adding NuPAGE LDS Sample Buffer (4X) and reducing agent with 
approximately 50mM dithiothreitol (DTT).  Samples were heated at 70°C for 
10mins then cooled on ice, or samples were reduced in a standard protein sample 
buffer: 0.001% (w/v) bromophenol blue, 4.3% (w/v) DTT,  % (w/v) glycerol, 
0.06M Tris-HCl pH 6.8, 2.2% (w/v) SDS and boiled at 100°C for 5 mins, then 
cooled on ice.  Samples were loaded onto Invitrogen NuPAGE Novex 4-12% 
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gradient Bis-Tris gel, with one lane containing 5µl of Invitrogen SeeBlue Plus2 
protein standards.  The gel was run at a constant voltage (200V) for 40 min. 
 
 
2.3.3 Coomassie blue staining of SDS-PAGE gels 
For detection of protein expression, gels were stained using Coomassie blue stain 
solution (0.1% (w/v) Coomassie brilliant blue R-250, 45% (v/v) methanol, and 
10% (v/v) glacial acetic acid for 5 to 10 mins at room temperature. The gels were 
then destained using multiple changes of destain solution: (10% (v/v) glacial 
acetic acid, 20% (v/v) methanol), until protein bands were clearly seen.  Gels were 
imaged by scanning and photographed (Gel Doc 2000 UV transilluminator 
/photography system; Bio-Rad UK).   
 
2.3.4 Western immunoblotting 
For identification of individual protein expression, proteins were transferred to a 
nitrocellulose membrane for western immunoblotting.  Proteins separated by 
SDS-PAGE were transferred to a nitrocellulose membrane using NuPAGE 
transfer buffer (Invitrogen), with added methanol (10%) and antioxidant in 
accordance with the manufacturer’s instructions.  Transfer was completed at 30V 
for 1hr (for proteins <100 kDa) or 25V for 1hr (proteins > 100 kDa).  Transfer 
was verified by staining membranes with Ponceau S solution (Sigma 0.1 % 
Ponceau S (w/v), 5% acetic acid) for 1 min at room temperature.  Excess Ponceau 
S was removed by washing with distilled water.  
Protein binding sites on nitrocellulose membrane were blocked by incubating the 
membrane in 5% (w/v) fat free powdered milk in PBS-T (0.1% (v/v) 
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polyoxyethylenesorbitan monolaurate (Tween-20) in PBS), either at 4°C 
overnight or 1-2hrs at room temperature.  Membranes were then washed with 
PBS-T and incubated for 1hr at room temperature, with the primary antibody 
diluted in 5% (w/v) fat-free powdered milk in PBS-T.  The primary antibody was 
removed by washing the membrane 3 times, for 10 mins with PBS-T.  Membranes 
were then were incubated for 1hr at room temperature, with horseradish 
peroxidase (HRP) conjugated secondary antibody, diluted with 5% (w/v) fat free 
powdered milk in PBS-T.   The membrane was washed 3 times, for 10 minutes 
with PBS-T.  Immunoreactive bands were visualised by enhanced 
chemiluminescence (Pierce west pico ECL), on Kodak X-Ray film, as per the 
manufacturers instructions. The antibodies used in proteomic studies for western 
blotting are shown in Table 2.1. 
 
Antibody Host Supplier Conc’n 
 used 
epitope 
specificity 
 
endophilin-1 
 
rabbit 
 
Zymed 
 
0.5 ug/ml 
middle region 
human, mouse, rat 
endophilin 1 
ATP 
synthase β 
monoclonal 
  
Pierce 
 
1.0 ug/ml 
human, mouse, rat 
 
Creatine 
Kinase 
polyclonal 
   
0.5 ug/ml 
mouse and rat 
 
PrxII 
 
rabbit 
 
Alexis 
 
0.5 ug/ml 
human, mouse, rat, 
hamster. 
Does not cross react 
with PrxI 
 
 
B Actin 
 
  
Pierce 
 
0.5 ug/ml 
 
 
Table 2.1. Antibodies used in the western blotting experiments in Chapter 4. 
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2.3.5 Stripping primary and secondary antibodies from a nitrocellulose 
membrane 
The nitrocellulose membrane was washed 3 times for 10 min in 10ml of distilled 
water and then incubated for 45min in stripping buffer (0.2M glycine, 0.1% SDS, 
1.0% Tween-20, pH 2.2) at room temperature.  The membrane was then washed a 
further 3 times for 10min in 10 ml of distilled water and incubated with the 
primary and secondary antibodies as described above.  
 
2.4 Cell viability assays 
Cellular toxicity was induced using a number of known cytotoxic compounds 
including: glutamate, actinomycin D, staurosporin and Aβ peptide (Biosource). 
 
Aβ peptide was solubilised to a concentration of 1mg/ml from lyophilised stock.  
This was incubated at 37°C for between 16 and 48hr to allow peptide folding to 
occur, since this seems necessary for the production of amyloid toxicity.  
However, even with this pre-incubation step, effects of Amyloid toxicity were 
difficult to reproduce.  An oligomeric form of the peptide was kindly donated by 
Aynun Begum from UCLA, for further toxic studies.  The dose response of this 
peptide was more reproducible. 
 
2.4.1 The MTT Assay 
Cell survival was measured using a colorimetric spectrophotometric assay, first 
described by Mossman et al 1983.  The tetrazolium ring of MTT (3-(4,5-
dimethylthiozyl-2-yl)-2,5-diphenyl tetrazolium bromide) is cleaved by active 
mitochondria, leaving a blue/purple formazan product, absorbing at a wavelength 
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of 570nm.  The spectrophotometric reading is directly proportional to the number 
of living cells in each well. 
Cells were seeded in a 96 well plate, at a seeding density of 1 x 104  cells (1 x 105 
cells cm-2) in 100µl medium per well, unless indicated otherwise, and incubated in 
DMEM 10%FCS for 18-24hr.  The toxins were then added at various 
concentrations and cells were incubated for a further 24hrs.  Cells of the negative 
control were 80-90% confluent at the time of assay.  25µl of 5mg/ml MTT was 
added to each well of the plate. (final concentration 1mg/ml).  The plate was 
covered in foil to protect from light and incubated at 37°C, 5% CO2, humidified 
for 4 hr.  After 4hr the plates were centrifuged at 1500g for 5min.  The medium 
and MTT were then discarded, leaving the formazan product in the wells.  This 
was dissolved by the addition of 200µl DMSO followed by 50ul Sörensens buffer 
(0.1M glycine and 0.1M NaCl pH 10.5).  The absorption at a wavelength of 
570nm was measured on a 96 well plate reader, (MRX-ELISA – Dynex 
Technologies, Virginia) with a setting of 570nm test wavelength and 690nm 
reference wavelength. 
 
2.4.2 Mitochondrial Fractionation (with the Actif Motif kit) 
For fractionation of ~5 x 107 cells: 
1. Cells were washed 1x with 10 ml ice-cold PBS.  
2. 10 ml of ice-cold PBS was added and the cells were scraped off the dish 
using a cell scraper, and transferred to a pre-chilled 15 ml centrifuge tube 
and spun at 600 x g for 5 minutes at 4°C.  
3. The supernatant was removed and the cell pellet washed 1x by gently 
resuspending it in 5 ml ice-cold PBS, and spun at 600 x g for 5 minutes at 
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4°C and the supernatant removed. 
4. 1 ml of ice-cold cytosolic buffer was added and the cell pellet resuspended 
by pipetting up and down gently with a pipette, followed by incubation on 
ice for 15 minutes, then transferred to a pre-chilled pestle homogenizer. 
5. On ice, the cells were homogenized using 30-50 strokes with the 
homogenizer, and the supernatant transferred to a pre-chilled 
microcentrifuge tube. 
6. The lysate was spun at 800 x g (~3000 rpm) for 20 minutes at 4°C, and the 
resulting pellet was the nuclei, cellular debris and intact cells, whereas the 
supernatant contained the cytosol, including the mitochondria. 
7. The supernatant was transferred to a fresh, pre-chilled microcentrifuge tube, 
and spun a second time at 800 x g (~3000 rpm) for 10 minutes at 4°C to 
remove any residual nuclei. 
8. The supernatant was transferred to a fresh, pre-chilled microcentrifuge tube 
and spun at 10,000 x g (~11,000 rpm) for 20 minutes at 4°C to pellet the 
mitochondria. The supernatant was the cytosolic fraction, which was 
transferred to a fresh pre-chilled microcentrifuge tube. 
9. The mitochondrial pellet was washed with 1x with 100 μl 1x cytosolic 
buffer and spun at 10,000 x g for 10 minutes at 4°C. The supernatant was 
discarded. 
10.  The mitochondrial pellet was lysed by adding 100 μl complete 
mitochondria buffer and incubated on ice for 15 minutes. After incubation, 
it was vortexed for 10 seconds to mix thoroughly. This was the 
mitochondrial fraction. 
11. The cytosolic supernatant was centrifuged at 16,000 x g (~14,000 rpm) for 
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at least 20 minutes at 4°C to remove any residual mitochondria. The 
cytosolic supernatant was transferred to a fresh, pre-chilled 
microcentrifuge tube. This was the cytosolic fraction. 
12.  The protein concentration of each fraction was measured by Bradford 
assay. 
13.  Fractions were aliquoted and stored at -80°C.  
 
 
2.5 Plasmid production and cloning procedures. 
2.5.1 Polymerase chain reaction (PCR). 
PCR was used to amplify cDNA.  Forward and reverse primer sequences were 
designed with restriction sites specific to the cDNA fragment.  Primers were 
supplied by Invitrogen UK.  A 50µl PCR reaction mix was made up of 200ng/µl 
DNA template, 200 µM dNTPs (Promega), 0.5µM of each primer and 0.8µl 
pfuTURBO polymerase (Stratagene), in enzyme buffer diluted with nuclease free 
dH2O.  PCR was carried out in a Biometra Thermocycler.  The PCR program 
conditions were: melting at 95°C for 45s, annealing at 55°C for 45s and extension 
at 72°C for 1min/kb.  The PCR was set for 30 cycles with an initial melting step 
of 95°C for 2min and a final extension at 72°C for 10min. 
 
2.5.2 Agarose gel electrophoresis 
Amplified and linearised DNA, and DNA fragments from restriction digests, were 
analysed by gel electrophoresis in horizontal mini-gels.  1µg/ml ethidium bromide 
was added to gels made of 1% (w/v) agarose/TBE buffer, and these gels were run 
in TBE buffer (0.045 M Tris-borate, 0.001 M EDTA.).  For analysis, 5µl DNA 
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samples were mixed with 1µl of 6x DNA loading buffer (Promega, United 
Kingdom), prior to electrophoresis.  Samples were separated at 60V constant 
volts, until bands were clearly resolved, approximately 45min.  Along with the 
samples, known DNA molecular weight markers were run (1kb ladder; Promega, 
United Kingdom.).  Electrophoresed DNA was exposed to UV light (λ365nm) 
and photographed (Gel Doc 2000 UV transilluminator/photography system; Bio-
Rad, United Kingdom).   
 
2.5.3 Purification of DNA fragments from agarose gels 
Following analysis of DNA by agarose gel electrophoresis, as described above, 
the DNA fragments of interest were subsequently purified by excision of resolved 
bands from the gel. The remaining samples were separated on a new gel and 
imaged by short wavelength UV light to prevent UV damage to DNA (λ320nm).  
The DNA bands were excised from the gel with a sterile scalpel blade.  DNA 
excised from the gel was then recovered using the Promega Wizard SV Gel and 
PCR Clean-UP System kit as per the manufacturer’s instructions. Typically, DNA 
was eluted in 50ml of nuclease free dH2O.  A fraction of the purified samples 
(usually 1/10 of the total volume of the eluate) was usually re-run on agarose gels, 
in order to check the purification of DNA. 
 
2.5.4 Restriction enzyme digests   
Restriction enzymes were used to digest 1 µg of plasmid DNA or PCR product for 
1 hour at the recommended temperature.  Restriction digest enzymes (Promega) 
were used according to the manufacturer’s instruction using the buffers supplied.  
In general, 10 units of the restriction enzyme reactions were subsequently 
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terminated by heat inactivation (65°C incubation for 15 min).  Restriction 
digested DNA that was to be used in further restriction digests or ligation 
reactions was eluted with nuclease free water, using the Promega Wizard SV Gel 
and PCR Clean-UP System kit as per the manufacturer’s instructions. 
 
2.5.5 Plasmid construct production 
Purified DNA insert and the vector were ligated using T4 ligase (Promega) with 
supplied buffer, incubated at 4°C overnight.  The final construct was checked by 
single and double restriction digest on agarose gel and finally by sequencing at 
DNA sequencing lab., University of Dundee. 
 
2.5.6 Preparation of competent E. coli cells (DH5α) using calcium chloride 
DH5α E. coli was cultured overnight in 5 ml of Luria Broth (LB) at 37°C.  50ml 
of pre-warmed LB was inoculated with 500 µl of overnight culture and grown in a 
1.0 litre flask (37°C, 210 rpm) for approximately 2 hrs.  When the absorbance of 
the bacterial culture reached 0.3 to 0.4 absorbance units at a wavelength of 
600nm, the culture was transferred to a pre-chilled 50ml plastic centrifuge tube.  
The cells were centrifuged at 3500 g for 10 minutes at 40C.  The supernatant was 
discarded and the pellet was resuspended in 20 ml of ice-cold filter sterile 100 
mM CaCl2 and incubated on ice for 30 minutes.  Bacteria were pelleted at 1500g 
for 5min. and the pellet was resuspended in 1 ml of 100 mM CaCl2.  Bacteria 
were left on ice for a further 30 minutes and either used immediately or DMSO 
was added slowly, to a final concentration of 10%, and the cells stored at -70°C 
for up to 4 weeks. 
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2.5.7 Transformation of competent E.coli cells and clonal isolation 
To replicate specific DNA, bacteria were transformed by adding either 0.5 µl of 
plasmid DNA or 10 µl of a ligation reaction mixture to 200 µl of calcium chloride 
competent cells (DH5α), and incubated on ice for 20 minutes.  The bacteria were 
then heat shocked at 42°C for 45 seconds and immediately incubated on ice for a 
further 3 to 4 minutes.  The bacterial culture was made up to 1 ml, with SOC 
medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract 10mM NaCl, 10mM KCl, 
5mM MgSO4, 5mM MgCl2 and 20mM glucose), and incubated at 37°C with 
vigorous shaking (210 rpm) for 1 hr.  100 µl of the culture medium was spread on 
to an agar plate containing the appropriate selection antibiotic(s) for the plasmid.  
The remaining bacteria were pelleted (13,000g for 10s) resuspended in 
approximately 100µl of culture medium and plated on a second agar plate.  Agar 
plates were placed agar side up into a 37°C incubator overnight.  The next day 
single colonies were isolated for inoculation into LB with antibiotics for further 
monoclonal culture. 
 
2.5.8 Preparation of glycerol stocks of transformed E. coli 
Glycerol stocks were prepared for all new plasmids.  600µl of overnight bacterial 
cultures was mixed with 400µl of sterile 50% glycerol (= 20% glycerol final 
concentration) and stored at -70°C. 
 
2.5.9 Bacterial culture 
Bacteria were cultured by adding a minute amount of the glycerol stock to 1-5ml 
LB and incubated at 30-37°C shaking for 12-16hr. 
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2.5.10 Preparation of plasmid DNA (‘mini’ and ‘midi’ preps) 
Small-scale preparation of DNA (50µl at 0.2ug/ul) for cloning and transfecting 
was prepared from a 5ml overnight bacterial culture, using the Promega plasmid 
miniprep kit in accordance with the manufacturer’s instruction.  Large-scale 
preparation of DNA (500-800µl at 0.6ug/ul) for analysis, cloning, and transfection 
into mammalian cell lines was prepared from a 50-100ml overnight bacterial 
culture, using the Promega plasmid midikit, in accordance with the 
manufacturer’s instructions. 
 
 
2.6 Proteomics 
2.6.1 2D gel electrophoresis 
Protein samples were prepared and separated, first dimension by isoelectric 
focusing (IEF), separating by isoelectric point then second dimension by 
molecular weight (SDS PAGE).  Amersham Biosciences equipment and 
chemicals used unless stated otherwise. 
 
2.6.2 1st dimension IEF 
400µl samples with load dye were placed in the channels of the Immobiline 
Drystrip Reswelling Tray.  The IEF strips (Immobiline Drystrip pH 4-7, 18cm) 
were placed in the channels, gel side down, with ‘+’ anode marks to the front.  
The sample was distributed evenly under strip avoiding trapping any air bubbles.  
The strips were covered with 2ml mineral oil (Drystrip Cover Fluid).  The 
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samples were covered and left to rehydrate at room temperature overnight (10-
20hr).  
The IEF equipment was prepared by pouring oil onto the base and placing the  
glass base plate onto this and then the electrodes were attached.  Oil was poured 
onto the base plate and the strip holder put onto this.  The rehydrated IEF strips 
were removed from the holder and rinsed well with dH2O.  The strips were dried 
on filter paper (gel side up) and covered with clingfilm.  The samples were placed 
in wells in the strip holder (gel side up) ‘+’ ends to the anode (red).  Two paper 
electrode strips were cut to 11cm and placed across both ends of IEF gel strips 
(touching the gels).  These were fixed in place with electrode clips (red top right  
and black bottom left) and the strips  were covered with oil. 
The program was set on power pack: 1hr at150V; 1hr at 300V; 1.5hr at 1500V; 
and 20.5hr at 3000V. Total run time 24hr.  This was left running for 24 hr with 
the equipment cooler set at 20°C.  After 24hr the strips were removed and frozen 
at -20°C, individually placed into plastic 10ml pipettes. 
 
2.6.3 2nd dimension SDS-PAGE 
Enough acrylamide gel was prepared to make a gel for each IEF strip.  For each 
10% gel:- 37ml 30% bis-acrylamide; 27ml 1.5M Tris pH 8.8; 43ml dH2O; 1.5ml 
10% SDS; 1.5ml 10% APS and 200ul 10% TEMED.  The gel rig was prepared 
with Perspex blocks and glass plates in the middle.  Thin plastic spacers were 
placed between each block and plate.  The acrylamide gel solution was poured 
into the rig through a tube in the base, until it reached approx. 5-10cm from the 
top of the glass plates.  Displacing fluid (50ml 1.5M Tris HCl pH 8.8, 100ml 50% 
glycerol, 50ml dH2O, 2mg bromophenol blue) was then poured into the tube until 
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the acrylamide was only 1cm from the top.  The tube was then clipped. 2-3ml 
H2O (or H2O saturated butanol) was poured onto gels and left to polymerise 
(minimum 1hr).  The top of the gels were rinsed thoroughly and covered with 
SDS electrophoresis buffer.  The IEF strips were thawed and equilibrated in SDS 
equilibration fluid for 15mins before applying firmly to the top of the gels, 
between the plates.  Molecular weight markers were pipetted onto filter paper and 
pushed into one end of each gel.  The strips were sealed into place with an agarose 
sealing solution to prevent movement of the strip.  The gels were placed in the 
vertical tank and submerged in the tank electrophoresis buffer. The 
electrophoresis conditions were selected at 30mA/gel for 1-2hr.   
 
For visualisation the gels were either stained with Coomassie blue stain or silver 
stain for better sensitivity.  For more detailed analysis of the spots, the gels were 
stained with SYPRO Ruby fluorescent protein stain (Invitrogen) and the gels were 
scanned with a laser scanner (Fujifilm FLA-5000).  The images of the protein 
spots were then analysed. 
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Chapter 3 
Investigation of Aβ  toxicity on SK-N-SH cells  
transfected with ABAD 
 
3.1 Background and aims 
 
The binding of Aβ peptide to plasma membranes has been shown to cause direct 
cell toxicity, producing a local inflammatory response and Aβ fibrillar production 
(Yan et al., 1997b).  This suggests that specific interactions of Aβ with cell 
surface receptors may trigger signal transduction early in AD, before the 
production of tau tangles and amyloid plaques (Yan et al., 1997a).  It is also 
known that Aβ toxicity induces apoptosis in primary neuronal cells (Kadowaki et 
al., 2005; Yankner, 1996), but whether or not Aβ toxicity causes apoptosis in 
vitro in immortal neuronal cell lines has remained to be disputed in different 
studies (Behl et al., 1994; Cotman and Su, 1996; Gschwind and Huber, 1995).  
Intracellular accumulation of Aβ has been identified in different cell types 
(LaFerla et al., 2007; Yamazaki et al., 1996), and the most characterised 
intracellular protein that has been identified to bind Aβ, is ABAD (Du et al., 
2008; Yan et al., 1997a).  The ABAD/Aβ complex has been shown to mediate 
cell toxicity and to induce apoptosis in several cell lines (Yan et al., 1999) 
(Oppermann et al., 1999).  
 
Confocal microscopy in the Yan study identified the protein distributed within the 
endoplasmic reticulum (ER) (Yan et al., 1997a).  Because of its reported cellular 
localisation, the protein was initially called ‘ERAB’ (Endoplasmic Reticulum 
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binding Amyloid Beta).  In the protein sequence, amino acid residues 169 - 173 
(YSASK) correspond to the highly conserved active site residues 153-157 
(YGASK) from the NADH-binding enzyme 3α,20β-hydroxysteroid 
dehydrogenase of Streptomyces hydrogenans (Yan et al., 1997a).  This indicated 
that ‘ERAB’ had potential enzyme activity, with the YSASK region putatively 
being part of the active site.  Both proteins also share NAD(H) binding domains. 
Yan also showed by site-directed mutagenesis experiments, at residues 168 and 
172, that a mutation at or near the active site reduced the toxicity of the Aβ 
peptide, suggesting that this enzyme could have an effect in AD (Yan et al., 
1999). 
 
The initial aim of this part of the project was to confirm and identify the cellular 
localisation of ABAD in a human neuroblastoma cell line, SK-N-SH cells, and to 
set up an in vitro model to investigate the effect of ABAD in these cells and thus 
help to define the role of ABAD in AD. Although animal models are critical for 
biomedical research and drug development in neurodegenerative diseases, no 
model perfectly mimics the human disease (Duyckaerts et al., 2008).  Animal 
experiments are time consuming and costly, therefore it is essential to have an 
effective and reliable in vitro model for neurotoxic and neuroprotective effects 
within the laboratory. 
 
To establish a cell line as an AD model, SK-N-SH cells were transfected with a 
plasmid referred to as ABAD-EGFP that included enhanced green fluorescent 
protein (EGFP) as a reporter of expression that was C-terminally tagged to 
ABAD.  Fluorescent microscope imaging was performed and cytotoxic assays 
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were designed to investigate the effect of ABAD overexpressed in these 
transfected cells.  Toxicity was induced using a synthetic Aβ42 peptide.  MTT 
cell viability assays and live cell imaging were used to monitor viability and 
potential toxic effects on the cells.  Further experiments were carried out to 
establish if cell death was due to apoptosis. The initial experiments consisted of 
western blot analysis of subcellular fractionated cells to identify cytochrome C 
release from mitochondria into the cytosol.  Further MTT assays were carried out 
to identify inhibition of Aβ42 toxicity by a pan-caspase inhibitor, BocD-fmk and 
also by a novel peptide inhibitor, TAT-ABAD, a peptide which was developed 
based on the amino acid protein sequence of ABAD that is thought to bind Aβ.  
There were several problems encountered during these experiments that are 
discussed.  However, it led to the search for different appropriate cell lines and 
forms of the Aβ42 peptide to try and develop an improved in vitro model for the 
future.  Some initial experiments were carried out to investigate the use of 
neuronal stem cells as a useful cell line closer in phenotype to primary cells in 
cultivation.  Murine cortical neuronal cells were also cultured and a system to 
produce neurospheres from murine stem cells was established. 
 
3.2 Cellular localisation of ABAD in SK-N-SH, a human 
      neuroblastoma cell line  
The cellular localisation and naming of this protein has been a contentious issue.  
It has been reported to be present in both the endoplasmic reticulum (ER) and 
mitochondria (Yan et al., 1997a), but other studies have it solely expressed in the 
mitochondria (He et al., 1999a).  It has been suggested that its cellular localisation 
is cell-line dependent (Frackowiak et al., 2001).  ABAD was identified as being 
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localised in the ER of SK-N-SH cells (Yan et al., 1997a), and its function would 
be dependent on its activity in its particular cellular localisation.  
 
3.2.1 Previous studies on the cellular location of ABAD 
Previous studies of ABAD have indicated that there are targeting sequences either 
for the lumen of ER and lysosomes (Sambamurti and Lahiri, 1998), or for 
mitochondria (Filling et al., 2001; He et al., 2001).  
 
Sambamurti and Lahiri detected a putative signal peptide, by computer analysis of 
the ABAD sequence, that could potentially direct the protein into the ER-Golgi 
secretory pathway.  The peroxisome signal sequence, AHL is found near the C 
terminus of the protein.  This signal sequence was found in human, rodent, and 
bovine isoforms of ABAD suggesting that it was a type II integral membrane 
protein in vertebrates (Sambamurti and Lahiri, 1998).  Peroxisomes can be 
derived from the ER (Hoepfner et al., 2005), but as this sequence was predicted 
by computer analysis it was recognised that this may not be a true localisation of 
the protein in the cell. 
 
He et al. had previously constructed an expression plasmid encoding a fusion 
protein consisting of the first eleven residues of ABAD: MAAACRSVKGL, 
highlighted in Figure 3.1, fused to GFP.  By fluorescent microscopy, they noted 
the GFP fusion protein expressed in organelles co-localised with a fluorescent 
stained mitochondrial marker, cytochrome oxidase, confirming this sequence to 
be a mitochondrial targeting sequence (He et al., 2001). 
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 MAAACRSVKG LVAVITGGAS GLGLATAERL VGQGASAVLL DLPNSGGEAQ AKKLGNNCVF  60 
 APADVTSEKD  VQTALALAKG KFGRVDVAVN CAGIAVASKT YNLKKGQTHT LEDFQRVLD    120 
 NLMGTFNVIR  LVAGEMGQNE PDQGGQRGVI INTASVAAFE GQVGQAAYSA SKGGIVGMTL  180 
 PIARDLAPIG  IRVMTIAPGL FGTPLLTSLP EKVCNFLASQ VPFPSRLGDP AEYAHLVQAI   240 
 IENPFLNGEV  IRLDGAIRMQ P 261 
 
Fig. 3.1. The human ABAD protein sequence. The first eleven amino acid residues are 
highlighted in red as a potential mitochondrial targeting sequence (He et al., 2001).  
Amino acid residues 168 to 172 are also highlighted to identify the conserved sequence in 
NADH binding enzymes and suggested active site for the enzyme ERAB/ABAD. The 
residues highlighted in blue are those predicted by computer analysis as a putative 
peroxisomal signal sequence. 
 
 
3.2.2 Cellular localisation of ABAD by fluorescent microscopy in SK-N-SH 
cells 
As the overall aim of this chapter was to establish a reliable cellular model in 
which to study ABAD, it was necessary to choose an appropriate cellular 
background and to clearly establish the exact subcellular localisation of ABAD 
within the selected cell line. Given the previous body of work, and to expand on 
the previous experiments (Yan et al., 1997a; Yan et al., 1999) (section 3.1), SK-
N-SH cells were selected for use in this study and an ABAD-EGFP fusion protein 
was used to visualise the ABAD localisation.   
 
The SK-N-SH cell line is derived from a human neuroblastoma and they are 
routinely and extensively used for cytotoxic assessments (Biedler et al., 1973). 
The cells are grown as an adherent monolayer with a long doubling time of 44hr.  
The growth remains constant and they can be trypsinised and passaged to 70-80% 
confluence more than 20 times.   It is possible to differentiate up to 50% of the 
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cells into a neuronal phenotype, characterized by extensive neurite outgrowth, 
thick neurite bundles, and large cellular aggregates by the addition of retinoic acid 
(Preis et al., 1988).  
 
3.2.3 Transient transfection of SK-N-SH cell line with ABAD-EGFP 
To confirm the cellular localisation of ABAD in SK-N-SH cells, the cells were 
transiently transfected with a plasmid coding for an ABAD-EGFP fusion protein, 
hereinafter called ABAD-EGFP. This plasmid had been cloned previously in the 
laboratory, using the full-length cDNA human ABAD clone and cloning into 
pEGFP-N3 vector (Clontech) by PCR, using Taq polymerase (Figure 3.2). 
 
Fig. 3.2. The ABAD-EGFP plasmid showing restriction sites EcoRI and BamHI for 
ABAD (grey) and BamH I and Not I for EGFP (green).  The vector and plasmid contain a  
kanamycin resistance gene (red).  
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The SK-N-SH cells were grown on glass cover slips and grown in DMEM growth 
media with glutamine, penicillin/streptomycin and 10% FCS (Section 2.2.1).  
After 24 hr, when 80% confluent, the cells were transfected with 1µg of the 
ABAD-EGFP plasmid, using Lipofectamine (Invitrogen), a lipid based 
transfection reagent. The transfected cells were incubated for a further 18hr to 
allow for protein expression and then were fixed with 4% paraformaldehyde, 
rinsed, mounted and then imaged by fluorescent microscopy (Figure 3.3). 
 
 
 
        
 
 
 
 
 
 
Fig. 3.3. A fluorescent microscope image of paraformaldehyde fixed SK-N-SH cells after 
transient transfection with ABAD-EGFP (imaged on Zeiss Axioscope fluorescence 
microscope).  This shows ABAD-EGFP protein was expressed in discreet spots 
surrounding the nucleus, which potentially were organelles.  However in the bottom cell 
there appeared to be diffuse green staining throughout the cell.  
 
Diffuse green staining was seen throughout some the cells, and at first it was 
unclear why this might be the case but may have been suggestive of mis-targeting 
of the ABAD-EGFP protein.  To overcome this, two methods were developed 
later to improve the targeting and expression of ABAD in the cells.  
5um 
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3.2.4 Further subcellular localisation by fluorescence microscopy 
Further transient transfections of SK-N-SH cells with ABAD-EGFP were carried 
out as above, in order to identify the organelle expressing ABAD.  The cells were 
co-transfected with Clontech subcellular localisation plasmids, to express 
fluorescent subcellular proteins. A plasmid for cyan fluorescent protein tagged 
with an ER targeting sequence (ER-CFP) or a plasmid for red fluorescent protein 
tagged with an ER targeting sequence (ER-Red) were transfected to identify the 
ER with either cyan or red fluorescent protein, respectively. A plasmid for a red 
fluorescent protein tagged with a mitochondrial targeting sequence (pDsRed2-
Mito) was transfected to identify the mitochondria with red fluorescent protein.  
Cells were fixed and mounted as before and imaged by fluorescence microscopy 
(Figures 3.4, 3.5 and 3.6). 
 
Figure 3.4 shows ABAD-EGFP and pDs-Red-Mito both expressed in the 
mitochondria.  Further imaging was done to identify the ER and mitochondria in 
SK-N-SH cells, to see if ABAD is expressed in both organelles. 
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Fig. 3.4. Fluorescent microscope images of two SK-N-SH cells, co-transfected with 
ABAD-EGFP and pDsRed2-Mito. (a) Cells imaged with FITC filter (ex. 490nm. em. 
528nm.) showing ABADEGFP. (b) Cells imaged with red filter (ex. 555nm. em. 617nm.) 
showing pDsRed2-Mito in mitochondria. (c) Converged image showing co-localisation of 
ABDGFP and pDsRed2-Mito.  This shows ABADEGFP and pDs-Red-Mito both 
expressed in the mitochondria confirming localisation of ABAD in mitochondria in SK-
N-SH cells. 
 
 
 
Fig. 3.5. Fluorescent microscope images of one SK-NS-H cell dividing, co-transfected 
with ERCFP and pDsRed2-Mito. (a) Cells imaged with cyan filter (ex. 436nM, em. 
470nM) showing ERCFP in ER. (b) Cells imaged with red filter (ex. 555nm. em. 617nm.)  
showing pDsRed2-Mito in mitochondria. (c) Converged image showing the ERCFP and 
pDsRed-Mito. This shows the ERCFP expressed in the endoplasmic reticulum and the 
pDsRed2-Mito expressed in the mitochondria.  The converged image shows the close 
association of the ER and mitochondria in SK-N-SH cells but no co-localisation of the 
ERCFP and pDsRed-Mito. 
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Figure 3.5 shows that the ER and mitochondria can be identified separately, 
suggesting that if ABAD was in the ER, it would show up clearly separate from 
the mitochondria in SK-N-SH cells.  To confirm this, further imaging was done 
with co-transfection of ABAD-EGFP and ER-Red. Figure 3.6 shows a small 
amount of co-localisation of ABAD-EGFP with ER-Red, indicating that ABAD 
may be expressed or translocated into the ER of SK-N-SH cells. Again there 
appears to be some diffuse GFP staining seen in or around the nucleus and in the 
cytoplasm.  This could be due either to mis-targeting or ABAD is secreted into the 
cytoplasm possibly due to cell stress.  Otherwise the cells look healthy in 
morphology, with healthy nuclei. 
      
 
       
  
Fig. 3.6. A 0.1µm section through SK-N-SH cells co-transfected with ABAD-GFP and 
ER-Red (imaged on the Deltavision deconvolution microscope).  (A) The converged 
image shows four cells expressing ABAD-GFP in the mitochondria with two of the cells 
co-expressing ER-Red in ER.  (B) The cell with co-expression enlarged for detail.  This 
possibly shows a little co-localisation of ABAD-EGFP with ER-Red . 
 
These imaging studies concluded that ABAD is expressed in the mitochondria of 
SK-N-SH cells and may be translocated into the ER.  More recent publications 
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have confirmed expression in the mitochondria and it is now accepted that ABAD 
is a mitochondrial enzyme. However there is evidence that lipids and membrane 
proteins can be exchanged directly between the ER and mitochondria via 
mitochondrial associated membranes (MAMS), membrane compartments that 
have close contact points with ER and mitochondria (Rusinol et al., 1994).  It is 
possible that ABAD is shuttled from one organelle to the other by this method 
(Stone et al., 2009). 
 
3.2.5 Stable expression of ABAD-EGFP in SK-N-SH cells 
Expression of ABAD-EGFP was confirmed to be in the mitochondria with 
transient transfections of SK-N-SH cells.  However there was also diffuse 
distribution of GFP within the cytosol of some of the cells (for example see 
Figures 3.3 and 3.6).  As indicated above, one possibility for this was due to the 
overexpression of ABAD-EGFP causing the mis-targeting of the protein at the 
sub-cellular level.  A similar effect had also been observed when using a different 
ABAD-GFP chimeric protein, where better targeting of GFP was found when it 
was expressed with a mitochondrial targeting sequence at the N terminal end (He 
et al., 1999b). Therefore, two methods were employed to improve the targeting of 
ABAD-EGFP:  1) a stable expressing cell line was produced; 2) a second plasmid 
was developed where a mitochondrial targeting sequence (MTS) was ligated on to 
the N-terminus of the original ABAD-EGFP construct.  The stable cell-line took 
several weeks to produce (see protocol in section 2.2.2 and 2.2.3) but as indicated 
in Figure 3.7, this new cell-line showed good stable expression of the ABAD-
EGFP within the mitochondria and with improved targeting (Figure 3.7).  
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Fig. 3.7. Fluorescent microscope image of a group of SK-N-SH cells stably transfected 
and expressing ABAD-EGFP. Note there is no diffuse green staining in the cytosol. 
 
 
 
3.2.6 Creation of new construct by cloning of a mitochondrial targeting 
sequence (MTS) into ABAD-EGFP plasmid. 
 
In parallel with the work to establish a stable expression of ABAD-EGFP, an 
alternative transient method for targeted expression of ABAD was also explored.  
The production of a new plasmid construct of ABAD containing a mitochondrial 
targeting sequence was undertaken. This had been done previously with good 
results (He et al., 2001).   
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3.2.6.1 Plasmid design 
The construct was designed by inserting an N-terminal mitochondrial targeting 
sequence (MTS), at the N-terminus of the ABAD-EGFP plasmid (Figure 3.8).  
The ABAD-EGFP expressing plasmid had been designed previously from the 
Clontech pEGFP-N3 plasmid (Figure 3.2).  The ‘vector’ encoding the ABAD-
EGFP gene was made first by removing the nucleotide sequence between the 
Nde1 and EcoR1 restriction sites in the ABAD-EGFP plasmid between 
nucleotides 234 and 629 (Figure 3.8b) using restriction enzymes Nde1 and EcoR1 
(New England Biolabs).  The insert was made from the sequence of the N-
terminal MTS from the Clontech pDsRed2mito (subunit VIII human cytochrome 
C oxidase) plasmid (hereafter called MTS) from a start codon ATG at nucleotide 
597 to nucleotide 683, 86 base pairs (Figure 3.8c).  The MTS insert was produced 
by PCR using the pDsRed2-Mito plasmid as a template with primers: 
  
 
 Primer 1 sequence, sense - (NdeI restriction site highlighted) 
  5’-AGTGTATCATATGCCAAGTACG-3’ 
 Primer 2 sequence, antisense – (EcoRI restriction site highlighted) 
  5’-GGAATTCGGCGACCGGTGGATCCCC-3’ 
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Fig. 3.8. Cloning strategy for pMTS-ABAD-EGFP.  (a) The pABAD-EGFP plasmid was 
digested sequentially with NdeI and EcoRI to produce the vector (b) pABAD-EGFP.  (c) 
The pDsRed2-Mito plasmid was used as the template for PCR of MTS to produce the 
PCR product (d).  The PCR product containing the MTS was cleaned and digested (e). 
The digested PCR product was ligated into the vector pABAD-EGFP to give a final 
construct of pMTS-ABAD-EGFP (f). 
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The resulting PCR product was sequentially digested with NdeI and EcoRI 
restriction enzymes.  This MTS insert and ABAD-EGFP vector were cleaned 
using a Promega Wizard DNA clean-up system. The MTS insert was then ligated 
into the ABAD-EGFP vector with T4 DNA ligase to produce MTS-ABAD-EGFP 
(Figure 3.8 e and f). DH5α competent cells were transformed with the MTS-
ABAD-EGFP plasmid DNA and spread on agar plates containing 50µg ml-1 
kanamycin.  The plates were incubated overnight at 37o C and four colonies were 
selected and cultured in LB for 18hr.  The DNA was extracted using a Promega 
Mini-Prep kit.  The new plasmid DNA was transfected into SK-N-SH cells. For 
comparison the new construct was also transfected into another neuronal cell line, 
PC12, which was also available in the laboratory. The cells were fixed, mounted 
and imaged under fluorescent microscopy (Figure 3.9).    
 
Figure 3.9 shows good transient transfection and targeting of ABAD to the 
mitochondria in both neuronal cell lines. The PC12 cells are smaller than SK-N-
SH cells with less cytosol (Figures 3.9, 3.10). They require slightly more 
complicated growth conditions and do not adhere well to plastic culture flasks 
unless treated with collagen IV. In general they are known to be more difficult to 
culture and transfect than SK-N-SH cells. However they are useful as a neuronal 
cell line as they cease proliferation when treated with NGF (nerve growth factor) 
and produce long neurites and show morphology consistent with neuronal 
differentiation (Foehr, 2000). They are useful as a model system for primary 
neuronal cells.  
 
 98 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9.  Fluorescent microscope images of transient transfections of cells with MTS-
ABAD-EGFP, with blue DAPI staining of nuclei. (a) SK-N-SH cells. (b) PC12 cell.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.10 Microscope phase contrast images of the cultivation of PC12 cells (top) and SK-
N-SH cells (bottom) for comparison (taken from ATCC product sheets). 
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Due to the ease of cultivation and transfection, it was decided to continue with the 
SK-N-SH cell line expressing ABAD to develop the AD model.  However, the 
MTS-ABAD-EGFP construct and the PC12 cells were used subsequently in the 
laboratory to develop other constructs for use in another cellular model and 
developing FRET experiments. 
 
3.3 Developing an in vitro model for AD 
During development of the in vitro model, both the stable cell line SK-N-SH cells 
transfected with ABAD-EGFP and SK-N-SH cells transiently transfected with 
MTS-ABAD-EGFP were used in further studies to test the toxicity of the 
synthetic human Aβ42 peptide (Biosource International). The toxicity at different 
concentrations of the Aβ42 peptide was tested both in MTT viability assays and 
also in assessing its ability to induce the potential reported translocation of ABAD 
to the plasma membrane (Yan et al., 1997a). 
 
3.3.1 MTT cell viability assays with Aβ42 
Prior to experiments studying the potential translocation of ABAD in SK-N-SH 
cells, it was first necessary to establish the toxic conditions required to initiate a 
cellular response. To assess the dose of Aβ42 required to show a toxic effect in 
cells over-expressing ABAD, a dose dependent, cell viability assay was 
performed using a MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay.  This is a colorimetric assay to determine cell viability, by noting 
the change in colour of the tetrazole substrate from yellow to purple, when it is 
reduced by active reductase enzymes from living cells (Mosmann, 1983).  
Lyophilised Aβ42 peptide (FW 4514, Biosource International) was reconstituted 
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(as per the manufacturer’s recommendations) in 100µl sterile nuclease free water 
to a concentration of 5mg ml-1, and then further diluted in PBS to make a working 
stock concentration of 1mg ml-1. 30-50µl aliquots of this stock were pre-incubated 
as required, at 370C for 24hr.   
A 96 well micro tissue culture plate was seeded with SK-N-SH (ABAD-EGFP) 
cells, at a cell density of 1 x 104 cells per well (approx. 2 x 104 cm-2).  The SK-N-
SH (ABAD-EGFP) stable cell line was used to enable a direct comparison 
between the different imaging studies.  The cells were incubated in normal growth 
medium for 12hr at 370C with 5% CO2.  The synthetic Aβ42 peptide was then 
added to the cells in the 96 well plate at different concentrations, as shown in 
Figure 3.11, and the cells further incubated for 16-18 hr, after which an MTT 
assay was performed and the results of this are shown in Figure 3.12. The control 
cells were assumed to have 100% viability and the other readings were then 
compared to this to give a final % of viability.  
 
Fig. 3.11. The template of the 96 well plate showing different concentrations of Aβ42 
peptide added.  Columns 3 and 4, negative controls, no Aβ added.  Columns 5 and 6, 
0.1µM Aβ added.  Columns 7 and 8, 1µM Aβ added.  Columns 9 and 10, 2µM Aβ added.  
The outer wells were filled with growth medium only, as readings at the edges of the 
plate can be unreliable.  Each condition had 12 individual readings. 
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Fig. 3.12. Results from the MTT readings of SK-N-SH (ABAD-EGFP) cells incubated 
for 16hr with Aβ42 as shown.  An average reading was taken from the 12 replicate 
samples. Error bars show one standard deviation. (a) Negative control.  (b)-(d) Cells 
incubated with increasing concentrations of Aβ42; (b) 0.1µM, (c)1µM, (d) 2µM. From 
the student t test, the probability (p) values are shown. 
 
Using the Student t-test, with a significance level of P=0.05.  P values above this 
are not significant and below this are taken as significant, Table 3.1. 
 No Aβ 0.1µM Aβ 1µM Aβ 2µM Aβ 
readings 
@ 570nm 
0.67 0.63 0.55 0.44 
SD 0.19 0.12 0.17 0.13 
t test 
P values  
 
  
P=0.26 
 
P=0.05 
 
 
P=0.0003 
 
 
Table 3.1 Student t test p values of the readings giving the results of the MTT assay in 
Figure 3.12. The average readings taken for the MTT assay and the standard deviation are 
also shown. The t test P values show that the readings for 1µM and 2µM Aβ compared to 
the reading with no Aβ are statistically significant. 
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The results from the MTT assay indicated that the addition of either 1µM and 
2µM Aβ42 was statistically different to the other treated cells, therefore a 
minimum of 1µM Aβ42 was used in the following toxicity studies. 
 
3.3.2 Fluorescence imaging studies of Aβ42 toxicity 
 
Previous studies have shown that ABAD is released into the cytosol and is 
subsequently rapidly translocated to the plasma membrane; however, this was 
performed at a single time point, 24hr after the addition of Aβ.  Therefore, it was 
unknown how early this event could occur.   
 
Therefore experiments were designed to monitor by live imaging, the stable SK-
N-SH (ABAD-EGFP) cell-line.  SK-N-SH (ABAD-EGFP) cells were grown in 
glass-bottomed WillCo-dish® tissue culture dishes with lids and incubated to 80% 
confluence (16-18hr) in an incubator at 370C with 5% CO2.  The cells were then 
further incubated for 20hr in an enclosed Perspex hood on a rig attached to the 
Deltavision deconvolution microscope.  The glass-bottomed dish was positioned 
on the microscope oil objective lens and focused onto a group of 3 or 4 cells.  The 
conditions were regulated over the 20hr:  the rig was heated at 370C and 5% CO2 
was continuously pumped into the WillCo-dish®, through a thin plastic tube 
introduced into a pre-drilled hole in the lid.  Images of the cells were taken every 
1-2hr (Figure 3.13). The live imaging showed that the cells grew and multiplied 
over a 17hr period with no shuttling of ABAD in and out of the mitochondria.  
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Fig. 3.13. Live imaging of stably transfected SK-N-SH (ABAD-EGFP) cells.  These 
images show a time-course to 17hr. (a) Four cells selected for imaging. (b) The same 
cells at 4 hr, with division of one cell, seen top left.  (c) The same cells at 11 hr. More 
division seen.  (d) At 17hr, cells alive with healthy morphology, showing that the cells 
survive and divide in these growth conditions, without requiring a change of growth 
medium. There is no evidence of ABAD-EGFP translocating to the plasma membrane. 
 
This experiment was repeated under the same conditions but with the addition of 
1µM Aβ42, to visualise the toxic effect on the cells, but also a mitochondrial 
marker pDsRed2-Mito (Clontech) was also transiently transfected into the cells 
(pDsRed2-Mito is a mammalian expression vector encoding a mitochondrial 
targeting sequence and the Discosoma sp. red fluorescent protein).  The pDsRed2-
Mito was included to compare the reaction of these two mitochondrial proteins 
when the cells are reacting to the addition of the Aβ peptide.   
 
The SK-N-SH (ABAD-EGFP) cells were grown as before in glass-bottomed 
WillCo-dish tissue culture dishes and incubated to 50-60% confluence (12-16 hr) 
in an incubator at 370C with 5% CO2. The cells were then transfected with 2µg 
pDsRed2-Mito DNA using lipofectamine (Invitrogen) and incubated to 80% 
confluence (12-16 hr). At this stage 50% growth medium was replaced with fresh 
20µm 
                   a      b                c                       d 
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pre-warmed medium. The Aβ42 peptide (Biosource) was pre-incubated for 24hr 
at 370C as before, and added to the growth medium at a final concentration of 
1µM.  The cells were further incubated for 20hr in an enclosed Perspex hood on a 
rig attached to the microscope.  The conditions were regulated: the rig was heated 
at 370C and 5% CO2 was continuously pumped into the Willco dish.  Images of 
the cells were taken every 1-2hr, using the Deltavision deconvolution microscope 
(Figure 3.14). 
 
As indicated in Figure 3.14, these images indicate the cytotoxic effect of 1µM 
Aβ42 on SK-N-SH (ABAD-EGFP) cells.  There appears to be a rapid toxic effect 
by 4hr post incubation with Aβ42.  By 4hr (b) approximately 50% of the cells are 
dead or showing considerable change in morphology, with shrinking and collapse 
of the mitochondria and the plasma membrane.  Significantly, in these cells there 
appears to be GFP, but not DsRed-Mito, expression in the cytosol and nucleus, 
indicating the selective export of ABAD. By 11hr (c) the cells affected continue to 
shrink and the mitochondria are reduced in volume and number.  By 17hr 
incubation (d), 90% of cells had shrunk showing a change in morphology 
consistent with cell death.  The nuclear membrane became indistinct and most 
cells were no longer attached to the tissue culture dish.  This live imaging 
experiment with the Aβ peptide shows a more rapid toxic effect and less cell 
viability at 16hr than was shown with the MTT assay using the same cells.  One 
possibility is that this may be due to changing the conditions slightly by co- 
transfecting with pDsRed Mito.  However, it was significant to observe that the 
pDsRed-Mito protein does not appear to be released from the mitochondria in the 
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same manner as ABAD-EGFP.  This may be reflected by the fact that ABAD is 
located to the matrix of the mitochondria whereas pDsRed mito is targeted to the 
mitochondrial inner membrane which could explain the differences in the reaction 
to Aβ toxic insult.  
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Fig. 3.14. Live imaging of stable SK-N-SH (ABAD-EGFP) cells, co transfected with 
pDsRed2-Mito and incubated with 1µM Aβ42 over 17hr.  The images show a time-
course to 17hr post incubation with Aβ.  Top row, cells imaged with FITC filter (ex. 
490nm. em. 528nm) Middle row: the same images with red filter (ex. 555nm. em. 
617nm).  Bottom row: converged images. (A) Before adding Aβ. (B) 4hr incubation with 
Aβ. (C) 11hr incubation with Aβ. (D) 17hr incubation with Aβ.   
t=0
hr 
t=4
hr 
t=11hr t=17hr 
10µm 
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3.4 Assays to assess apoptosis 
The live imaging showed that a 1µM dose of synthetic Aβ42 produced a toxic 
effect within 17hr, to cells overexpressing ABAD.   Further studies were designed 
to assess if this toxicity in vitro was due to apoptosis.  Apoptosis is characterised 
by an increase in cytosolic Ca2+ due to ion channel receptors being activated by a 
toxin.  A major stage of the cascade of cellular events involved in apoptosis is the 
release of cytochrome C from the mitochondria into the cytosol, which has been 
reported to occur within about five minutes, however the mechanism by which it 
translocates to the cytosol during apoptosis is the subject of debate (Goldstein et 
al., 2000; Martinou et al., 2000). It is proposed that cytochrome C is released 
either by the swelling of the mitochondrial matrix causing rupture of the outer 
mitochondrial membrane or a pore is developed in the mitochondrial membrane 
large enough to allow the protein to pass through.   
 
3.4.1 Toxic effects of actinomycin D, PBS and Aβ42 on SK-N-SH (ABAD-
EGFP) cells 
Prior to experiments to study apoptosis in SK-N-SH cells, it was necessary to 
establish the toxic conditions required to initiate a cellular response in these cells 
expressing the ABAD-EGFP, to confirm that the EGFP tag did not enhance/alter 
the cell’s sensitivity.  An experiment was therefore designed using the two toxins 
to compare results.  MTT assays were carried out as before such that SK-N-SH 
(ABAD-EGFP) cells were incubated in 96 well tissue culture plates with either 
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100µM actinomycin D or 2µM Aβ42 for 24hr. 75% PBS was added as a positive 
control to kill the cells. PBS maintains a buffered environment at pH 7.4 but 
contains no growth factors such as provided by serum to maintain the cells and  
no glutamine to prevent degradation and ammonia build up. Therefore the cells 
cannot survive in PBS alone. The results are shown in Figure 3.15. 
 
 
Fig. 3.15. Results of MTT assay with actinomycin D or Aβ42. SK-N-SH (ABAD-EGFP) 
cells were incubated for 24hr with toxins.  Readings are averaged from replicates of 8 and 
error bars show ± SD. (a) Negative control. (b) Incubation with 100µM actinomycin D 
produces 65% survival. (c) Incubation with 2µM Aβ produces 40% survival. (d) Positive 
control with 75% PBS shows <5% survival. This shows at these doses, both Aβ and 
actinomycin D show evidence of toxicity but 2µM Aβ is more toxic than 100µM 
actinomycin D over a 24hr incubation period.   
 
At these concentrations, 2µM Aβ is more toxic than 100µM actinomycin D over 
24hr incubation.  Further doses of actinomycin D were not tested at this stage and 
further assays for apoptosis were carried out at 100µM.   
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3.4.2  Subcellular fractionation and western blots 
Initial experiments were designed to identify cytochrome C release from the 
mitochondria to the cytosol. In order to confirm that SK-N-SH (ABAD-EGFP) 
cells undergo apoptosis when incubated with Aβ42, subcellular fractionation was 
carried out on the cells after incubation for 24hr with 2µM Aβ42 peptide.  For 
comparison and as a positive control, SK-N-SH (ABAD-EGFP) cells were also 
incubated with actinomycin D which is an antineoplastic antibiotic and inhibits 
cell proliferation by binding to double stranded DNA, inhibiting RNA synthesis 
and thus transcription (Sobell, 1985). It is a known inducer of apoptosis in tumour 
cells (Kleeff et al., 2000).   
 
The live imaging studies (section 3.3.2) appeared to show GFP release into the 
cytosol after a 4hr incubation with 2µM Aβ42 (Figure 3.14).  Therefore it was 
proposed that ABAD-EGFP may be released rapidly from the mitochondria into 
the cytosol in a similar manner to cytochrome C and this could be another initial 
marker for apoptosis.  
 
The experiment was designed to isolate the mitochondria from the cells by 
cellular fractionation after the addition of Aβ, and identify whether cytochrome C 
and/or ABAD were released into the cytosol by western immunoblotting.  The 
SK-N-SH (ABAD-EGFP) cells were fractionated using a mitochondrial 
fractionation kit (Active Motif), which is designed to provide an optimized 
protocol to eliminate cross-contamination and produce high yields of properly 
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segregated mitochondrial and cytosolic fractions.  The kit provides gentle lysis 
buffers and requires only a pestle homogeniser and the use of a benchtop 
centrifuge. The detailed protocol is found in section 2.4.2. The isolated fractions 
were analysed by western blot analysis using 0.5µg ml-1 anti-cytochrome C 
primary antibody (Santa Cruz mouse anti-cytochrome C) and 0.5µg ml-1 anti-
mouse HRP (horseradish peroxidase) secondary antibody (Figure 3.16).  
 
     
Fig. 3.16. Western blot of fractionated SK-N-SH (ABAD-EGFP) cells incubated for 24hr 
with 100µM actinomycin D or 2µM Aβ42, using anti-cytochrome C antibody.  Lanes 1, 
2, 3: mitochondrial fractions. Lanes 5, 6, 7: cytosolic fractions. Lanes 1&5: no toxins 
(negative control). Lanes 2&6: actinomycin D incubation. Lanes 3&7: Aβ incubation.  
Lane 4: empty lane. Lane 9: molecular weight markers. Lane 10: positive control for 
cytochrome C. This shows that cytochrome C is present in the mitochondria but only 
present in the cytosol after addition of the toxins, actinomycin D and Aβ (lanes 6&7), 
indicating that both toxins cause apoptosis after 24hr incubation with SK-N-SH (ABAD-
EGFP) cells.  
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In order to identify if ABAD-EGFP is released from the mitochondria into the 
cytosol in a similar manner to cytochrome C, a repeat experiment was carried out.  
The SK-N-SH (ABAD-EGFP) cells were incubated with Aβ42 overnight for 16hr. 
The cells were fractionated as before. The isolated fractions were analysed by 
western blot using 0.5µg ml-1 anti-ABAD antibody (kindly donated by SD Yan, 
Columbia University NY, USA) (Figure 3.17).   
 
 
 
 
Fig. 3.17.  Western blot of fractionated SK-N-SH (ABAD-EGFP) cells incubated for 
16hr, using 0.5µg ml-1 anti-ABAD antibody.  Lane 1, mitochondrial fraction, lane 2, 
cytosolic fraction and lane 3, positive control for ABAD.  This shows that ABAD-EGFP 
is not released into the cytosol when SK-N-SH (ABAD-EGFP) cells are incubated with 
2µM Aβ42 for 16hr.   
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These western blot analysis results did not appear to match the live imaging 
results.  To verify if ABAD-EGFP release into the cytosol is time dependent, a 
further experiment was carried out where SK-N-SH (ABAD-EGFP) cells were 
incubated with 2µM Aβ42 for up to 48hr.  Samples were taken and fractionated at 
18hr, 26hr and 48hr after incubation with Aβ (Figure 3.18). 
 
 
 
Fig. 3.18. Western blot of fractionated SK-N-SH (ABAD-EGFP) cells incubated for up to 
48hr with 2µM Aβ42. Western blot analysis using anti-ABAD antibody.  Lanes (a), (c), 
(e) and (h) mitochondrial  fractions and lanes (b), (d), (f) and (i) cytosolic fractions (green 
arrows). Lanes (a) and (b) cells with no Aβ incubation. Lanes (c) and (d) cells after 48hr 
incubation with Aβ. Lanes (e) and (f) cells after 26hr incubation with Aβ.  Lane (g) 
Positive control for ABAD.  Lanes (h) and (i) cells after 18hr incubation with Aβ.  This 
shows that when SK-N-SH (ABAD-EGFP) cells are incubated with 2µM Aβ42 for 48h, 
ABAD is released into cytosol.  There is no evidence of ABAD being released before 
48hr indicating that the release of ABAD into the cytosol is time dependent. 
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These results may indicate that ABAD is released from the mitochondria late in 
the death of a cell, or these results may be due to the poor sensitivity of the 
antibodies used that may only detect high concentrations of the proteins in the 
cellular lysate.  The live imaging experiments performed previously appeared to 
show ABAD-EGFP beginning to be released into the cytosol after 4hr incubation 
with 2µM Aβ42.  This may indicate that ABAD-EGFP is released slowly from 
the mitochondria over a period of hours.  This is supported by the western blots 
after 24hr and 48hr incubation with the Aβ42 peptide. It is therefore difficult to 
make a direct comparison of the results here, using these different techniques.  
Similarly the MTT assays may not be sensitive enough and the results could be 
masked by the cells dividing.   
 
However, all the western blots show that Aβ42 peptide induces apoptosis in SK-
N-SH (ABAD-EGFP) cells, shown by cytochrome C release from the 
mitochondria into the cytosol within 16hr.  ABAD is seen in the cytosol after 48hr 
incubation with the Aβ peptide.  From these results in SK-N-SH cells, ABAD 
does not appear to be mimicking the rapid release of cytochrome C into the 
cytosol and it is therefore not an early marker for apoptosis. 
 
3.4.3 Investigation of apoptotic pathways induced in SK-N-SH (ABAD-
EGFP) cells 
 
3.4.3.1 Investigation of caspase inhibition of apoptosis 
Further MTT assays were carried out with a pan-caspase inhibitor Boc D-fmk 
(Kamiya Biomedical Co.), to identify if the apoptotic pathway was caspase 
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mediated. Cells were incubated for 24hr in a 96 well tissue culture dish with the 
toxins Aβ or actinomycin D or the pan-caspase inhibitor (Figure 3.19).  
 
Fig. 3.19. Results of the MTT assay with actinomycin D or Aβ. SK-N-SH (ABAD-
EGFP) cells were incubated for 24hr with toxins, without and with the pan caspase 
inhibitor Boc D-fmk. (a) Negative control  (b) incubation with caspase inhibitor only (c) 
Incubation with 100µM actinomycin D shows reduced viability to 74%.(d) Incubation 
with 100µM actinomycin D and caspase inhibitor (e) Incubation with 2µM shows 
reduced viability to 62.5% (f) Incubation with 2µM Aβ  and caspase inhibitor (g) 
Incubation with 1µM Aβ shows reduced viability to 71 % (h) Incubation with 1µM Aβ  
and caspase inhibitor (i) Positive control with 75% PBS. Readings are averaged from 
replicates of 7 and error bars show +1SD.  The t test gave P values as shown. 
 
These results show that the caspase inhibitor had a significant effect on toxicity 
caused by actinomycin D (p=0.016), but not on toxicity caused by the Aβ peptide 
(P=0.142 and P= 0.09).  This would indicate that actinomycin D and Aβ induce 
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apoptosis by different pathways: actinomycin D activates the caspase pathway but 
Aβ does not. 
 
3.4.3.2 Investigation of inhibition of apoptosis by the novel inhibitor TAT24 
 
Further studies were carried out using the peptide inhibitor, TAT24.  This was 
developed using the amino acid sequence 93-116 from ABAD fused to a TAT 
sequence from the HIV virus.  The TAT sequence allows the peptide to enter the 
cell membrane (Lustbader et al., 2004). Two MTT assays were carried out with 
this inhibitor peptide: 1) Cells were incubated for 24hr in a 96 well tissue culture 
dish with Aβ without or with TAT24; results are shown in Figure 3.20. and 2) 
Cells were incubated for 24hr in a 96 well tissue culture dish with actinomycin D 
without or with TAT24; results shown in Figure 3.21. 
 
Fig. 3.20. Results of the MTT assay with 1µM Aβ.  SK-N-SH (ABAD-EGFP) cells were 
incubated for 24hr with Aβ without or with the TAT24 peptide inhibitor. Lane (a) 
negative control. Lanes (b) to (e) show cells incubated with increasing concentrations of 
TAT24 peptide only. Lane (f) cells incubated with 1uM AB. Lanes (g) to (j) show cells 
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incubated with 1uM AB and with TAT24 inhibitor at increasing concentrations.  Error 
bars show +1 SD. The t test gave P values as shown. 
 
These results show that 1µM Aβ had a significant toxic effect on the SK-N-SH 
cells (lane f) but the TAT24 peptide inhibitor did not significantly inhibit the 
toxicity caused by the Aβ peptide (p=0.19).   Figure 3.21 also shows that 50µM 
actinomycin D had a significant toxic effect on the SK-N-SH cells (lane f) but 
adding the TAT24 inhibitor had no significant change in the cell viability.  
Therefore from these initial experiments the TAT24 peptide inhibitor appears to 
be unable to inhibit Aβ toxicity on SK-N-SH (ABAD-EGFP) cells. 
 
 
 
Fig. 3.21. Results of the MTT assay with 50µM actinomycin D.  SK-N-SH (ABAD-
EGFP) cells were incubated for 24hr with actinomycin D without or with the TAT24 
peptide inhibitor. Lane (a) negative control. Lanes (b) to (e) show cells incubated with 
increasing concentrations of TAT24 peptide only. Lane (f) cells incubated with 50µM 
actinomycin D. Lanes (g) to (j) show cells incubated with 5050µM actinomycin  D and 
with the TAT24 inhibitor at increasing concentrations.  Error bars show +1 SD. The t test 
gave P values as shown. 
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3.5 Investigating the Aβ42 peptide 
 
There were many problems duplicating many of these experiments, with 
inconsistent cell viability after toxic insult.  The cause was unclear.   It was 
possibly due to problems incubating with the Aβ peptide or a problem using the 
SK-N-SH cell line.  To check growth conditions for the SK-N-SH cells, an 
experiment was performed changing the concentration of serum in the growth 
media, as it was proposed that the serum may be inhibiting the Aβ42 peptide 
toxicity.  Comparison of cell viability was carried out using the MTT assay on the 
SK-N-SH (ABAD-EGFP) cells incubated with either Aβ42 or 500nM 
staurosporin or in concentrations from 1µM to 20µM, and lowering the serum 
concentration to 2% (from 5-10%) and lowering seeding cell density to 5x103 
cells per well (from 1x104 ).  Staurosporin was chosen as another inducer of 
apoptosis, as earlier results had indicated that Aβ and actinomycin D possibly 
induce apoptosis by different pathways.  Staurosporin induces apoptosis by 
inhibiting protein kinases (Ruegg and Burgess, 1989).  The results are shown in 
Figure 3.22 and indicate that the cell viability after incubation with Aβ42 peptide 
remained inconsistent and will require much more extensive investigation. 
Specifically, the results with staurosporin and serum free media were as expected 
with greatly reduced cell viability.  From these results the change in growth 
conditions appeared to make little difference with the addition of the Aβ peptide.  
This was also shown by the inconsistency of the dose of Aβ required to causing 
cell death when compared to previous assays (Figures 3.12 and 3.14).  Previously 
2µM Aβ reduced viability to ~78%. Whilst in the current experiment 2µM Aβ 
reduced viability to ~ 81%.  But >5µM Aβ was required to reduce cell viability to 
 117 
~78% and 10µM reduced cell viability to 21%.  500nM staurosporin was adequate 
to show toxicity with cell viability below 15%.  Cells incubated without serum 
showed viability reduced to ~20%. 
 
Fig. 3.22. Results of the MTT assay with staurosporin or Aβ.  SK-N-SH (ABAD-EGFP) 
cells were cultured in reduced serum medium in a 96 well plate and the toxins added as 
shown. (a) Negative control, no toxins. (b) Incubation with 1µM Aβ. (c) Incubation with 
2µM Aβ. (d) Incubation with 5µM Aβ. (e) Incubation with 10µM Aβ. (f) Incubation with 
20µM Aβ. (g) Incubation with 500nM staurosporin. (h) incubation in serum free medium.  
Error bars show +1 SD.  The t test gave p values as shown.   
 
 
3.5.1 Investigating the oligomeric and fibrillar forms of the Aβ42  peptide 
The experiments presented in this chapter aimed to assess the suitability of SK-N-
SH cells and pre-incubated synthetic Aβ, as an in vitro model for AD.  
Reproducibility of results was difficult after extensive attempts to keep all 
conditions consistent.  During this time, there had been some debate focussed on 
whether Aβ fibrils or soluble oligomers of Aβ were the toxic form causing 
neurodegeneration and dementia (Kayed et al., 2003). Protocols have been 
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published for consistent production of stable oligomeric or fibrillar preparations of 
Aβ42 (Dahlgren et al., 2002).   In these protocols, it was reported that oligomeric 
Aβ peptide inhibited neuronal viability 10-fold more than fibrils and 40 fold more 
than non-aggregated peptide, with significant reduction in cell viability with 
10nM Aβ42. A further publication reported that the formation of oligomers, 
fibrils, and fibrillar aggregates is determined by time, concentration, temperature, 
pH, ionic strength, and Aβ species. A complete study of Aβ, either in vivo or in 
vitro, requires an understanding of the conditions that drive peptide assembly 
toward one conformational state or another. Any change that affects the 
conformation of Aβ likely affects its biological activity (Stine et al., 2003).  
Soluble oligomers of Aβ have been isolated from brain, plasma and cerebrospinal 
fluid of canines (Head et al., 2010) and AD patients (Fukumoto et al., 2010).  
Subsequently, it is now recognised that soluble intermediate oligomeric Aβ is a 
toxic form of the peptide before amyloid plaques are deposited in the brain. 
 
3.5.2 Immunostaining of Aβ added topically to growth medium 
Experiments were designed to further investigate the synthetic Aβ peptide used in 
the laboratory.  The first experiment fixed SK-N-SH (ABAD-EGFP) cells after 
incubation with Aβ.  Immunostaining of the Aβ peptide was carried out using 
0.5µg ml-1 anti-Aβ monoclonal antibody (Upstate clone 4G8), which binds to the 
epitope between amino acid residues 18 and 22 followed by staining with Alexa 
568 red fluorescent secondary antibody (Figure 3.23). This immunostaining of the 
Aβ peptide confirmed aggregation outside the cell after topical application to the 
growth media. 
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Fig. 3.23. SK-N-SH (ABAD-EGFP) cells incubated with Aβ peptide, fixed and stained. 
The Aβ peptide was immunostained with anti-Aβ primary antibody (Upstate clone 4G8), 
and Alexa 568 fluorescent secondary antibody.  The nuclei are stained blue with DAPI. 
The red staining is consistent with aggregated peptide on the extracellular surface of the 
plasma membrane. 
3.5.3 Electron microscopy of the Aβ peptide  
Having identified the aggregated peptide by immunocytochemistry, some of the 
incubated peptide was examined by electron microscopy (Figure 3.24). A small 
sample of reconstituted Aβ peptide was examined by EM. The sample was 
pipetted onto a conductive screen and stained with uranyl acetate. The EM images 
confirmed the presence of multiple aggregated fibrils in the incubated peptide 
used in the experiments.  Experimentally, it was impossible to control the amount 
of fibrillar Aβ produced during incubation of the peptide.  It is possible that when 
there was more fibrillar peptide formed, the soluble and toxic monomeric form 
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was reduced. This then required an overall higher concentration of the Aβ peptide 
to attain the same level of toxicity in the cell viability assays  
 
.  
Fig. 3.24. Electron microscope images of synthetic Aβ. All the EM images show multiple 
tangled fibrillar structures.  This suggested the Aβ peptide was mainly aggregated and 
fibrillar.  
 
3.5.4 Introducing Aβ to cells using a carrier peptide - Chariot™(Actif Motif) 
Because the direct addition of the synthetic peptide to the growth medium was 
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causing the peptide to aggregate outside the cell, another method of introducing 
the Aβ peptide to the inside of the cell was tried using a carrier peptide. The 
Active Motif Chariot™ system was used (section 2.2.8). This system uses a 
carrier peptide to bind to a peptide or protein and carry it through the cell 
membrane by permeabolisation and deposit it within the cytosol, where it is then 
released from the carrier peptide. The cells were incubated with the Aβ peptide 
together with the carrier peptide for up to 8hr (as per manufacturer’s instructions), 
then fixed, immunostained and analysed under fluorescent microscopy (Figure 
3.25). 
 
The Chariot carrier peptide is able to introduce the Aβ peptide into the cells 
within four hours, which then show signs of severe toxicity.  The Chariot carrier 
peptide is a good method to introduce the Aβ peptide into cells for toxicity 
studies. 
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Fig. 3.25. SK-N-SH cells transiently transfected with MTS-ABAD-EGFP.  After 
incubation for 16hr, the cells were then incubated further.  
Image 1. As a negative control, cells were incubated for 4 hr with the chariot carrier 
peptide only. The nuclei stained blue with DAPI show a healthy morphology.  The cell 
expressing ABAD-EGFP is also normal in shape.  There is some red staining in all the 
cells which may be due to non- specific antibody binding or some endogenously 
expressed Aβ within the cells. However no significant toxicity was seen. 
Image 2. Cells incubated for 4 hr with synthetic Aβ peptide using the Active Motif 
Chariot carrier peptide.  
The cells were fixed and immunostained with 0.5µg ml-1 anti-Aβ monoclonal antibody 
(Upstate clone 4G8), and Alexa 568 red fluorescent secondary antibody, and the nuclei 
stained with DAPI.  This clearly shows the toxic effect on the cells after 4 hr incubation 
with Aβ peptide.  The cells are shrunken and have no clear outline.  The Aβ is seen 
within the cell, stained red, surrounding the nucleus that is stained blue.  The nuclei show 
DNA fragmentation consistent with the formation of apoptotic bodies (blue arrow).  Only 
two of the cells, on the left in image 2, are expressing ABAD-EGFP.  There are two or 
three small areas of yellow indicating co-localisation of ABAD with Aβ (green arrow). In 
these cells there are discrete red spots which look like a perinuclear red stained ring (red 
arrow). 
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3.5.5. Transfection with mAPPswe plasmid 
Another method used to try and overcome the problem of the aggregated Aβ 
peptide, was to transfect SK-N-SH cells with a mutant APP plasmid (mAPPswe). 
This plasmid comprises a mammalian Cre/Lox vector which expresses mAPPswe , 
with a double mutation K670N/M671L, which after translation produces excess 
Aβ peptide within the cell (Thinakaran et al., 1996).  The cells were transfected 
with 1µg of plasmid DNA and incubated for 18 hr before being fixed and 
immunostained for Aβ peptide as before with anti-Aβ primary antibody (Upstate 
clone 4G8), and Alexa 568 fluorescent secondary antibody, and then imaged 
using fluorescent microscopy (Figure 3.26). 
 
Fig. 3.26. Two example images of SK-N-SH (ABAD-EGFP) cells transfected with 
mutant APP and incubated for 18 hr before fixing and staining. The Aβ peptide was 
immunostained with anti-Aβ primary antibody (Upstate clone 4G8), and Alexa 568 
fluorescent secondary antibody.  The cells on the right have blue DAPI staining of nuclei.  
The ABAD-EGFP is seen expressed green in the mitochondria. There is a clear red 
perinuclear ring in all cells, indicating localisation of Aβ around the nucleus. There is no 
obvious co-localisation of ABAD with Aβ. 
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The cells transfected with mAPP and incubated for 18hr showed no sign of 
apoptosis with the nuclei clearly seen, indicating that these cells appear quite 
healthy. Further experiments were conducted, transfecting cells and incubating for 
48hr before fixing, to see if a longer incubation was required for co-localisation of 
ABAD and Aβ and to induce apoptosis (Figure 3.27). 
 
 
Fig. 3.27. SK-N-SH cells transfected with mutant APP and incubated for 48hr before 
fixing and staining.  (a) cells imaged with FITC filter (ex. 490nm. em. 528nm.). (b) cells 
imaged with red filter (ex. 555nm. em. 617nm.). (c) converged image. This shows 
cellular toxicity with shrunken and misshapen cell outlines and little or no integrity of the 
mitochondria.  The red stained Aβ peptide appears to be located as discrete spots within 
the cell and possibly still in a perinuclear ring.  The Aβ is not completely colocalised with 
the mitochondria as there are clear green areas.  However there is some evidence of 
localised colocalisation marked with arrows. The nuclei were not stained with DAPI in 
this experiment. 
 
Transfection with mAPP for 48hrs shows a strong toxic effect on the cells but 
with only limited co-localisation seen of Aβ peptide with ABAD-EGFP.  The 
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mAPPswe plasmid is also a good method to introduce Aβ into the cell by 
translation of the mAPP gene followed by cleavage to produce the peptide. 
 
A perinuclear collection of Aβ has been reported before (Georgopoulou et al., 
2001).  That study reported alteration in the glycosylation state of APP resulting 
in a decrease in the secretion of the neuroprotective, soluble form of the protein 
and a parallel increase in the deposition of the cellular protein within the 
perinuclear region of the cell.  APP is also reported to be found in endosomes in a 
perinuclear pattern and introduction of copper compounds promotes trafficking of 
APP to the cell surface (Acevedo et al., 2011). It is also reported that Aβ 
accumulates with SOD1 and aggregates in the perinuclear region (Yoon et al., 
2009). SOD1 is a key antioxidant enzyme, one of the major targets for oxidative 
damage in the brains of patients suffering from Alzheimers disease (AD).   It is 
possible that these images are showing one or more of these conditions.  Binding 
to SOD1 could be evidence that these experiments are simultaneously showing 
another intracellular interaction in this in vitro AD model. 
 
3.5.6 MTT assays using soluble oligomeric Aβ  
Some soluble oligomeric Aβ was obtained (by kind donation from Aynun Begum 
Dept Medicine UCLA) from the laboratory where the original oligomers were 
produced (Kayed and Glabe, 2006).  There was only enough to try some limited 
MTT assay experiments, to verify toxicity with the soluble oligomeric Aβ peptide 
compared with the synthetic peptide previously used.  Some inhibitory studies 
were also carried out using the inhibitory peptide TAT24 (amino acid residues 
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corresponding to residues 93-116 of the ABAD sequence), labelled as ‘TAT’ in 
Figure 3.28.  
 
 
Fig. 3.28. Results of the MTT assay with oligomeric Aβ +/- inhibitor TAT24.  SK-N-SH 
(ABAD-EGFP) cells were cultured as shown.  (a): negative control. No toxins. (b) 
220nM soluble Aβ.  (c) 220nM soluble Aβ with 1uM inhibitor. (d) 220nM soluble Aβ 
with 10uM inhibitor. (e) 220nM soluble Aβ with 100uM inhibitor. (f) 440nM soluble Aβ. 
(g) 880nM soluble Aβ. (h) 880nM soluble Aβ with 1uM inhibitor. (i) 500nM 
staurosporin. The t test gave Pvalues as shown. 
 
These results show that the soluble peptide proved to be much more toxic than the 
peptide used previously; 50% viability with 440nM (lane f).  The concentration 
was 10x lower than the synthetic peptide used before and similar to physiological 
concentrations. Endogenous Aβ is <100nM where its production or breakdown is 
modified (Pearson and Peers 2006).  Interestingly the TAT24 peptide inhibitor 
showed significant inhibition at 1µM with 880 nM oligomeric Aβ peptide (lanes g 
and h. P= 0.02).  However 1uM  showed no significant inhibition with 220nM Aβ 
(lanes b and c. P=0.39).  Also the data showed that the addition of 10uM and 
100uM of the TAT inhibitor with 220 nM Aβ increased the toxicity to the cells, 
 127 
(lanes d and e).  A very limited supply of the soluble oligomeric Aβ allowed only 
this one experiment and not all the variables of Aβ concentrations with TAT24 
concentrations could be tested. The TAT24 inhibitor was tested with the lowest 
and highest Aβ concentrations, ie 220nM and 880nM Aβ.  
 
3.6 Primary neurons from murine embryonic cells 
Experiments with primary neurons was not possible due to problems with 
availability of mice.  However in collaboration with Dr C. Connolly, university of 
Dundee, we provided the plasmids ABAD-EGFP and pDsRedmito2 to be 
transfected into their primary cell cultures.  Once transfected the cells were 
incubated for 18hr then fixed. The cells showed ABAD-EGFP co-localised with 
pDsRedmito2 in discreet areas along the axons and around the nucleus in the cell 
body (Figure 3.29). 
 
Fig. 3.29. Primary cortical cells co-transfected with ABAD-EGFP and with pDsRedmito2.  (a) 
cells imaged with green FITC filter (ex. 490nm. em. 528nm.) (b) cells imaged with red filter (ex. 
555nm. em. 617nm.). (c) converged image.  These cells show ABAD-EGFP colocalised with 
pDsRedmito2 in discreet areas along the axons and around the nucleus in the cell body 
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3.7 Culture of multipotent neurospheres from murine neuronal 
       stem cells  
 
To obtain a primary cell system that would reduce the number of mice required 
and would provide cell cultures that could last for six to eight weeks, a system 
was established to grow neurospheres from murine neuronal stem cells (see 
section 2.2.3 for protocol). This work was carried out in the laboratory of 
Professor Alessandra D’Azzo, St Jude Children’s Hospital, Memphis. 
 
From two mouse pups (p3-p6), a supply of neurospheres was cultured for 6-8 
weeks  in serum free medium. When required, neurospheres were differentiated 
into the three primary phenotypes, astrocytes, oligodendrocytes and neurons, by 
removing epidermal growth factor (EGF) from the growth media and adding a 
low concentration of serum (Figure 3.30). 
  
 
 
 
                   
  a                b      c 
Fig. 3.30. Phase Contrast microscope images of neurospheres from murine neural stem 
cells. (a) Proliferating neurospheres in suspension, six days in culture. (b) Isolated 
neurosphere, containing approximately 10,000 cells. (c) Adherent cells differentiating 
48hr after removal of EGF and addition of serum. 
 
100 µm 
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3.7.1 Immunostaining neurospheres 
It is possible to stain neurospheres before differentiation. They can be fixed and  
stained with different neuronal markers and the different neuronal cells can be 
identified. Figure 3.31 shows an example of neurospheres that have been stained 
to identify glial cells and neurons.  
  
Fig 3.31. An example of stained neurospheres, taken from (Tessitore et al., 2004). A. Neurosphere 
from a wild type mouse and B. Neurosphere from a transgenic mouse.  mouse. The cells have been 
immunostained with antibody markers for astrocytes, anti-GFAP polyclonal antibody (Immunon) 
(Glial fibrillary acidic protein-GFAP) green, and neurons, anti-β III-tubulin monoclonal antibody 
(Covance) (β-III tubilin) red.  Nuclei Hoechst stain blue. 
 
For the purpose of  establishing a reliable cytotoxic system to investigate ABAD 
and Aβ, by culturing neurospheres, some immunostaining experiments were 
performed with differentiated neurospheres cultured from wild type (WT) and 
mAPP mice.  The neurospheres were cultured then processed into a single cell 
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suspension and differentiated for three days by withdrawal of EGF (section 2.2.3). 
The cells were then fixed and permeabilised and stained with 0.5µg anti-ABAD 
primary polyclonal antibody (Pierce) for endogenous expression of ABAD 
(Figure 3.32). 
 
 
Fig. 3.32.  Endogenous expressed ABAD in WT murine neurospheres, differentiated for 
three days then fixed and immunostained with anti-ABAD primary polyclonal antibody 
(Pierce) and Alexa 568 fluorescent secondary antibody (red). 
 
Having identified ABAD endogenously expressed in the differentiated cells, the 
experiment was repeated, staining also for the mitochondrial translocase protein 
TOM40 using anti-TOM40 (Santa Cruz Biotech.). Figure 3.33 indicates that co-
localisation of the two mitochondrial proteins was clearly seen. 
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Fig. 3.33. Immunostaining showing co-localisation of endogenous expressed ABAD 
stained red and TOM40, stained green.  
 
 
Double immunostaining was done with an anti APP polyclonal antibody specific 
for APP770 and an anti-ABAD polyclonal antibody, for another experiment with 
cells cultured from a Tg mAPP mouse.  Figure 3.34 shows that these cells show 
APP stained green, spread throughout the cytosol and ABAD stained red, shown 
by co-localisation with the APP as discreet yellow spots in the cytosol (orange 
arrow). 
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Fig. 3.34. Differentiated neurospheres from Tg mAPP mouse. DAPI stained nuclei. APP 
stained green. Some yellow co-localisation seen (orange arrow) with ABAD stained red. 
 
These preliminary experiments indicated that this system appears to be robust and 
worth developing further.  The neurospheres can be transfected and differentiated 
into different neuronal phenotypes and comparisons can be made between wild 
type and different transgenic mouse models. 
 
3.8 Discussion 
From these experiments it was possible to confirm that ABAD is expressed in the 
mitochondria of SK-N-SH cells but may be translocated to the ER. Figure 3.6 
shows some co-localisation of ABAD-EGFP with ER-Red.  Recent publications, 
now report ABAD interacting with Aβ in the mitochondria (Lustbader et al., 
2004; Yan and Stern, 2005; Yao et al., 2011) supporting these in vitro studies.  
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For further in vitro studies, a cellular AD model was produced by transfecting a 
plasmid expressing ABAD-EGFP into SK-N-SH cells and developing a stably 
expressing cell line.  Another construct was developed with a mitochondrial 
targeting sequence for transient transfections to express the fusion protein MTS-
ABAD-EGFP.  This provided the capability of allowing rapid transient 
transfections of cells and was subsequently used as a template for other cellular 
studies in the laboratory requiring ABAD expression, e.g. using FRET to analyse 
possible binding partners for ABAD within the cell.   
 
SK-N-SH cells were chosen based on previous experiments where they had been 
used to study ABAD, to confirm cellular localisation and effects of toxicity when 
incubated with Aβ (Yan et al., 1997a; Yan et al., 1999).  This cell line was also 
well characterised for neuronal cytotoxic studies.  However, several studies 
identified this cell line as having a protective effect against some toxic insults, 
shown to be toxic to other cell types and some studies were not able to reproduce 
apoptosis with the addition of Aβ ((Ba et al., 2003). This poses the question, is 
this the best cell line to use for investigating AD.  During the period of this 
research, another group developed and published a system to provide a reliable 
cytotoxic and neuroprotective screen for AD using SK-N-SH cells (Ba et al., 
2003). They used four cytotoxic insults: the Aβ peptide, 1-methyl-4-phenyl-
1.2.3.6-tetrahydropyridine (MPTP), high cell density culture and serum 
deprivation. SK-N-SH cells were incubated with the toxins for 96hr. The ability of 
all toxic insults to induce apoptosis was tested and all induced apoptosis except 
the Aβ peptide.  However several protein kinase inhibitors were then trialled to 
provide information on the cell death pathways activated under these conditions. 
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The p38 MAP kinase inhibitor, SB203580 (1 μM), and the PKC inhibitor, 
chelerythrine (5 μM) successfully inhibited the loss in viability caused by Aβ and 
the high density culture, respectively but not the other toxins.  This would indicate 
that the cell toxicity caused by Aβ was due to apoptosis. The results were 
confusing, indicating that the cytotoxic models used may each have its unique 
cytotoxic pathway.  Ba et al incubated the cells for 96 hours whereas in the 
experiments for this thesis, possible toxic effects were seen as early as 4-11hr, 
using fluorescent microscopy.  However MTT assays and western blots needed 24 
– 48hr to show significant changes.  These results indicate that it is important to 
identify the most sensitive assay, but also it is necessary to compare the effects on 
different neuronal cell lines to identify the cellular pathways involved in the 
cytotoxic events.  It may be necessary for further in vitro experiments to incubate 
cells for much longer, up to 96hr (Ba et al., 2003). 
 
In these experiments, toxicity has been shown in the SK-N-SH (ABAD-EGFP) 
cell line using the synthetic Aβ42 peptide.  However, doses required to produce a 
toxic effect were inconsistent and generally high concentrations were required.  
Generally 1- 2µM Aβ42 was needed to show a significant change in the cells, but 
in some experiments this needed to be increased to 5-10µM Aβ42, whilst it is 
interesting to note that physiological concentrations are in the region of 20nM 
(Yan et al., 1997a).   It was difficult to show consistent and reliable cytotoxic 
results, and this seem to stem from the fact that there was a problem with the 
consistency of the Aβ42 peptide used, despite extensive trials.  EM studies did 
show that the Aβ42 peptide used in most of the experiments did develop into 
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fibrils.  At the time that these experiments were being performed, it was being 
reported that it was probably the soluble prefibrillar Aβ that was toxic (Glabe, 
2005).   A limited supply of the soluble oligomeric form of Aβ was provided and 
this did give more consistent results at a much lower concentrations. In the future, 
a good consistent supply of the soluble oligomeric form would allow more 
reliable experiments and give more consistent results. 
 
Fluorescent immunostaining was able to confirm Aβ aggregation on the exterior 
of the cell surface with no evidence of toxicity.  Another two methods were used 
to introduce the same Aβ peptide within the cell.  First using a carrier peptide to 
permeate the cell membrane and transfer the synthetic peptide from the growth 
medium into the cell.   Second a plasmid expressing a mutant form of APP that 
produces excess Aβ peptide was transfected into the cells.  Both of these methods 
showed greater toxicity than by topical application of Aβ alone. The experiments 
indicated that when the Aβ peptide is in closer proximity with intracellular ABAD 
a strong toxic effect is seen.  These two methods were more reliable at introducing 
Aβ into the cell by two distinct and different methods, direct import and 
transcription, translation of the mAPP gene followed by proteolytic cleavage. 
 
In summary, SK-N-SH proved a useful cell line to investigate some aspects of 
toxicity but it may not be the cell line of choice to show apoptosis.  SK-N-SH 
cells are consistent with a neuronal phenotype (Ba et al., 2003). However, SK-N-
SH cells have few glutamate receptors, and there is evidence that SK-N-SH cells 
resist toxic insults due to lack of NMDA receptors (Pizzi et al., 2002).  This could 
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be overcome by differentiation of SK-N-SH cells by retinoic acid that may 
provide a better model as they produce functional NR1 and NR2B-type NMDA 
receptors.  Other factors that affected cell growth and behaviour were cell density 
and growth medium conditions.  Seeding cell density was critical to cell growth 
and survival.  An average of 10-15 x 103 cells cm-2 was optimum.  Different 
batches of serum in the growth medium also affected results.  Sometimes a 
difference of 2% to 10% serum was required to obtain comparable results.  It was 
possible, however, to monitor the location of ABAD in living cells and the toxic 
effect of Aβ over several hours. 
 
Three techniques were used to compare the results of intracellular Aβ; fluorescent 
microscopy, MTT assays of whole cell tissue cultures followed by western blots 
of cellular fractionation to isolate the mitochondria. Fluorescent microscopy 
shows a toxic effect on cells transfected with ABAD within 11hrs.  However, 
western blot analysis of ABAD released from the mitochondria to the cytosol 
occurs at a later stage of cell death (approximately 48hr), unlike cytochrome C 
that is released within 4-6hrs.  This indicates that ABAD is probably not a useful 
early marker for apoptosis and responds differently to cytochrome C.  The early 
release of cytochrome C indicates that Aβ induces apoptosis in this cell line.  This 
disagrees with the results shown using SK-N-SH cell alone, where they could not 
show apoptosis (Ba et al., 2003).  This would indicate that ABAD has a crucial 
role in inducing apoptosis in SK-N-SH cells.  Further investigation using the 
oligomeric Aβ peptide would provide a more reliable toxic Aβ source. 
 
Producing a primary murine embryonic cell culture was possible but it was time 
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consuming and relied on good breeding of the laboratory mice.  This proved to be  
a problem on several occasions. The transfections of the primary cells were 
improved by use of the Amaxa nucleofection system, but contamination of the 
cells and the necessity to complete an experiment within a week made this an 
unreliable system to use. Therefore, development of the murine neurosphere cell 
culture system could be a way forward as it can be easily set up in a tissue culture 
laboratory with minimal animal usage.  It is also cost efficient, reliable and robust 
system and would be a useful system to adopt.   The cells can be cultured in 
suspension for 6-8 weeks minimum and have little or no problems with 
contamination.   For experiments they can be differentiated into the three main 
neuronal cell phenotypes and can be grown as monolayers for fixing and staining. 
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Chapter 4 
Proteomic analysis of brain tissue from novel transgenic mouse 
models for Alzheimer’s disease. 
 
4.1 Background and aims 
The original amyloid cascade hypothesis states that neurodegeneration begins 
with abnormal processing of APP and results in extracellular Aβ deposition 
(Hardy and Higgins, 1992). The original neuronal cytoskeleton degeneration 
hypothesis, led by tau expression, states that cytoskeletal changes lead to 
neurofibrillary tangle formation, leading to the neuronal changes seen in AD 
(Neve and Robakis, 1998).  These two original hypotheses still cause debate about 
the cellular changes occurring before or at the time of onset of the disease.  
Knowledge of the changes in protein expression and post-translational 
modification in vivo, may lead to identifying biomarkers to aid in the diagnosis 
but also in following the progression of AD.  The proteins that are identified may 
also provide good targets for drug development to aid the treatment of this 
disease.  
 
Proteomics is now widely used to investigate proteins involved in 
neurodegenerative disorders (Korolainen et al., 2010), and the application of 
proteomics to AD research was first published in 2001/2002 (Butterfield, 2002; 
Butterfield et al., 2003; Schonberger et al., 2001).  Proteomics is the analysis of 
an organism’s complete complement of proteins, often repeated under different 
conditions, e.g. a normal cell versus a disease affected cell, in order to identify 
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changes in protein expression in these different conditions. For analysis, proteins 
are usually identified by their separation by two-dimensional (2D) gel 
electrophoresis that separates on the basis of mass and charge differences. The 
proteins of interest are cut from the gel and digested by trypsin, followed by a 
choice of methods to identify the peptides and computer database analysis to 
identify the proteins.  For the study reported here, the determination of the 
molecular mass of the resulting peptides was made by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry and then 
database searching to identify the protein. 
 
For this thesis, the aim was to investigate changes in protein expression in vivo, 
from the mouse brain of novel AD models. Proteomic analysis of brain tissue 
from novel transgenic mice, developed to increase neuronal expression of ABAD 
and/or mAPP (mutant amyloid precursor protein), was carried out in order to 
investigate the effect of this over-expression on other proteins in the central 
nervous system (CNS).  
 
Preliminary proteomic studies had been carried out using mice aged between 8 
and 12 months, as an age match for middle to late stage AD, by Dr Jim Aiton 
(Senior Lecturer in School of Medicine, University of St Andrews) while 
affiliated with Dr Gunn-Moore’s research group.  The protein expression in 
mouse brain was investigated by comparing protein profiles between control (wild 
type - WT) and transgenic (Tg) mice.  2D gel electrophoresis was used to separate 
the proteins and MALDI-TOF mass spectrometry was used to identify the 
proteins.  Any novel proteins that were found to be up-regulated in the transgenic 
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models when compared to WT, were followed up by further western blot analysis 
on 4-8 month old mice.  This was carried out to try and confirm these changes in 
expression and also identify how early the changes in protein expression could be 
detected.  For the initial experiments, whole brain tissue samples were used.   
 
The progression of AD pathology affects different areas of the brain (Braak and 
Braak, 1991).  However some studies have shown that protein changes in human 
AD brain were not specific to regions of severe degeneration (Schonberger et al., 
2001).   For this thesis further experiments analysed the proteins expressed in the 
hippocampus and the cortex of 4-8 month mice. Further detailed analysis was 
attempted by pre-fractionation of the samples to isolate just the mitochondria, 
where ABAD is expressed.  This was performed to remove other cellular proteins, 
common to all samples, hoping to allow better identification of mitochondrial 
proteins, and so provide useful information on other expression changing 
mitochondrial proteins and potentially identify those involved with mitochondrial 
dysfunction. 
 
4.2 Protein expression in vivo using novel AD transgenic mouse 
      models 
 
Mice have been used as animal models in research for over one hundred years due 
to the ease with which they can be kept in laboratory conditions.  They can 
reproduce rapidly, are easy and inexpensive to handle, have short life-spans and 
can be genetically manipulated. Transgenic mice were developed in the 1980’s by 
introducing specific genes into the oocytes of mice and then continued by 
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selective breeding.  This allowed genetic animal models to be produced for 
research into specific diseases.  Due to their rapid rate of reproduction, effects of 
specific diseases can be monitored over a life-time of the animal (Duyckaerts et 
al., 2008). As discussed in section 1.10, human and mouse brains are very similar 
in gene expression and brain structure (Strand et al., 2007).  
 
Several genetically modified mice have been bred as models for AD, each suitable 
for examining different AD phenotypes. The following are five genes that have 
been associated with the disease: amyloid precursor protein (APP), presenilin 1 
(PS1), presenilin 2 (PS2), apolipoprotein allele 4 (ApoE4), and the tau protein.  
Several double transgenic mice have also been bred to express a combination of 
two of these proteins.  More recently, a triple transgenic model has been bred, 
PS1(M146V), APP(Swe), and tau(P301L) (Oddo et al., 2003). This model 
exhibits Aβ plaques by 6 months of age as well as neurofibrillary tangles by 10-12 
months of age, and therefore shows both AD phenotypes in one model. 
  
For this study, three transgenic models were used: a transgenic mutant APP (Tg 
mAPP) where mice produce an excess of the Aβ peptide, and two novel 
transgenic mice that were developed as models for AD by our collaborators at 
Columbia university, New York, USA (Lustbader et al., 2004; Takuma et al., 
2005b).  These models either over-express ABAD (Tg ABAD), or over-express 
ABAD in an Aβ rich environment (2 x Tg mAPP/ABAD).  The models 
expressing ABAD were produced with neuronal-targeted expression of ABAD 
generated under the control of the PDGF-B chain promoter (Lustbader et al., 
2004; Takuma et al., 2005b).  An existing transgenic mouse strain was provided 
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by Dr Mucke (University of California), expressing a mutant form of human 
amyloid precursor protein, a minigene encoding hAPP695, 751 and hAPP770 
bearing V717/F, K670M, N671L mutations: Tg mAPP mice, J-20 line (Mucke et 
al., 2000).  Tg ABAD mice were also crossed with Tg mAPP mice to produce 
double transgenics (2xTg mAPP/ABAD).  Transgenic mice in this study were on 
the C57BL/6 background (Lustbader et al., 2004; Takuma et al., 2005c; Yan et 
al., 2000a; Yao et al., 2007). 
The double transgenic mice express high levels of ABAD and produce high 
concentrations of Aβ peptide (Lustbader et al., 2004).  Neurons from the double 
transgenic mice show evidence of free radical-induced stress.  In the radial arm 
water maze test they demonstrate accelerated decline in spatial learning/memory 
(Bliss and Collingridge, 1993; Morgan et al., 2000) compared to non-transgenic 
littermates.  This was evident from 5 months of age (Lustbader et al., 2004). 
Pathological changes include generation of super-oxide anion and hydrogen 
peroxide in response to leakage of reactive oxygen species from the mitochondria 
(Takuma et al., 2005c; Yan and Stern, 2005). Using these novel transgenic 
animals, changes in protein expression in the mouse brain were analysed for these 
three transgenic models against controls (WT) non-transgenic littermates. 
 
4.3 Mouse brain protein identification by 2D gel electrophoresis 
      from mature (8-12 months) transgenic AD models.  
 
Previous studies had already shown that ABAD and Aβ were over-expressed in 
these transgenic mice, and evidence of their co-localisation is shown in Figure 4.1 
taken from (Lustbader et al., 2004). In this chapter, preliminary proteomic studies 
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were carried out using transgenic mice aged between 8 and 12 months old, age 
matched as a useful model to examine the middle to late stages of dementia in 
Alzheimer’s disease (Clancy et al., 2001; Finlay and Darlington, 1995; Finlay et 
al., 2001).  More recent work has characterized gene expression and 
transcriptional changes in different tissues, as a function of age in mice (Zahn et 
al., 2007) providing a more accurate time line for protein expression and 
indicating the importance of age matching when comparing protein expression in 
tissues.   
 
 
 
 
Fig. 4.1. Demonstration of ABAD-Aβ complex in brains of Tg mAPP/ABAD mice.  (A) 
Western blot analysis of co-immunoprecipitation of ABAD and Aβ from mitochondria of 
transgenic mice. Mitchondrial fractions (500 mg) from cerebral cortex of (1) non Tg, (2) 
Tg mAPP and (3) Tg mAPP/ABAD mice were immunoprecipitated with mouse anti-
Aβ IgG (6E10; 8 μg/ml), or (4) nonimmune IgG (8 μg/ml) at 4°C overnight followed by 
Western blotting with mouse anti-ABAD (1:10,000). The middle panel shows total input 
protein reprobed with anti-Aβ antibody (6E 10). Lower panel shows immunoblotting of 
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β-actin for crude extracts from mouse brains. (B) Co-localization of ABAD and Aβ in the 
brain of a Tg mAPP/ABAD mouse using confocal microscopy with antibodies to ABAD 
(red) and Aβ (green) (magnification 300-fold). (C) Co-localization of ABAD and Aβ in 
mitochondria of brains from Tg mAPP/ABAD mouse using electron microscopy. Double 
immunogold staining was performed with rabbit anti-Aβ IgG and mouse anti-ABAD IgG 
followed by goat anti-rabbit IgG conjugated to 12 nm gold particles (for Aβ1-42) and 
goat anti-mouse IgG conjugated to 18 nM gold particles (for ABAD). Arrowheads depict 
gold particles localizing ABAD antigen. The smaller gold particles represent sites of 
localization of Aβ. (Taken from (Lustbader et al., 2004)) 
 
For the initial experiments, 2D gel proteomic analysis (Section 2.6) was 
performed on whole mouse brain tissue from three mice of each genotype (Tg 
mAPP,  Tg ABAD, 2 x Tg mAPP/ABAD and WT) matched for age and sex.  
Using the whole brain tissue gave a high total protein concentration, which 
provided multiple well-defined protein spots on the gels.  This enabled good 
comparison of protein expression between all the transgenic and wild type mice 
(Figure 4.2). 
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Fig. 4.2. 2D gels from tissue samples of each genotype. (Taken from (Yao et al., 2007). 
The square (blue arrow) outlines the area on the gels identifying an example protein 
expressed only in the Tg mAPP/ABAD sample, subsequently identified as peroxiredoxin 
II (MW 22kDa). 
 
Results from the 2D gels of whole brain tissue (Figure 4.2) showed several 
enhanced spots, equivalent to up-regulated proteins, in the transgenic or double 
transgenic phenotypes. Magnified sections from the 2D gels for four of these up-
regulated proteins are shown in Figure 4.3. The double transgenic (2xTg 
mAPP/ABAD) showed proteins with increased expression (identified by blue 
ring) that are not expressed in the control samples.  
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Fig. 4.3.  Magnified detail from 2D gels with tissue samples from each genotype (as 
Figure 4.2) from whole brain tissue of eight month old mice.  Four novel proteins were 
subsequently identified from the spots as upregulated in 2xTg ABAD/mAPP genotype 
(ringed in blue), A. peroxiredoxin II, B. creatinine Kinase β subunit, C. endophilin I, and 
D. ATP synthase β subunit. It was also noted that peroxiredoxin II was also expressed in 
the Tg mAPP model. 
 
 
4.3.1 Choice of method for identification of proteins 
In order to identify the proteins in these spots, the amino acid sequence needed to 
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be determined.  There are two main methods of protein sequencing, by mass 
spectrometry or Edman degradation using N-terminal residue identification.  Both 
methods require the protein to be identified by the smaller peptide chains within 
the protein.  Further computer analysis of the peptide sequences reconstructs the 
overall sequence and identifies the protein.  The Edman degradation method uses 
the chemicals 2,4-dinitrofluorobenzene (DFNB - Sanger's reagent), dansyl 
chloride, and phenylisothiocyanate (PITC, Edman's reagent) to label the free 
unprotonated amino groups to identify the N-terminal residues of the peptide 
sequences within the protein  (Niall, 1973).  The main disadvantage of the Edman 
degradation is that the size of the peptide chains identified is limited.  The 
peptides need in reality to be a length of ≤ 30 residues or the degradation process 
is incomplete.  This can be overcome by cleaving the larger peptides into smaller 
fragments but it is time consuming.  However Mass Spectrometry is now 
available and easily automated and provides accurate data on the peptide 
sequences.   The data is produced as a peak list of molecular weights of the 
peptides and when compared against numerous protein sequence databases such 
as UniprotKB or Genebank, the protein can be identified.  Mass spectrometry was 
used to identify the protein spots in this study. 
 
4.3.2 Mass Spectrometry analysis 
The protein spots were cut from the gels. The gel was then destained with 
acetonitrile and subjected to reduction and alkylation before digestion with trypsin 
at 370C (Rosenfeld et al., 1992). The peptides were extracted with 10% formic 
acid.  The spots were cut from the gels and trypsinised. The trypsin digest cleaves 
the protein after all lysine (K) and arginine (R) amino acid residues, except when 
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followed by a proline (P) residue.  The proteins were individually digested into a 
number of peptide chains.   For analysis by MALDI-TOF mass spectrometry, 
0.5µl of the digest solution was applied to the MALDI target with 0.5µl alpha-
cyano-4- hydroxycinnamic acid matrix (0.5 mL, 10 mg/mL in 50:50 acetonitrile: 
0.1% TFA) and allowed to dry. MALDI MS was acquired using a 4800 MALDI-
TOF/TOF Analyser (Applied Biosystems, Foster City, CA) equipped with an 
Nd/YAG 355 nm laser and calibrated using a mixture of peptides.  Mass 
spectrometry MALDI-TOF analysis obtained information related to the peptides’ 
mass and charge. The masses of these peptides are very accurate and provide a 
‘peptide mass fingerprint’.  The peptide sequences and masses were entered into 
the ‘MASCOT’ search engine, which uses mass spectrometry data to identify 
proteins from primary sequence databases.  The proteins were identified from the 
data, which showed the peptides matched to the highest scoring protein match or 
alternative protein match if so indicated. The mass spectrometry results gave a 
combined score, based on the statistical chance that the group of peptides 
matching a particular protein could occur by chance.  Scores above a certain 
‘identity’ threshold were generally considered valid as the match has a less than 
5% chance of occurring randomly (Lahm and Langen, 2000; Steen and Mann, 
2004).  
 
Using endophilin 1 as an example: there are three isoforms of endophilin I, II and 
III, and their protein sequences are different as shown in Figure 4.4, and the 
expected peptide sequences from the tryptic digest of endophilin I are shown in 
Figure 4.5. 
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Q62420 Endophilin I- mouse 
 
10         20         30         40         50         60  
MSVAGLKKQF HKATQKVSEK VGGAEGTKLD DDFKEMERKV DVTSRAVMEI MTKTIEYLQP  
        70         80         90        100        110        120  
NPASRAKLSM INTMSKIRGQ EKGPGYPQAE ALLAEAMLKF GRELGDDCNF GPALGEVGEA  
       130        140        150        160        170        180  
MRELSEVKDS LDMEVKQNFI DPLQNLHDKD LREIQHHLKK LEGRRLDFDY KKKRQGKIPD  
       190        200        210        220        230        240  
EELRQALEKF DESKEIAESS MFNLLEMDIE QVSQLSALVQ AQLEYHKQAV QILQQVTVRL  
       250        260        270        280        290        300  
EERIRQASSQ PRREYQPKPR MSLEFATGDS TQPNGGLSHT GTPKPPGVQM DQPCCRALYD  
       310        320        330        340        350  
FEPENEGELG FKEGDIITLT NQIDENWYEG MLHGQSGFFP INYVEILVAL PH 
 
 
Q62419 Endophilin II- mouse 
 
10         20         30         40         50         60  
MSVAGLKKQF YKASQLVSEK VGGAEGTKLD DDFKDMEKKV DVTSKAVAEV LVRTIEYLQP  
        70         80         90        100        110        120  
NPASRAKLTM LNTVSKIRGQ VKNPGYPQSE GLLGECMVRH GKELGGESNF GDALLDAGES  
       130        140        150        160        170        180  
MKRLAEVKDS LDIEVKQNFI DPLQNLCDKD LKEIQHHLKK LEGRRLDFDY KKKRQGKIPD  
       190        200        210        220        230        240  
EELRQALEKF EESKEVAETS MHNLLETDIE QVSQLSALVD AQLDYHRQAV QILEELADKL  
       250        260        270        280        290        300  
KRRVREASSR PKREFKPRPR EPFELGELEQ PNGGFPCAPA PKITASSSFR SSDKPIRMPS  
       310        320        330        340        350        360  
KSMPPLDQPS CKALYDFEPE NDGELGFREG DLITLTNQID ENWYEGMLHG QSGFFPLSYV  
 
QVLVPLPQ 
 
 
Q62421 Endophilin III- mouse 
 
10         20         30         40         50         60  
MSVAGLKKQF HKASQLFSEK ISGAEGTKLD EEFLNMEKKI DITSKAVAEI LSKATEYLQP  
        70         80         90        100        110        120  
NPAYRAKLGM LNTVSKLRGQ VKATGYPQTE GLLGDCMLKY GKELGEDSAF GNSLVDVGEA  
       130        140        150        160        170        180  
LKLMAEVKDS LDINVKQTFI DPLQLLQDKD LKEIGHHLRK LEGRRLDYDY KKRRVGKIPE  
       190        200        210        220        230        240  
EEIRQAVEKF EESKELAERS MFNFLENDVE QVSQLAVFVE AALDYHRQST EILQELQSKL  
       250        260        270        280        290        300  
ELRISLASKV PKREFMPKPV NMSSTDANGV GPSSSSKTPG TDTPADQPCC RGLYDFEPEN  
       310        320        330        340  
EGELGFKEGD IITLTNQIDE NWYEGMLRGE SGFFPINYVE VIVPLPP 
 
 
Fig. 4.4. Protein sequences of the three isoforms of mouse endophilin from the SwissProt 
database.  The residues highlighted in red show the sequence specificity of the Zymed 
anti-endophilin I antibody used in the western blots (section 4.4.3 and 4.4.4).  The 
residues highlighted in green identify some of the differences in the sequences in this 
central section. 
 
 151 
 
Fig. 4.5. Peptide sequences expected from the tryptic digest of endophilin I, shown in 
order of residue length.  The order of peptides in the protein sequence is shown in the left 
hand column, T1 being first.  
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From the sequences in Figure 4.4, it can be seen that the peptide sequences 
expected from the tryptic digests of the different isoforms will also be different. 
The expected tryptic digests of endophilin I is shown in figure 4.5 and the 
expected tryptic digests of endophilin II and III are shown in the Appendix. 
Database searching of the peptide sequences identified isoform endophilin I. 
 
4.3.3 Results from mass spectrometry analysis 
Table 4.1 shows the results from mass spectrometry analysis, identifying five 
upregulated proteins in the 2 x Tg mAPP/ABAD AD mouse model compared to 
WT. The proteins were identified as apolipoprotein E, peroxiredoxin II, creatine 
kinase β subunit, endophilin I, and the β-subunit of ATP synthase.  
Apolipoprotein E (ApoE) is well known to be associated with late onset AD.  
Having identified ApoE in these transgenic models provides evidence that these 
are good phenotypes for the AD model, but as the main aim was to identify novel 
biomarkers for AD, ApoE was not selected for further investigation at this stage.  
However, the other proteins could be potential novel biomarkers for AD whose 
expression correlate with over-expression of Aβ in Alzheimer’s disease brains.  
These four proteins were therefore investigated further.  
The columns in Table 4.1 indicate the peptide masses, molecular weight and PI 
that match with a database of known digests.  The results give a predicted result 
and observed result.  The masses matched are a probability that the peptide 
masses match a particular protein. A good match is between 5 and 20%.  The 
predicted and observed molecular weights sometimes differ if there is only part of 
the protein or the protein is part of a complex, as with ATP synthase β subunit.  
However all the PI’s match well. 
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Table 4.1.  Details of the five proteins identified from mass spectrometry. 
 
 
4.3.4 Characterisation of the four proteins chosen for further study 
It was interesting to note that all of these proteins are reported to be active in 
pathways involved with neuronal growth, lipid transport or cellular stress 
responses.  The identification in a change in these proteins’ expression in this AD 
model, suggests either a protective or toxic effect in the developing pathology of 
AD.  Some of the proteins identified are involved with energy supplying 
pathways. Of the identified proteins, their potential significance is briefly 
described below, and for some they are discussed further in the discussion.  
 
4.3.4.1 Peroxiredoxin II  
Peroxiredoxin II (PrxII) is a cytosolic member of a family of peroxidases with 
high antioxidant efficiency and regulates H2O2 mediated signaling (Wood et al., 
2003).  Mammalian peroxiredoxins have six distinct members located in 
subcellular compartments, mainly where oxidative stress occurs (Table 4.2).   
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Prx 
Subtype 
PrxI PrxII PrxIII PrxIV PrxV PrxVI 
       
Cellular 
location 
Cytosol, 
Nucleus 
Cytosol, 
Membrane 
Mitochondria Cytosol, 
Golgi. 
Secreted 
Mitochondria, 
Peroxisome, 
Cytosol 
Cytosol 
 
Table 4.2 Cellular locations of peroxiredoxin subgroups. 
 
Induction of peroxiredoxins is observed as a response to increased production of 
reactive oxygen species (Kang et al., 1998). The increased expression of PrxII is 
linked to oxidative stress that correlates well with the development of AD 
pathology. Increased protein levels of PrxII could provide protection against 
neuronal cell death induced by hydrogen peroxide (Kim et al., 2001).  PrxII has 
also been reported to have increased expression in the frontal cortex of patients 
with AD, Parkinson’s disease, Pick’s disease and Down’s syndrome (Kim et al., 
2001; Krapfenbauer et al., 2003), and so its identification as being up-regulated in 
these transgenic animals provided confidence in them being a relevant AD animal 
model. 
 
4.3.2.2 Endophilin 1 
Endophilin 1 is a presynaptic protein that binds to dynamin, a GTPase involved 
with endocytosis and recycling of synaptic vesicles (Schmidt et al., 1999). 
Endophilins contain an SH3 domain at their C-terminus and are involved in 
membrane trafficking in the endocytic pathway. Endophilin 1 also acts as a 
substrate for the endosome-localised ubiquitin ligase, Itch and this interaction may 
be involved in ubiquitin-mediated sorting mechanisms operating at the level of 
endosomes (Angers et al., 2004).  Endophilin binds other endocytic proteins, 
synaptojanin and dynamin (Reutens and Begley, 2002) and is known to have a 
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role in vesicle formation. The binding of endophilin 1 with dynamin mediates 
synaptic vesicle invagination from the plasma membrane, to create channels in the 
membrane, as such this may be linked to abnormal transition of peptides or lipids 
through the plasma membrane in AD (Sundborger et al., 2011).  In addition, it is 
known that phospholipid metabolites can accumulate in cell membranes that 
contribute to Aβ deposition (Breteler, 2000) and potentially endophilin I may 
contribute to this as well. 
 
4.3.4.3 ATP synthase β  subunit 
This is part of the intermembranous, five protein complex in the mitochondria 
which drives protons between the intermembrane space and the matrix. This 
complex catalyses ATP synthesis, and is essential for cell energy and survival.  
The identified β chain is the catalytic subunit (Ackrell, 2000). CNS tissue uses 
ATP rapidly and requires a constant energy reservoir for rapid regeneration of 
ATP. There is evidence that suggests expression of ATP synthase β subunit is 
tissue specific, the highest levels in the heart and the lowest in liver and kidney 
(Neckelmann et al., 1989).  ABAD and Aβ disrupt mitochondrial function in AD 
and so it is probable that this relationship alters the regulation of this protein 
during the progression of AD. 
 
4.3.4.4 Creatine kinase β  subunit 
Creatine kinases (CK) are a family of enzymes that regulate ATP levels and as 
such are central in energy homeostasis in tissues with large fluctuating energy 
changes.  This is particularly so in muscle and the brain (Monge et al., 2008). CK 
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is elevated in serum after injury and is a significant marker for myocardial 
infarction (Alpert et al., 2000).  It is also known to be elevated in fatty acid and 
glycerol metabolism disorders: medium-chain acyl dehydrogenase deficiency 
(MCADD) and long-chain hydroxyacyl-CoA dehydrogenase deficiency 
(LCHADD) (Lund et al., 2010). Therefore an abnormal increase in expression of 
this protein could be related to the over-expression of ABAD and its catabolism of 
fatty acids.  Other studies have noted an increase in CK expression in early stages 
of AD with a significant decrease in CK in the late stages in human AD brain 
(Lynn et al., 2010). 
 
4.3.4.5 ApoE 
The protein ApoE transports fat-soluble proteins, cholesterol and lipoproteins into 
the lymphatic system. ApoE generally aids proteolytic disruption of the Aβ 
peptide. However the ApoE4 isoform has been linked with AD as it is less 
efficient at this proteolysis (Deane et al., 2008). Individuals with the ApoE4 
isoform gene are more susceptible to late stage AD.  Cerebrospinal fluid (CSF) 
contains only high-density lipoproteins composed of ApoE and ApoJ secreted 
from astrocytes and of ApoA-I and ApoA-II transported via the blood brain 
barrier (Suzuki et al., 2002). These apolipoproteins can bind to Aβ and possibly 
relate to its clearance. In this study, the 2D gel analysis on 8-12 month mice 
showed increase expression of ApoE in 2 x Tg mAPP/ABAD, and therefore 
indicates that ABAD and APP expression levels may affect ApoE expression, but 
due to commitments, further study was not pursued in this thesis. 
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4.4 Protein identification in immature (4-8 months) mouse model 
      by western immunoblotting 
Having identified novel proteins over-expressing in these AD transgenic models, 
further studies on four proteins were carried out to investigate how early the 
changes in expression could be identified.   The 2 x Tg mAPP/ABAD AD mice 
had previously shown some cognitive behavioural changes at 5 months (Bliss and 
Collingridge, 1993; Caspersen et al., 2005; Lustbader et al., 2004; Morgan et al., 
2000; Yan and Stern, 2005).  Therefore samples of brain tissue were extracted 
from freshly sacrificed 4- and 8-month old mice of wild type, and the 2 x Tg 
mAPP/ABAD phenotypes.  To analyse the hippocampus, this was isolated from 
the cortex before the preparation of the samples (carried out during a visit to 
Professor SD Yan, Columbia University).  Four or five samples each of 
hippocampal and remaining cortex tissue were obtained from each transgenic 
model and non-transgenic littermates. The tissue samples were homogenized 
immediately, flash frozen and stored at -800C until required.  For the western blot 
analysis, total protein concentration was first assessed by Bradford assay (section 
2.3.1). Each of the tissue samples was divided into 4, for western blot analysis 
with antibodies against peroxiredoxin II, creatine kinase β subunit, endophilin I, 
and the β-subunit of ATP synthase.  The samples were prepared for SDS-PAGE 
by adding protein denaturing buffer containing bromophenol blue dye, and run on 
mini 10 or 12% SDS-PAGE gels.  The proteins were transferred to nitrocellulose 
membranes for western immunoblotting.  The western blotting antibodies against 
the proteins of interest were rabbit endophilin I, anti-peroxiredoxin II, anti ATP 
synthase and anti creatine kinase, β-Actin was used as a control. In the following 
Figures 4.4 to 4.11 are shown the results of these western blot analyses.   
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4.4.1 Peroxiredoxin (PrxII) – hippocampal samples 
 
 
 
 
Fig. 4.4. Western blots using 0.5µg/ml rabbit anti-PrxII antibody (Alexis CA) on 
hippocampus tissue samples. 12µg protein was loaded in each lane.  Blot A (top) shows 
tissue samples from 4-month old mice, comparing four WT samples (lanes a-d) with three 
2 x Tg mAPP/ABAD samples (lanes f-h).  Blot B (bottom) shows tissue samples from 8-
month old mice, comparing five WT samples (lanes a-e) with four double transgenic 
samples, 2 x Tg mAPP/ABAD (lanes g-i).  PrxII expression in 2 x Tg mAPP/ABAD mice 
is shown circled. Blot A shows little or no difference in the PrxII expression in WT and 2 
x Tg mAPP/ABAD mice at 4-months age.   Blot B shows increase in expression of PrxII 
in two of the 2 x Tg mAPP/ABAD samples (lanes i and j) at 8-months age. 
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4.4.2 Peroxiredoxin (PrxII)  – cortex sample 
 
 
Fig. 4.5. Western blots using 0.5µg/ml rabbit anti-PrxII antibody (Alexis CA) on cortex 
tissue samples.  50µg protein was loaded in each lane.  Blot A (top) shows tissue samples 
from 4-month old mice, comparing four WT samples (lanes a-d) with four 2 x Tg 
mAPP/ABAD samples (lanes f-i). Blot B (bottom) shows tissue samples from 8-month 
old mice, comparing five WT samples (lanes a-e) with four double transgenic samples, 2 
x Tg mAPP/ABAD. (lanes g-j).  PrxII expression in 2 x Tg mAPP/ABAD mice is shown 
circled.  Blot A shows a little increase in the PrxII expression in 2 x Tg mAPP/ABAD 
mice at 4-months age.   Blot B shows a slight increase in expression of PrxII in all 2 x Tg 
mAPP/ABAD samples (lanes g,h,i and j) at 8-months age. 
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4.4.3 Endophilin – hippocampal samples 
 
 
 
 
 
Fig. 4.6. Western blots using 0.5µg/ml anti-endophilin I antibody (Zymed laboratories) 
on hippocampus tissue samples. 12µg protein was loaded in each lane.  Blot A (top left) 
shows tissue samples from 4-month old mice, comparing four WT samples with three 2 x 
Tg mAPP/ABAD samples.  The membrane was stripped and reprobed to identify β-actin 
separately as the molecular weights were very similar (top right).  Blot B (bottom left) 
shows tissue samples from 8-month old mice, comparing five WT samples with four 2 x 
Tg mAPP/ABAD samples.  Again the membrane was stripped and reprobed to identify β-
actin (bottom right).  Endophilin expression in 2 x Tg mAPP/ABAD mice is shown 
circled.  The 8-month blots show little or no difference in the endophilin expression in 
WT and 2 x Tg mAPP/ABAD mice.   At 4-months there is increased expression in 2 x Tg 
mAPP/ABAD compared to WT.  
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4.4.4. Endophilin – cortex samples 
 
 
 
 
 
Fig. 4.7. Western blots using 0.5µg/ml anti-endophilin I antibody (Zymed laboratories) 
on cortex tissue samples. 12µg protein was loaded in each lane.  Blot A (top left) shows 
tissue samples from 4-month old mice, comparing four WT samples with four 2 x Tg 
mAPP/ABAD (labelled 2xTg in the figure) samples.  The membrane was stripped and 
reprobed to identify β-actin separately, as the molecular weights were very similar (top 
right).  Blot B (bottom left) shows tissue samples from 8-month old mice, comparing five 
WT samples with four 2 x Tg mAPP/ABAD samples. Endophilin expression in 2 x Tg 
mAPP/ABAD mice is shown circled. Again the membrane was stripped and reprobed to 
identify β-actin (bottom right).  Blot B shows little or no difference in the endophilin 
expression in WT and 2 x Tg mAPP/ABAD mice at 8-months age.   However blot A 
shows a definite increase in expression of endophilin in all the 2 x Tg mAPP/ABAD 
samples at 4-months age. 
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4.4.5 ATP synthase  β  subunit- hippocampus samples 
 
 
Fig. 4.8. Western blots using 1.0µg/ml anti-ATP synthase antibody (Pierce) on 
hippocampus tissue samples. 12µg protein was loaded in each lane for the 4-month 
samples. 5µg protein was loaded in each lane for the 8-month samples.   Blot A (top) 
shows tissue samples from 4-month old mice, comparing four WT samples with three 2 x 
Tg mAPP/ABAD samples.  Blot B (bottom) shows tissue samples from 8-month old 
mice, comparing five WT samples with four double transgenic samples, 2 xT g 
mAPP/ABAD.  Both blots show little or no difference in the ATP synthase expression in 
WT and 2 x Tg mAPP/ABAD mice at 4 and 8 months of age.  However because less 
sample (5µg) was needed to obtain optimal staining of the 8-month samples, this may 
indicate that the ATP synthase expression is generally higher in the 8-month old mice.   
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4.4.6 ATP synthase  β  subunit – cortex samples 
 
 
 
 
Fig. 4.9. Western blots using 1.0µg/ml anti-ATP synthase antibody (Pierce) on cortex 
tissue samples. 5µg protein was loaded in each lane for all samples. Blot A (top) shows 
tissue samples from 4-month old mice, comparing four WT samples with three 2 x Tg 
mAPP/ABAD samples.  Blot B (bottom) shows tissue samples from 8-month old mice, 
comparing five WT samples with four double transgenic samples, 2 x Tg mAPP/ABAD.  
Blot A (4 months) shows little or no difference in the ATP synthase expression in WT 
and 2 x Tg mAPP/ABAD mice.  Blot B (8 months) shows reduced expression in two of 
the WT (lanes b and c) and also in two of the 2 x Tg mAPP/ABAD (lanes h and j), 
compared with the β-actin control. 
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4.4.7 Creatine kinase β  subunit  - hippocampus samples 
  
 
 
Fig. 4.10. Western blots using 0.5µg/ml anti-CKβ antibody (Santa Cruz) on hippocampus 
tissue samples. 12µg protein was loaded in each lane for the 4-month and the 8-month 
samples.  Blot A (top) shows tissue samples from 4-month old mice, comparing four WT 
samples with three 2 x Tg mAPP/ABAD samples.  Blot B (bottom) shows tissue samples 
from 8-month old mice, comparing five WT samples with four double transgenic 
samples, 2 x Tg mAPP/ABAD.  Both blots show little or no difference in CKβ expression 
in WT and 2 x Tg mAPP/ABAD mice at 4 and 8 months of age. 
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4.4.8 Creatine kinase β  subunit  - cortex samples 
 
 
 
Fig. 4.11. Western blots using 0.5µg/ml anti-CKβ antibody (Santa Cruz) on cortex tissue 
samples. 12µg protein was loaded in each lane for the 4-month and the 8-month samples.   
Blot A (top) shows tissue samples from 4-month old mice, comparing four WT samples 
with four 2 x Tg mAPP/ABAD samples.  Blot B (bottom) shows tissue samples from 8-
month old mice, comparing four WT samples with four double transgenic samples, 2 x 
Tg mAPP/ABAD.  Both blots show little or no difference in CKβ expression in WT and 
2 x Tg mAPP/ABAD mice at 4 and 8 months of age. 
 
 
 
A summary of the results from Figures 4.4 to 4.11 is shown in Table 4.3, where 
the protein expression in 2 x Tg mAPP/ABAD is compared to WT.  This Table 
shows that PrxII and endophilin I are both up-regulated in the 4-month AD model.  
PrxII appeared to remain to be up-regulated at 8 months and the other proteins 
remained constant in expression.   
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Table 4.3 Protein expression in samples as shown by the western blots, between WT and 
2 x Tg mAPP/ABAD mice at 4 and 8 months of age. 
+ up-regulated expression. – down-regulated expression.  = no difference. 
 
4.5 Protein identification in isolated mitochondria 
Because ABAD expression is predominantly in the mitochondria in neurons, 
proteomic analysis of isolated brain mitochondria was also carried out, as it was 
hoped that this could provide more detailed protein markers specifically for 
mitochondrial function. Therefore the mitochondria were isolated from whole 
brain tissue. Three wild type and three double transgenic (2 x Tg mAPP/ABAD) 
mice were sacrificed, to provide six samples for this study.  The brains were 
extracted from 8-month old mice and the mitochondria isolated by centrifugal 
fractionation (section 2.4.2). The mitochondrial fractions were prepared for 2D 
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gel analysis to a final volume of 150µl (section 2.6.2 and 2.6.3). The protein 
expression from these isolated mitochondria was again analysed using 2D gel 
analysis and MALDI-TOF mass spectrometry.  Unfortunately there was only a 
very small quantity of mitochondrial protein from each individual sample for 
adequate resolution on a 2D gel.  Therefore two or three samples were pooled 
together for further analysis.  This only allowed two gels for comparison of each 
different paradigm and unfortunately the protein separation was slightly different 
each time.  An example of a comparison of samples from WT and 2 x Tg 
mAPP/ABAD mice on 2D gels is shown in Figures 4.12, 4.13 and 4.14. 
 
Fig. 4.12. A 2D gel of mitochondrial tissue from WT mouse 8 months of age. The green 
arrows show protein spots identified which were not seen in 2 x Tg mAPP/ABAD mice. 
Identified proteins are labelled and described below. 
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The proteins as indicated in Figure 4.12 were selected for identification by 
MALDI-TOF mass spectrometry and were subsequently identified as: A and B: 
succinate dehydrogenase (SDH), 72.5kDa, 1: glycerol phosphate dehydrogenase 
(GPDH), 81kDa, 2, 3 and 4: hypothetical proteins, and X, Y and Z: keratin 
probably as a result of contamination. 
 
 
Fig. 4.13. Two 2D gels of mitochondrial samples comparing WT with 2 xTg 
mAPP/ABAD samples.  The top gel is from WT mice, the bottom gel is from the 2 x Tg 
mAPP/ABAD mice.  The green arrows point to protein spots A and B, two proteins that 
expressed in WT mice but not in the 2 x Tg mAPP/ABAD.  Areas in blue squares are 
shown in more detail in Figure 4.14. 
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Fig. 4.14. Magnified detail from 2D gels shown in Figure 4.12. This shows proteins 
expressed in WT mice but not in 2 x Tg mAPP/ABAD mice. Mass spectrometry 
identified the three spots as succinate dehydrogenase.  The isolated protein (ringed in 
blue, bottom left) was identified as a hypothetical protein (a protein without any known 
function or family).  The three spots show succinate dehydrogenase as different isomers 
probably with different post-translational modifications, producing changes in the pI with 
little or no change in the mass.    
 
SDH is part of the intermembranous 4-protein complex, complex II, bound to the 
inner mitochondrial membrane where it participates in the citric acid cycle and the 
electron transfer chain. GPDH lies on the cytosolic side of the outer mitochondrial 
membrane and contributes to the electron transport chain in the mitochondria.  
Both these proteins are down regulated in the 2 x Tg mAPP/ABAD model 
(Figures 4.12 and 4.13).  This is possibly as a response to cellular stress and a sign 
of mitochondrial dysfunction, and as such provides more evidence that ABAD 
and Aβ are implicated in mitochondrial dysfunction. The 2D gel analysis of 
mitochondrial samples from 8-month mice showed significantly down-regulation 
of SDH and GPDH in the 2 xTg ABAD/mAPP model indicating that the energy 
production is compromised in these cells. 
 
WT 2x Tg 
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4.6 Protein changes seen in transgenic mice and Alzheimer’s 
      patients 
To confirm and extend the results of the proteomic analysis, PrxII and endophilin 
I were analysed by immunostaining the temporal cortex from brains of 2 x Tg 
mAPP/ABAD mice and post mortem tissue from Alzheimer’s patients, by our 
collaborators (Professor Yan’s laboratory, Columbia University, New York 
(Figures 4.15 and 4.16).   
 
Fig. 4.15. Staining of excess PrxII in the 2 x Tg mAPP/ABAD tissue in mice and in 
human AD brain tissue.  This confirms increased expression of PrxII in 2 x Tg 
mAPP/ABAD mice. (A) Immunocytochemistry of mouse brain tissue. (B) Western blot 
of PrxII and β-actin in AD brain tissue. (C) Immunocytochemistry of AD brain (temporal 
cortex). Scale bar 5µm. (Figure taken from (Yao et al., 2007)). 
Alzheimer sufferer Aged match 
control 
l i r ff r r  t  
tr l 
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Fig. 4.16. Staining of excess endophilin I in the 2 x Tg mAPP/ABAD tissue in mice and 
in human AD brain tissue.  This confirms the increased expression of endophilin I in 2 x 
Tg mAPP/ABAD mice. (A) Immunocytochemistry of mouse brain tissue. (B) 
Immunocytochemistry of AD brain, temporal cortex. Scale bar 5µm. Western blot 
analysis of endophilin I and β-actin from temporal cortex of Alzheimer patients (AD, n = 
7) and non-demented age matched controls (ND, n = 6) showing a significant increase in 
endophilin I expression in the AD compared to age matched non demented (ND) brain. 
(Taken from (Ren et al., 2008) 
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The first study (Figure 4.15 from (Yao et al., 2007)) concluded that increased 
expression of PrxII was able to protect cortical neurons in the presence of excess 
Aβ.  This implies that the increased expression of PrxII was a cellular response to 
diseased brains attempting to protect from further oxidative damage.  
Significantly, the expression of PrxII in living mice could be returned to normal 
when treated with a novel peptide inhibitor, TAT-mito-ABAD (Section 3.4.3.2).   
 
The second study (Figure 4.16 from (Ren et al., 2008)) concluded that the 
increased expression of endophilin was partly responsible for activating JNK and 
contributed to a decrease in cell viability.  Endophilin I expression could also be 
reversed to normal in mice treated with the novel peptide inhibitor, TAT-mito-
ABAD. 
 
These combined data confirm that the interaction of ABAD and Aβ increases the 
expression of PrxII and endophilin I and the novel TAT-mito-ABAD peptide can 
disrupt the interaction. 
 
4.7 Discussion 
As AD is a neurodegenerative disease, it would be expected that there would be 
protein abnormalities in the brain, and so a proteomic analysis is an ideal 
methodology for identifying these changes. However, it is important to note that 
the use of 2-D gels has its limitations in the range of proteins that can be detected. 
The two-dimensional gel method is generally incompatible with proteins of 
extreme size, pI, and/or hydrophobicity, and it is difficult and time consuming to 
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determine the identity of hundreds of protein spots displayed on a two-
dimensional gel (Liao et al., 2004). Only the soluble and most abundant proteins 
will be visualised, excluding many membrane proteins.  Very low and very high 
molecular weight proteins, outside the limits of the gel, or those outside the pI 
limits of the IEF strips will be excluded.  However, the technique does provide 
valuable information, adequate for studying disease processes involving the CNS.  
One interesting finding was that several spots appeared grouped in lines, having a 
similar mass but different pI.  This phenomenon has been noted before (Kim et 
al., 2001; Schonberger et al., 2001) and has been assumed to be due to either 
proteolysis or different isoforms of the protein. The different isoforms are most 
likely due to post-translational modifications of the proteins, for example 
phosphorylation or more likely oxidation.  This was particularly seen in the 
mitochondrial 2D gel with the three spots identified as succinate dehydrogenase 
(Figure 4.14).   
 
The proteomic experiments described here have successfully identified proteins 
that were up-regulated in mature mice (8-12 months) in novel transgenic mouse 
models for AD, where ABAD is over expressed in the presence of excess Aβ. The 
proteins identified were ApoE, endophilin I, peroxiredoxin II, the ATP synthase β 
subunit and the creatinine kinase β subunit.  All, apart from ApoE, were 
investigated further in younger mice (4-8 months) to discover how early the 
changes in protein expression could be detected. In addition, two mitochondrial 
proteins were also found to be down regulated in the 2 x Tg mAPP/ABAD AD 
model: SDH and GPDH. For two of these proteins identified, peroxiredoxin II and 
endophilin I, subsequent work has now shown the significance of these findings.  
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Peroxiredoxin II (PrxII) 
In this study PrxII was identified as being up-regulated in the cortex and 
hippocampus of the double transgenic AD model over-expressing ABAD and 
mAPP (figures 4.4 and 4.5). These results are supported by other studies, where 
PrxII has now been identified and confirmed as a protein elevated early and late in 
the AD mouse model and it can also be identified in AD brain tissue at post 
mortem (Figure 4.15) (Yao et al., 2007).  It is now thought that the increase in 
expression probably acts as a protective antioxidant that can protect neurons from 
Aβ induced toxicity, as it has been shown that cortical neurons expressing 
elevated levels of PrxII are protected against toxic levels of Aβ (Yao et al., 2007).  
In addition, it is has been subsequently shown that PrxII expression can also be 
used as a means of assessing the progression of the disease. Specifically it has 
been shown that 2 x Tg mAPP/ABAD mice injected peritoneally for 2 weeks with 
a synthetic peptide (residues 93-116 of ABAD linked to TAT and a mitochondrial 
targeting sequence) show a decreased expression of PrxII (Yao et al., 2007).  This 
indicates that this synthetic peptide disrupts the ABAD-Aβ interaction in vivo, but 
also that PrxII expression can be used as a means of assessing this interaction.  It 
is interesting to note that previous studies have shown that the expression of PrxII 
is induced following the production of reactive oxygen species in damaged 
neurons (Han et al., 2005; Simzar et al., 2000).  
 
Endophilin I 
In this study endophilin 1 was identified as being elevated in expression in both 4-
month samples from the cortex and hippocampus, suggesting its involvement in 
cell destruction at an early stage in AD pathology.  By 8 months it did not appear 
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to be up-regulated with respect to the WT mouse brains. However, studies from 
our collaborators did confirm that endophilin I expression is indeed elevated in the 
AD brain (Figures 4.6, 4.7 and 4.16 (Ren et al., 2008)). This is significant as this 
was the first recorded increased expression of this protein in the AD brain. Unlike 
the other proteins isolated, endophilin I does not appear to be connected with 
energy supplying pathways, but further studies have shown that the increase of 
endophilin I in neurons is linked to an increase in activation of the stress kinase 
JNK with subsequent death of neurons (Ren et al., 2008). It has also been shown 
to be an indicator of the interaction between ABAD and Aβ, as endophilin I 
expression levels return to normal if the interaction of ABAD and Aβ is perturbed 
in the same manner as was shown in PrxII (Ren et al., 2008). Other proteomic 
studies have identified increased expression of synaptojanin in human AD 
(Schonberger et al., 2001) responsible for neuronal growth and synaptic 
transmission. 
 
The CKβ subunit expression and the ATP synthase β subunit were not seen in the 
4 month AD mouse model, indicating that they are probably only activated late in 
AD pathology, as detected in the 2D gel analysis.  Both proteins are actively 
involved in energy production in cells. CKβ is known to regenerate ATP and is 
induced by cellular stress and it has been reported as being up regulated in other 
AD proteomic studies (Aksenov et al., 2001; Shiozaki and Iseki, 2004). 
Subsequently, increased expression of the ATP synthase β subunit has been 
reported in other AD proteomic studies (Korolainen et al., 2006; Pamplona et al., 
2005).   
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Two proteins were identified as being down-regulated in the 2x Tg mAPP/ABAD 
model: SDH and GPDH.   This is probably as a response to cellular stress and a 
sign of mitochondrial dysfunction consistent with LOAD. Both proteins are 
involved in normal mitochondrial function. SDH is active within mitochondria, 
involved in both the citric acid cycle and the electron transport chain, and it has 
been reported that Aβ targets SDH, suppressing its activity (Kaneko et al., 1995).  
Recently there was evidence that Complex I is down regulated in a triple 
transgenic model expressing tau and in the same model Complex IV is down 
regulated, but Aβ dependent (Eckert et al., 2010).  GPDH is a major contributor 
of electrons to the electron transport chain in mitochondria and is a major link 
between lipid metabolism and carbohydrate metabolism (Ackrell, 2000).  
 
GPDH along with ATP synthase and CK, have all been reported to be oxidatively 
modified and dysfunctional in AD brain, indicating a damaged energy metabolic 
pathway reducing the overall levels of ATP (Castegna et al., 2002).  Changes in 
cell potential, Ca2+ withdrawal, and opening of voltage gated Ca2+ channels would 
all be altered by decreased levels of ATP secondary to energy metabolism 
changes in the brain. Changes in ATP levels could also allow phosphatidylserine 
to activate the outer membrane, a signal for apoptosis (Castegna et al., 2004).  
ATP levels are very important at nerve terminals for normal neuronal function and 
decreased ATP levels may lead to loss of synapses and synaptic function which 
leads to memory loss, eventually leading to cell death and consequently to 
cognitive decline in AD patients.  
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If the anomalous concentrations of any of these proteins could be detected in CSF 
or plasma, these proteins could be useful as biomarkers for the early stages of the 
disease. For one of the identified proteins this now appears to be the case as 
subsequent studies identified that hydroxyoctadecadienoic acid (HODE) and 
oxidatively modified peroxiredoxins (oxPrx-2 and oxPrx-6) levels in plasma 
and/or erythrocytes in AD patients were significantly higher than those in the 
healthy controls (Yoshida et al., 2009).  The HODE levels correlated with clinical 
dementia scores. Plasma and erythrocyte levels of HODE, or erythrocyte levels of 
both HODE and oxPrx, correlated with vascular dementia and was able to 
distinguish it from AD, indicating that measures of oxPrx in erythrocytes is a 
potential biomarker for AD diagnosis.    
 
From these studies it appears that in AD, when Aβ inhibits ABAD activity, there 
is a consequence that specific genes are activated. It is interesting to note that for 
two of these proteins, their functions appear to be in direct opposition to one 
another at an early stage of AD. For example Prx-II expression promotes cell 
survival while endophilin I expression promotes neuronal death until the 
equilibrium in AD eventually shifts to cell death.  This indicates that throughout 
the development of AD pathology there is a continuous battle between proteins 
expressed to protect the neurons and proteins expressed as a part of the cascade 
towards cell death.  This study has identified proteins that are involved in this 
battle.  However it is still unknown whether these proteins can act as specific 
biomarkers in AD diagnosis.  As yet there is no evidence of them showing up in 
CSF analyses.  However the results add to the continuing search for an early 
diagnosis and subsequent treatment for AD.  
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Chapter 5 
Identifying small molecule inhibitors to the ABAD/Aβ  complex 
using fragment based screening. 
 
 
5.1 Background and aims 
The ABAD/Aβ complex has been shown to be involved in the early stages of AD, 
mediating Aβ toxicity.  Finding an inhibitor to the formation of this complex may 
help in identifying a useful drug towards the treatment for AD.  High throughput 
screening of the ABAD/Aβ complex, using the identification of low molecular 
weight compounds that bind to ABAD, (fragment based screening, FBS), might 
provide lead compounds for further chemical synthesis aimed at producing a 
therapeutic compound. 
 
5.2 Fragment-based screening for drug discovery and design 
Drug development is long and expensive, taking approximately 15 years to bring 
a drug to market.  Therefore the aim of FBS is to attempt to shorten the process by 
producing high quality lead, drug-like compounds.   
 
5.2.1 Conventional high-throughput screening (HTS)  
HTS has been widely used in drug discovery.  During the 1990’s pharmaceutical 
companies developed large libraries of drug-like compounds, comprising typically 
over 200,000 compounds with diverse chemical properties.  The compounds in a 
HTS library were required to be chemically diverse and show good absorption and 
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permeability properties, demonstrating good ‘ADME’ (Absorption, Distribution, 
Metabolism and Excretion) profiles.   
The pharmaceutical company Pfizer developed a smaller library using the clinical 
phase II selection process as a filter (Lipinski et al., 2001).  This used the 
hypothesis that most poor compounds would fail at pre-clinical and stage I 
Phases.  All compounds entering Phase II trials are registered internationally as an 
International Non-proprietary Name (INN) and in the United States as United 
States Adopted Names (USAN).   Pfizer selected a subset of compounds by 
filtering out drugs from The World Drug Index (WDI).  WDI is a large 
computerised database of approximately 50,000 drugs, and the final library 
contained 2245 compounds (Lipinski et al., 2001).  Pfizer then analysed the 
physico-chemical properties of these compounds, identifying four important 
parameters that are described below:  
 
1. Molecular weight (MW).   A high MW is related to poor intestinal and 
blood-brain barrier permeability (Pardridge et al., 1995).   
2. Lipophilicity (clogP).  Lipophilicity is related to absorption.  Almost all 
studies analyse the physico-chemical properties of compounds using the 
ratio of solubility in octanol compared to the solubility in water.  This ratio 
is measured as the calculated LogP (clogP) (Abraham, 2010).  
3. Hydrogen bond donor groups. An excessive number of hydrogen bond 
donor groups impairs permeability across membrane bilayers (Abraham, 
2010).  A quick and simple calculation of hydrogen bond donors can be 
made by adding the number of NH bonds and OH bonds.   
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4. Hydrogen bond acceptor groups. Similarly too many hydrogen bond 
acceptor groups also hinder permeability across a membrane bilayer.  The 
sum of Ns and Os are a rough guide to the H bond accepting properties. 
 
Having analysed this library of compounds, using the four parameters mentioned, 
Christopher Lipinski drew up the following rules for suitable lead compounds for 
HTS, (the so-called ‘Lipinski’s rule of 5’ (Lipinski et al., 2001) because the cut-
offs for each parameter were all close to 5 or a multiple of 5.  
 
5.2.2 Lipinski’s ‘rule of 5’ 
The compounds should have:  
• Molecular Weight  < 500 Da 
• CLogP < 5  
• H-bond donors   5 (in aromatic rings) 
• H-bond acceptors  10 
‘The rule of 5’ became the framework for the development of orally bioavailable 
drug candidates.  It was based on the distribution of calculated properties of 
several thousand drugs.  There are therefore always some drugs that lie outside the 
parameter cut-offs.  Noticeable exceptions to the rules are vitamins, cardiac 
glycosides, antibiotics and antifungals (Lipinski et al., 2001).  It was suggested 
that these break the rules by acting as substrates to naturally occurring 
transporters.  However most compounds fulfil ‘The rule of 5’ requirements. 
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Previously, conventional HTS of biological compounds of clinical interest was 
carried out using biochemical and cell based assays. The instrumentation required 
expensive robotic liquid handling equipment that could pipette µl volumes into 
384 well microplates.  However, the results from the primary screens failed to 
produce many hits with up to 70% of the compounds failing to progress to further 
drug development. 
 
5.2.3 Fragment based screening 
Fragment based screening (FBS) was developed as a tool for drug discovery, 
using a target-based approach (Ciulli and Abell, 2007; Hajduk and Greer, 2007; 
Jhoti, 2005). The last decade has produced much structural information on soluble 
proteins and structure-based methods are now being used increasingly in the role 
of drug discovery. Many drug discovery projects on protein targets now use FBS 
involving biophysical verification of protein-ligand interactions using NMR, 
surface plasmon resonance (SPR), X-ray crystallography and mass spectrometry 
at some stage during development.  Several drugs are now entering clinical usage, 
particularly in oncology and these methods are being used more in drug discovery 
for CNS diseases and conditions such as Alzheimer’s Disease (Hubbard, 2011).  
An example of a drug currently in use, developed in 2003 using this method is 
Imatinib/Gleevec (Novartis) – which blocks ATP binding sites on specific mutant 
tyrosine kinases, inhibiting proliferation pathways in chronic myeloid leukaemia, 
and gastrointestinal stromal tumours (cytokine independent) (Fabbro et al., 2002). 
 
FBS has now become the predominant initial screening in most pharmaceutical 
research today.  It is a method of rapid high throughput screening of low 
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molecular weight compounds (<300Da), or fragments, binding to a biological 
target.  When fragments are identified that bind to the protein, they can be 
chemically elaborated to form a combined larger compound, with a higher binding 
affinity, with the aim of producing a pharmaceutical product.   
 
The first stage in FBS was to develop libraries of fragments (Teague et al., 1999).  
It was found to be more efficient to screen collections of small 
molecules/fragments (<=300Da) and then expand, merge or link them (Erlanson 
et al., 2004b).  This approach had been described earlier in 1981 (Jencks, 1981), 
but linking several weak-binding ligands to produce one high affinity binding 
compound was and still remains a challenge.  The ability to show ‘Structure-
Activity Relationships’ by nuclear magnetic resonance, ‘SAR by NMR’ (Shuker 
et al., 1996), demonstrated how compounds with nanomolar affinities for a 
protein were rapidly discovered by linking together two ligands with micromolar 
affinities. This method reduced the amount of chemical synthesis and time 
required for the discovery of high-affinity ligands and was particularly useful in 
target-directed drug research.  This ‘fragment-based’ approach was further 
developed and fragments were combined and used as initial lead compounds in 
drug discovery, with the aim of identifying novel compounds with improved 
affinity, selectivity and pharmaceutical properties (Hann et al., 2001).  
 
For a fragment based screening library, the ‘Rule of 5’ was further developed to a 
‘Rule of 3’ and included two other parameters; the number of rotatable bonds and 
the polar surface area (Congreve et al., 2003):  
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• Molecular weight  ≤ 300 Da 
• Octanol/water partition coefficient, CLogP < 3  
• H-bond donors ≤ 3  
• H-bond acceptors ≤ 3 
• Flexible bonds ≤ 3 
• Polar surface area ≤ 60Å 
 
Several commercial small molecule compound libraries are available now.  For 
this study the ‘Maybridge Ro3 Fragment Library’ was used.  This library is 
composed of ~1000 compounds ≤300Da. The compounds all demonstrate good 
ADME (Absorption, Distribution, Metabolism and Excretion) profiles. This 
makes them ideal candidates for development beyond the initial screening assay, 
showing a good probability for an oral drug surviving the development stages. 
The compounds are stored at 200mM in 100% DMSO in ten polypropylene 96-
well deep-well plates.  Plate 1 holds compounds 1- 96, Plate 2 compounds 97- 
192, etc.. 
 
5.2.4 FBS improvements over conventional HTS 
A conventional HTS uses typically > 1 x 106 compounds with molecular weight 
~500Da, ‘drug-sized’ molecules. They are more potent but less efficient binders. 
They have a high binding affinity (Kd ∼1µM - 20µM) but with low ligand 
efficiency (Figure 5.1 (A)). In contrast FBS compounds exhibit low binding 
affinity, (Kd ∼1-20 mM), but a high ligand efficiency (Figure 5.1 (B)). 
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 (A)     (B) 
 
Fig. 5.1. Comparison of HTS with FBS.  This shows an example of a large HTS 
compound in (A) and two separate small fragment compounds in (B) binding to the same 
biological target. The HTS hit binds strongly but is inefficient.  The small fragments (1) 
and (2) are very efficient but have weak binding affinities.  The binding is improved 
when the two fragments are merged or linked (shown circled).  (Taken from (Hajduk and 
Greer, 2007). 
 
On average the compounds with a MW ~ 200Da require a half maximal inhibitory 
concentration (IC50), from 100µM to 1mM.  FBS has developed an increased 
quality of lead compounds, with less false positives.  Compared to HTS 
compounds, most FBS compounds are more soluble.  Because of the low 
molecular weight of FBS compounds, they exhibit a lower complexity providing a 
higher probability of matching a protein-binding site.  They contain discrete 
functional groups, e.g. carboxylates and amines, and the atoms in the fragments 
are directly involved in the desired protein binding interaction, creating efficient 
binders.  In reality, fewer compounds are used but have a higher success rate.  
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5.3 Overall rationale of FBS 
The overall rationale of FBS is as follows: 
1. Select the biological target protein 
2. Screen with FBS compounds, using a suitable quick assay e.g. thermal 
shift assay. 
3. Validate the ‘hits’ by NMR, SPR, X-Ray crystallography or mass 
spectrometry. 
4. Optimise the selection of fragments by chemical structure in collaboration 
with combinatorial chemists. 
5. Combinatorial chemistry links or merges the fragments together to 
produce a high binding affinity ‘drug’ compound for in vitro and in vivo 
trials. 
 
5.3.1 Benefits of the thermal shift assay 
In this study, the thermal shift assay was used to screen the compounds. This 
assay is easy to set up in a routine research laboratory and the equipment required 
is comparatively low cost. Equipment required for this assay is a high temperature 
fluorescence microplate reader.  This study used the Stratagene Mx3005P system.  
This system has a rapid temperature ramping and allows very accurate 
temperature control from 25°C up to 95°C, in 0.5°C increments, heating for 60s at 
each increment.  Fluorescence readings are taken at each temperature increment. 
The software available allows the data to be shown in a graphic format, either as 
melting (dissociation) curves or showing the peak dissociation temperatures.  
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The assay can identify ligand binding without prior structural information of the 
protein. Molecules that bind to unfolded proteins which tend to be destabilisers 
can be identified by a reduction in dissociation temperature and can be excluded 
as lead compounds early in the screening, reducing time and cost.  Only small 
volumes (<100µl) of protein and compounds are used in the microplates.  Each 96 
well plate assay is completed within 2 – 21/2 hr, allowing for a screen of a 
fragment library of 1000 compounds in 1-2 days. 
 
5.3.2 Principle of the thermal shift assay 
The thermal shift assay uses the principle that a protein unfolds when heat energy 
is applied to the protein until there is enough energy to exert a conformational 
entropy change (Murphy et al., 1990).  A positive thermal shift is seen when the 
protein is made more energetically stable and unfolds at a higher temperature.  A 
ligand binding to a target protein can alter the protein’s native state, normally 
making it more stable. This can be shown by an increase in the protein’s 
dissociation temperature. The midpoint of the melting curve for the protein will 
increase when a ligand binds more tightly to the native state than in the unfolded 
state. The assay follows the fluorescent signal from the protein dye Sypro Orange 
(Invitrogen), when a temperature gradient is applied to the samples (Figure 5.2). 
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Fig 5.2. Examples of dissociation curves from a 96 well microplate thermal shift assay, 
heating the protein and compounds from 25°C to 90°C.  This shows a native protein (in 
well G10) and thermal shifts (positive ‘hits’) with the same protein binding to eight 
different low molecular weight fragments (in wells A5, A9, B3, B11, B12, C9, F8 and 
F9). The red lines show the centre of the dissociation curve for the native protein, 
showing a dissociation temperature of 46°C.  The other dissociation curves show an 
increase in the dissociation temperatures, between 55°C and 60°C, when the compounds 
bind to the protein. 
 
Figure 5.2 shows the data as a graph comparing temperature vs. fluorescence 
signal. This same data can also be shown as dissociation temperature peaks 
(Figure 5.3). 
 189 
 
Fig. 5.3. Data shown as dissociation temperature peaks of native protein (in well G10), at 
46°C, with a corresponding increase in dissociation temperatures of ligand-protein 
complexes (in wells A5, A9, B3, B11, B12, C9, F8 and F9). Assay as Figure 5.2.   
 
The assay uses the protein-binding fluorescent dye, Sypro Orange. This dye is 
excited by UV light or light filtered with a wavelength peak of 470nm and emits 
at a wavelength of 570nm. The fluorescent signal of Sypro Orange changes as the 
protein undergoes structural change. The fluorescence is measured at discreet time 
points as the temperature of the protein is gradually increased over time, from 
25°C and the protein unfolds. When Sypro Orange is initially added to a folded 
protein in solution, it is exposed to an aqueous environment and the fluorescent 
signal is quenched. As the temperature rises and the protein unfolds, the dye 
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preferentially binds to the protein’s hydrophobic core.  The dye becomes 
unquenched and so there is an increase in the fluorescent signal.  
 
5.4. Determination of the dissociation temperature for ABAD 
The fluorescent signal and dissociation temperature is protein specific. It is 
necessary first to optimise the concentration of protein required to give an optimal 
fluorescent reading on dissociation. Most buffers are suitable for the assay.  
 
5.4.1 Initial optimisation of ABAD concentration with Sypro Orange 
The concentration of ABAD required for the thermal shift assays was optimised 
using one negative control and seven different protein concentrations repeated in 
triplicates.  A sample of 50µM ABAD was prepared with PBS buffer.  This was 
diluted in the wells of a 96 well microplate to give final concentrations between 
1µM and 20µM. Sypro Orange (Invitrogen) is supplied as a 5000X concentrated 
solution in dimethylsulfoxide (DMSO). Aliquots of purified human ABAD 
(hABAD) were mixed in PBS buffer with Sypro Orange at a final concentration 
of 5x, in a total volume of 100µl for each well in a 96 well microplate as shown in 
Table 5.1.    
 
The Sypro Orange was prepared first and diluted 1:1000 with PBS buffer to 5x 
concentration from a stock of 5000x.  This mixture was pipetted into 24 wells in a 
96 well microplate, A1, A2, A3 to H1, H2, H3 as shown in Table 5.2, using 
volumes as shown in Table 5.1. 
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Per well A1-
3 
B1-
3 
C1-
3 
D1-
3 
E1-
3 
F1-
3 
G1-
3 
H1-
3 
Final µM Protein 0 1 2 3 4 5 8 10 
Vol Protein (50µM) 0 2 4 6 8 10 16 20 
buffer/SyproO(5x) mix µl 100  98  96  94  92 90 84 80 
Total Vol µl 100 100 100 100 100 100 100 100 
 
Table 5.1. Experimental setup for optimisation of Sypro Orange concentration.  
 
 
 1 2 3 
A A1 A2 A3 
B B1 B2 B3 
C C1 C2 C3 
D D1 D2 D3 
E E1 E2 E3 
F F1 F2 F3 
G G1 G2 G3 
H H1 H2 H3 
 
Table 5.2. Wells charged with Sypro Orange optimisation as described in the text. 
 
 
The ABAD was next added from a 50µM stock to produce final concentrations of 
1, 2, 3, 4, 5, 8, 10 μM, as shown in Table 5.1. The microplate was sealed with 
optically clear, heatproof tape, placed in the fluorescence microplate reader and 
heated from 25°C to 80°C in 0.5°C increments for 60s at each temperature 
increment.  Readings were taken at each temperature increment.  The dissociation 
peak temperatures are shown in Figure 5.4. 
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Fig. 5.4. The thermal dissociation assay for native ABAD at concentrations between 1–
10µM, heated from 25°C to 70°C, showing the dissociation peak temperatures.  The 
readings for each concentration are averaged from the three sets of readings (eg A = A1-
A3) giving one final trace.  Peaks are seen clearly for concentrations of ABAD above 
3µM (D-H).  
 
From this optimisation, it can be seen that changes in protein concentration can 
alter the dissociation temperature by up to 3°C. Because of the possibility of 
pipetting errors when preparing protein samples at different times, it was therefore 
important to use the same prepared sample of protein for each assay. 
 
A concentration of 5µM ABAD was chosen for the initial screening with the 
chemical fragment compounds.  This concentration used the least volume of stock 
protein and gave stable readings over the temperature range.  
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5.5  FBS of ABAD with Maybridge compounds 1-96  
The chemical fragment compounds are stored long term in deep well (1ml) 
polypropylene 96 well plates, at a concentration of 200mM in 100%DMSO at 
4°C, covered with aluminium sealing strips and further light protected by 
covering the entire plate with aluminium foil. 
 
For the assay, DMSO should be no more than 5% in the final samples. On the day 
of the assay, 96 well, deep microplates (1ml wells) were prepared by further 
dilution of the compounds with PBS, equivalent to 4000x concentration of the 
protein (5µM) as selected from the optimisation assay. The compounds were 
prepared at room temperature, diluting 1:10 with PBS buffer to 20mM in 10% 
DMSO (Table 5.3a). The protein stock was diluted to a 2x concentration of the 
protein, as selected from the optimisation assay.  In the 96 well plate assay, this 
gave a final protein concentration of 5µM and a final compound concentration of 
10mM in 5% DMSO. 
      
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 A11 A12 
B B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 
C C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 
D D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 
E E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 E11 E12 
F F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
G G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 
H H1 H2 H3 H4 H5 H6 H7 H8 H9 H10 H11 H12 
 
Table 5.3a. A 96-well microplate template showing wells containing chemical fragment 
compounds – 1 ml of 20mM chemical fragment compounds in 10% DMSO + PBS buffer. 
The chemical fragment compounds are shown numerically in Table 5.3b. 
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WELL 
NUMBERS 
CHEMICAL FRAGMENT 
COMPOUNDS 
  
A1 – A12 1 - 12 
B1 – B12 13 - 24 
C1 – C12 25 – 36 
D1 – D12 37 – 48 
E1 – E12 49 – 60 
F1 – F12 61 – 72 
G1 – G12 73 - 84 
H1 – H12 85 - 96 
  
 
Table 5.3b. Distribution of fragments among the 96 wells for Plate 1. Some compounds 
were unavailable at the time of this study. Therefore wells A1, B2, B9, B10, D5, E6, E11 
and G5 contained no compounds and were used as controls. 
 
ABAD was mixed at a concentration of 10 µM with Sypro Orange in PBS and 
50µl aliquots were pipetted into a 96 well non-skirted microplate (0.2ml wells), 
suitable for a thermal cycler. 50µl aliquots of the 20mM fragments were then 
added to the plate, in the same 96 well format shown in Fig 5.5. This gave a final 
protein concentration of 5µM and a final compound concentration of 10mM in 
5% DMSO.  The eight blank wells were used as controls, containing 5µM ABAD 
with Sypro Orange and PBS but no compounds.  A thermal shift assay was carried 
out as before with increments of temperature to 75°C.  Some of the dissociation 
curves are shown in Figures 5.5 and 5.6. 
 
From compounds 1-96, in Plate 1, 23 compounds gave a positive thermal shifts     
≥ 3°C, indicating that they could bind to ABAD.  The 23 compounds are shown in 
Table 5.4. 
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Fig. 5.5. Dissociation peak of ABAD.  This shows an averaged trace from the eight 
control samples of ABAD, showing a dissociation temperature of 50°C.  
 
 
Fig. 5.6.  Dissociation curves of ABAD control and four examples of compounds binding 
that indicate a positive thermal shift.  The ABAD control is shown as a single blue trace, 
showing a dissociation temperature of 50°C.  The other four traces show four ligand-
protein complexes in wells C7, C12, E8 and E9, all showing a positive thermal shift >3°C 
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due to increased stability. The largest shift, the ligand-protein complex in well C7, shown 
in orange, was ~54°C (+4°C). 
 
Well 
No. 
Compound 
No. 
Compound name  Formula MW Compound structure 
A4 4 3,5-dimethylisoxazole C5 H7 N O 97.1 
N
O CH3
CH3
 
A5 5 3-furylmethylamine C5 H7 N O 97.1 
O
NH2
 
A6 6 3-methyl-1H-pyrazol-5-
amine 
C4 H7 N3 97.1 
N
N NH2
CH3
 
A7 7 1-methyl-1H-pyrazol-5-
ylamine 
C4 H7 N3 97.1 
N
N NH2
CH3  
A8 8 1-methyl-1H-pyrazol-3-
amine 
C4 H7 N3 97.1 
N
N
NH2
CH3  
A12 12 tetrahydro-4H-pyran-4-
one 
C5 H8 O2 
 
100.1 O
O  
B1 13 1,4-diazepane C5 H12 N2 100.2 N
N  
B3 15 1-methyl-1H-imidazole-5-
carbonitrile 
C5 H5 N3 107.1 
N
N
N
CH3  
B4 16 5-methylpyridin-2-amine C6 H8 N2 
 
108.1 
N NH2
CH3
 
B7 19 6-methylpyridin-2-ol C6 H7 N O 109.1 
N OHCH3  
B8 20 1-(1H-pyrrol-3-yl)ethan-
1-one 
C6 H7 N O 109.1 
N
O
CH3
 
B9 21 pyridine-2,3-diamine C5 H7 N3 109.1 
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B12 24 1,3,5-trimethyl-1H-
pyrazole 
C6 H10 N2 
 
110.2 
N
N
CH3
CH3
CH3
 
C7 31 6-methyl-2,3,4,5-
tetrahydropyridazin-3-one 
C5 H8 N2 O 112.1 
N
N
O
CH3  
C12 36 2,5-dimethylpiperazine C6 H14 N2 
 
114.2 
 
E8 56 N-methyl-N-(4-
pyridinylmethyl)amine 
C7 H10 N2 122.2 
N
N
CH3
 
E9 57 N-methyl-N-(3-
pyridylmethyl)amine 
C7 H10 N2 122.2 
N
N
CH3
 
G4 76 (1,5-dimethyl-1H-pyrazol-
3-yl)methanol 
C6 H10 N2 O 126.2 
N
N
CH3
CH3
OH
 
H3 87 azepan-2-one oxime C6 H12 N2 O 
 
128.2 
N
N
OH
 
H5 89 3,5-difluoroaniline C6 H5 F2 N 
 
129.1 
NH2
F
F  
H6 90 piperidine-4-carboxylic 
acid 
C6 H11 N O2 129.2 
 
H7 91 3-piperidinecarboxylic 
acid 
C6 H11 N O2 129.2  
H12 96 1-eth-1-ynyl-4-
methoxybenzene 
C9 H8 O 
 
132.2 
CH
O
CH3
 
 
Table 5.4. Chemical details of the fragments giving ≥ 3°C thermal shift.  
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5.6 FBS of ABAD with NAD+ cofactor 
As ABAD binds nicotinamide adenine dinucleotide (NAD+ ) during its enzymatic 
activity, a repeat optimisation of concentrations was carried out for ABAD in the 
presence of NAD+.   Six aliquots of purified ABAD from 5 -12 µM were mixed 
with aliquots of NAD+ at concentrations 50 - 200 µM, in a total volume of 100µl 
in an 8 well strip.  A control was included without NAD+. The samples were 
sealed with optically clear and heat-proof tape and heated from 25°C to 80°C, in 
0.5°C steps. The results of the thermal shift are shown in Figure 5.7. 
 
 
Fig. 5.7. Dissociation peak temperatures of ABAD and mixes of ABAD in the presence 
of NAD+.  ABAD without NAD+ (blue trace) shows a dissociation peak temperature ~ 
44-45°C.  The samples with NAD+ began showing dissociation peak temperatures at the 
end of the assay, at ≥80°C.  The peaks at ~80°0C would indicate ABAD is very stable 
 199 
with the addition of the NAD+ cofactor . The optimal mixture, shown by the red trace 
(B7) was 10 µM ABAD with 100 µM NAD+. 
 
5.6.1 FBS of ABAD with NAD+ against compounds 289-300 and 337-348 
Approximately 5% of the chemical fragment compounds are expected to bind to a 
protein in any one assay.  ABAD bound to 23 compounds in Plate 1, equivalent to 
26% of the compounds in that plate.  Plate 1 contained the compounds with the 
lowest molecular weights (MW 94-132Da). Therefore, it was decided to use 
compounds with a higher MW for the thermal shift assay of ABAD in the 
presence of NAD+.  The compounds were taken from Plate 4 (MW 162- 170Da). 
This was chosen to try to limit the positive hits to ~ 5%.   Due to a limited amount 
of the stock of ABAD protein, an initial thermal shift assay was performed with a 
reduced number of compounds.   24 chemical fragment compounds were used for 
this assay (Table 5.5). The dissociation peak temperatures for compounds 337-
348 are shown in Figure 5.8. 
 
 
 
WELL 
NUMBERS 
CHEMICAL FRAGMENT 
COMPOUNDS 
  
A1 – A12 289-300 
E1 – E12 337-348 
 
  Table 5.5. Compounds selected from plate 4. 
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Fig. 5.8. Thermal shift assay from 25°C to 90°C for ABAD with NAD+ cofactor and 
compounds 337 – 348 in wells E1-E12.   Wells E1 and E5 are controls with only ABAD 
showing a peak dissociation temperature of 440C. The compounds in E2, E4, and E9 
show a range of high dissociation temperatures from 80°C - 84°C.  Although a control for 
ABAD with NAD+ was not included in this assay, the optimisation assay had shown a 
peak dissociation temperature of ~80°C.  The compounds in wells E4 and E9 show 
positive thermal shifts of around 3°C. 
 
 
 
From this limited assay compounds 340 and 345 produce positive thermal shifts 
Table 5.6. 
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Well 
No. 
Compound 
No. 
Compound name  Formula MW Compound structure 
 
E4 
 
340 
2-(1H-pyrazol-1-
yl)benzonitrile 
 
C10 H7 N3 
 
169.2 
 
 
E9 
 
345 
2-
hydroxybicyclo[3.2.
1]octane-6-
carboxylic acid 
 
C9 H14 O3 
 
170.2 
 
 
Table 5.6. Chemical details of compounds 340 and 345 
 
 
5.7 Discussion 
The extracellular accumulation of Aβ peptide plaques in the brain has been 
associated with the development of AD (Masters and Beyreuther, 1987).  
However there is now increasing evidence that soluble Aβ within cells and its 
interaction with the mitochondria plays a significant role in the progression of the 
disease (Muirhead et al., 2010).  Therefore modulating mitochondrial interactions 
therapeutically could prevent neuronal cell death in AD.  Aβ binding to 
mitochondrial proteins interferes with the normal function of the proteins, 
resulting in mitochondrial dysfunction, disruption of cell homeostasis and 
ultimately cell death.  Recent electron microscopy of Aβ in mouse neuroblastoma 
cells has shown fragmentation of the mitochondria (Manczak et al., 2010).  
ABAD is an example of a mitochondrial protein that has been shown to bind Aβ 
within the mitochondrial matrix.   This complex has been shown to have a toxic 
response in cells in AD mouse models and human brain post mortem tissue 
(Lustbader et al., 2004).   
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Methods to prevent cell death due to mitochondrial dysfunction are being 
currently investigated, including the development of cell-permeable 
mitochondrial-penetrating peptides (Horton et al., 2008).  These peptides are 
synthesised using repeats of synthetic cyclohexylanine residue attached to a D-
arginine.  These mitochondrial-penetrating peptides are limited by their size and 
hydrophobicity, as only repeats of 3 or 4 (of a synthetic cyclohexylanine residue 
attached to a D-arginine) allow them to accumulate in the mitochondrial matrix 
without interfering with cellular activity.  Larger peptides disrupt the 
mitochondrial function.   However this has been shown to be useful for 
transporting chemotherapy agents for the purpose of disrupting cellular function 
in tumour cells (Horton et al., 2008). 
 
Previous studies that have identified compounds that inhibit ABAD or the 
ABAD/Aβ interaction, and include a compound that Pfizer designated ‘AG18501’  
(1-azepan-1-yl-2-phenyl-2-(4-thioxo-1,4-dihydro-pyrazolo[3,4-d]pyrimidin-5-yl)-
ethanone) that was observed bound in the crystal structure of rat ABAD 
(Kissinger et al., 2004).  Fig 5.11 
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Fig. 5.11. Chemical structure of Pfizer compound AG18501. 
 
AG18501 inhibited ABAD activity with an IC50 = 92nM.  The crystallographic 
studies showed AG18501 bound to the substrate-binding cavity of ABAD 
simultaneously also binding to the cofactor NAD+.  Isothermal titration 
calorimetry (ITC) confirmed the necessity of NAD+ to be present for AG18501 to 
be active (Kissinger et al., 2004).  Further studies with AG18051 showed no 
detectable inhibition of two closely related members of the SDR family, at 
concentrations as high as 100 μM, showing AG18501 to be a novel small 
molecule specific inhibitor for ABAD.  A very recent study has now indicated that 
AG18501 also prevents the ABAD/Aβ interaction (Lim et al., 2011).  As such 
AG18501 shows a neuroprotective effect in vitro, promoting cell survival in part 
by preventing the generation of ROS and stabilizing estradiol levels. This is 
significant as one of ABAD’s functions is to convert estrone to estradiol, and this 
is disrupted in the ABAD/Aβ interaction (Yang et al., 2007). 
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In another study, (Xie et al., 2006) frentizole (1-(6-Methoxybenzothiazol-2-yl)-3-
phenylurea, Figure 5.12) was found to also act as an inhibitor of the Aβ binding to 
ABAD.   
 
Fig. 5.12. Chemical structure of frentizole. 
 
Frentizole is a benzothiazole urea, an analogue of thioflavine T, which was 
initially identified as the inhibitor of the ABAD/Aβ interaction.  Frentizole is a 
Food and Drug Administration (FDA) approved immunosuppressive drug and is a 
non-toxic antiviral agent used clinically in rheumatoid arthritis and systemic lupus 
erythematosus (Xie et al., 2006).  Analogues of frentizole were developed with 
variations at the aromatic rings and their linking group. Two analogues where 
identified as the most potent inhibitors with IC50s of <10uM.  These were low 
molecular weight compounds with logP values of 1.34 and 1.15 show a good 
possibility of crossing the blood brain barrier, and so are being further tested for 
their CNS penetration capability and will be tested on animal models if 
successful. 
 
However, finding suitable therapeutics for AD is complicated by the need to find 
drugs that are suitable for the target patients, i.e. the elderly.  Frentizole has 
already been used clinically as an immunosuppressive drug and as an antiviral in 
the USA, but as with many drugs, it has notable side-effects that would not be 
recommended for treatment of the elderly e.g. hepatic toxicity (Kay et al., 1980).  
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In addition, though Kissinger and Lim have produced specific inhibitor of a 
mitochondrial dysfunction, inhibiting the ABAD/Aβ interaction in vitro, it 
remains whether these compounds will work in vivo. 
 
In the last decade FBS has become the chosen method for initial screening for 
small molecule therapeutic compounds against a biological target of interest 
(Erlanson et al., 2004a).  In this initial study, ABAD was screened with the first 
88 compounds of the Maybridge Ro3 library and 23 of these were shown to bind 
producing a thermal shift ≥3°C.  In addition, limited initial screening of ABAD 
with its cofactor NAD+ also showed another two compounds that bound, 
producing a thermal shift >2°C.   
 
These screens need repeating for verification and expanded to include the whole 
library for a complete analysis of possible combinations of ligand binding with 
ABAD/Aβ complex.  Also further screens should include conditions when the 
ABAD protein is in an ABAD/Aβ complex with the FBS compounds, but also in 
the presence of NAD+ and a substrate such as acetoacyl CoA.   It is important to 
examine ABAD as an active enzyme with its substrates and products, as the 
binding of any of these molecules could affect the binding with the Aβ peptide 
and the FBS compounds.  Screening the Aβ peptide alone will also give useful 
information on ligand binding to the peptide without ABAD. With optimised 
conditions for protein, cofactor, substrate, peptide and compounds, FBS will 
provide information on good ligand binding to ABAD/Aβ complex.  Screening 
using the 1000 Maybridge compounds aims to provide approximately 50 lead 
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compounds (5% of total).  The ligand binding of these compounds could next be 
verified further using the NMR technique of Saturation Transfer Difference (STD) 
(Haselhorst et al., 2009).  This is a robust technique suitable for proteins 
approximately 30kDa or larger, which can detect weak binding ligands with a Kd 
~10mM.  The compounds finally verified by NMR, can then act as chemical 
building blocks for further manipulation and synthesis in collaboration with 
combinatorial chemists. This information will complement other kinetic, SPR, 
NMR (Yan et al., 2007b) and crystallographic information known for ABAD 
(Lustbader et al., 2004; Powell et al., 2000). 
 
In summary the availability of potent, specific inhibitors of ABAD should help 
elucidate the role of this enzyme in AD pathogenesis.  FBS is a very useful 
technique for finding lead compounds for possible drug development by 
identifying small molecule compounds that bind to ABAD and the ABAD/Aβ 
complex. These starting compounds can then be manipulated to synthesise larger 
compounds with a higher binding efficiency.  The study presented here has 
identified 25 lead compounds that bind to ABAD. These are presented for 
consideration as the starting point of future therapeutic strategies that will 
hopefully provide new compounds for the treatment of AD.   
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Chapter 6 
Thesis summary and discussion 
 
Alzheimer’s disease remains a non-discriminating disease, mainly affecting the 
elderly, for which there is no curative treatment or a diagnostic biomarker to 
monitor progression of the disease. It is characterised by accumulation of 
extracellular amyloid plaques and intracellular neurofibrillary tangles in the brain 
(Selkoe and Abraham, 1986).  Treatments at present have not developed from 
using acetyl-cholinesterase inhibitors to alleviate the symptoms, and/or the 
introduction of an NMDA receptor inhibitor that also alleviates symptoms.  None 
of these treatments halt or cure the disease (Herrmann et al., 2011a).  Current 
research into possible treatments concentrates on reducing the expression or 
activity of the toxic Aβ peptide or preventing the production of 
hyperphosphorylated tau.  This includes development of β-secretase inhibitors and 
inhibitors of tau aggregation (Herrmann et al., 2011a). 
 
Mitochondrial dysfunction has been shown to play a major role in 
neurodegenerative diseases including AD (Brown et al., 2001). Therefore, the 
causes and consequences of mitochondrial dysfunction in AD might impact on 
future therapeutic approaches to this disease. Mitochondrial dysfunction in AD 
was first recognized by analysis of two mitochondrial proteins, pyruvate 
dehydrogenase and α ketoglutarate dehydrogenase, the rate-limiting steps of the 
Krebs cycle, that showed defects in energy metabolism (Gibson et al., 1998). 
Neuropsychological deficits similar to those in AD are seen in other situations e.g. 
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hypoglycemia in diabetics, hypoxic hypoxia, urinary tract infections in the elderly 
and vitamin deficiencies (Gibson and Duffy, 1981; Gibson et al., 1981) but these 
are temporary and reversible. In AD, the neuropsychological deficits become 
irreversible.   
 
ABAD is a mitochondrial protein that was first identified by a yeast 2 hybrid 
screen as an intracellular binding partner to the Aβ peptide (Yan et al., 1997a).  
ABAD is an enzyme whose primary function is catalysing the third stage of the β-
oxidation of fatty acids.  
 
This thesis began by establishing a reliable in vitro cytotoxic system.  This system 
used SK-N-SH neuroblastoma cell culture to confirm expression and/or 
translocation of ABAD within the cell. Further toxicity experiments used this cell 
line with the addition of a synthetic Aβ42 peptide.  At first a stably transfected 
SK-N-SH cell line was developed, expressing ABAD fused with EGFP.   
Transient transfections of ABAD-EGFP produced inconsistent ABAD expression, 
often with apparent non-targeted expression of the EGFP tagged protein within 
the cell.  This had been previously reported (He et al., 2001), and so expression 
was improved by two approaches.  First, a stable expressing cell-line was 
produced that indicated that when the ABAD-EGFP fusion protein was expressed 
this resulted in exclusive expression within the mitochondria.  Second, a 
mitochondrial targeting sequence (MTS) was added to the N-terminus of the 
fusion protein, which produced well-targeted expression in mitochondria.  This 
construct enabled the design of further experiments using transient transfection of 
cells.  
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Further studies investigated the toxic effect of the ABAD/Aβ interaction. Using 
the stable cell line, live fluorescent imaging over a 24hr period showed the toxic 
effects of incubating the cells with a synthetic Aβ peptide in real-time.  Cells died 
within 11hr of incubation with the peptide.  To verify this result, the experiments 
were repeated in 96-well tissue culture dishes and analysed for cell viability using 
an MTT assay.  The experiments were also repeated in T75 tissue culture flasks, 
but here the cells were harvested and fractionated to isolate the mitochondria.  
These fractionated samples were analysed by western blot analysis for expression 
of ABAD and cytochrome C, and for evidence of apoptosis by release of the 
proteins from the mitochondria into the cytosol.  Using these three techniques, the 
results were not consistent. Of note was the observation that the seeding density 
was kept consistent but the final area for cell growth in the flasks and dishes 
varied greatly.   The 96-well plate wells have a growth area of  ~0.2 cm2, the 
growth area in the Willco dish for live fluorescent imaging was ~9.5 cm2 and the 
T75 flask is 75cm2.  It is possible that the difference in final cell numbers 
influenced the result in each case.  The fluorescent imaging is the most sensitive 
technique, however the western blot analysis should be sensitive although we 
have found that antibodies vary in their sensitivity and efficiency of detection.  
The MTT assays were performed on the smallest number of cells and growth area.  
It is possible that the results were masked by the dividing cells, as SK-N-SH cells 
are known to clump when over confluent (Biedler et al., 1973). 
 
It was unclear for some time how ABAD and the Aβ peptide interacted within the 
cell.  ABAD is expressed in the mitochondrial matrix.  The Aβ peptide is the 
result of proteolytic cleavage of the APP protein and was originally thought to be 
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cleaved outside the cell, aggregated and formed the recognisable plaques 
identified in AD.  However Aβ exists in several forms ranging from soluble 
monomers, to intermediate soluble oligomers, to insoluble fibrils and has been 
shown to enter the cell and the mitochondria in vitro by two pathways, direct 
import and localised synthesis.  The soluble Aβ has been shown to enter the cell 
and has been identified in the mitochondria with ABAD (Lustbader et al., 2004).  
Translocation of APP and Aβ has been shown to be dependent on the 
mitochondrial translocase, via the mitochondrial receptors TOM20, TOM70 and 
the general mitochondrial import pore of the outer membrane TOM40 and also the 
translocase of the inner membrane TIM23 (Hansson Petersen et al., 2008). The 
translocase system imports Aβ40 directly into the mitochondria of neuroblastoma 
cells, SH-SY5Y.   Both Aβ40 and Aβ42 were imported into isolated rat liver 
mitochondria by the same mechanism. The translocation of Aβ into mitochondria 
is independent of the mitochondrial membrane potential. Aβ40 was clearly 
associated with the mitochondrial inner membrane and not the matrix. Gold 
labelling of Aβ42 showed 75% of the peptide in mitochondrial cristae, 18% in 
matrix and 7% outer membrane (Hansson Petersen et al., 2008).  These results 
provide evidence for the ABAD/Aβ42 interaction in the mitochondria. 
 
Many of the cellular experiments performed in this thesis exhibited problems with 
the synthetic Aβ42 peptide used, which gave inconsistent results.  The synthetic 
peptide was provided in a non-toxic lyophilised form, reconstituted in dH2O to a 
concentration of 5 mg ml-1 and then further dilution with buffer to 1 mg ml-1, then 
aliquoted and frozen at -200C until required.  The manufacturers recommended 
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pre-incubation at 370C for 24–36 hr before use, however trials incubating at 
different concentrations and for different times, indicated that an optimum 
concentration of 20µM incubated for 12hrs produced the most toxic sample.  
Immunostaining cells after incubation with this Aβ peptide, showed that the 
peptide aggregated outside of the cells (Figure 3.23). Other studies at that time 
had identified that it was the soluble monomeric and oligomeric form of Aβ that 
was most toxic (Kayed and Glabe, 2006).  Electron microscopy of the pre-
incubated peptide, showed that the Aβ peptide formed mainly fibrils (Figure 
3.24). This most likely explained the problems of inconsistent toxicity using this 
product.  It was also thought that fibrillar Aβ may be protective by sequestering 
the Aβ into deposits (Tomiyama, 2010).  Two other methods were therefore used 
to introduce Aβ into the cell to investigate the ABAD/Aβ interaction.  First, 
transient transfection with a mutated full-length form of the APP molecule 
(mAPP) into the ABAD-EGFP stably expressing SK-N-SH cells produced an 
excess of the Aβ peptide within the cells and cell death was observed within 
48hrs.  Another method used a carrier peptide (Chariot® Active Motif) to 
permeabolise the cell membrane and carry the Aβ peptide inside the cell and cell 
death was noted within 4hrs. Toxic effects were seen with both these methods by 
fluorescent microscopy, indicating that when Aβ and ABAD are in close 
proximity a strong toxic effect occurs. When soluble oligomeric peptide was 
obtained, a lower concentration of the peptide (nM) showed strong toxic effects, 
compared to the µM concentration with the synthetic peptide. There are now more 
reliable recombinant Aβ peptides, which prove to be more soluble, due to the 
purification techniques used, e.g. expressed as a fusion protein, with ubiquitin, 
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preventing aggregation (Lee et al., 2005). Evidence also suggests they are more 
toxic in vitro and in vivo (Finder et al., 2009).  
 
The results from this thesis indicate that the SK-N-SH cell line may not be the 
best neuronal cell line to investigate Aβ toxicity, as there are studies that indicate 
that the cell line promotes a protective mechanism on the cells particularly when 
seeded at high density (Ba et al., 2003).  Experiments in this thesis could not 
conclusively show that Aβ induced apoptosis in the SK-N-SH cells.   Another 
study also had evidence that Aβ was not able to induce apoptosis in this cell line 
(Ba et al., 2003).  To establish a more reliable system, murine neurospheres were 
cultured and some preliminary fluorescent microscopy experiments showed it to 
be a robust and useful system to use in the future.  
 
The in vitro cytotoxic system used for this thesis was problematic but was able to 
show toxic effects in the cells when ABAD and Aβ interacted. This in vitro 
system could be improved for the future by the use of soluble monomeric Aβ and 
culturing murine neurospheres. 
 
Further information on downstream effects of the ABAD/Aβ complex was 
investigated by proteomic studies using 2D gel electrophoresis and mass 
spectrometry analysis. Methodological limitations in 2D gel electrophoresis 
proteomics have been reviewed previously (Garbis et al., 2005). Proteins at the 
extremes of the pI or MW range are generally not included due to the physical 
limitations of the equipment used.  And although tissue samples are prepared in a 
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denaturing buffer containing 8M urea, some very insoluble proteins will not be 
mobilised, which may include many membrane proteins.  2D gel electrophoresis 
cannot identify all proteins but it does contribute to the wider knowledge of AD 
when used with other cell and animal studies.  The studies for this thesis were 
carried out using samples from two novel transgenic mouse models for AD, 
developed by Prof. Shi Du Yan (Columbia University, NY, USA).  The mouse 
models expressed ABAD (Tg ABAD) or ABAD with mutant APP (2 x Tg 
mAPP/ABAD).  Proteomic analysis of mouse brains by 2D gel electrophoresis 
was carried out using these transgenic mice.  Seven proteins of interest linked 
with AD were identified: ApoE, PrxII, ATP synthase β subunit, creatine kinase β 
subunit, SDH, GPDH and endophilin I.  The first six were involved with 
maintaining energy metabolism in the cell, only endophilin I was involved in 
activating JNK and promoting cell death.  Three of the proteins were 
mitochondrial (ATP synthase, SDH and GPDH), promoting mitochondrial 
function and ATP synthesis.  Five proteins were up regulated (ApoE, PrxII, ATP 
synthase β subunit, creatine kinase β subunit, and endophilin I) and two of the 
mitochondrial proteins were down regulated (SDH and GPDH) in the transgenic 
model compared to the WT.  Further experiments identified that PrxII and 
endophilin I were over expressed in a 4-month, early AD mouse model (Table 
4.3). These results indicate that the ABAD/Aβ complex activates protein 
expression, of which several are involved in mitochondrial function.  The proteins 
expressed as a result of this complex mainly try to promote and sustain cellular 
health with only endophilin I involved in the destruction of the cells. This has 
since been confirmed and several studies on the ABAD/Aβ complex now show it 
to be involved in mitochondrial dysfunction (Ren et al., 2008; Yao et al., 2007). 
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The proteomic studies for this thesis have contributed to the wider knowledge of 
AD. 
 
Because of its involvement with mitochondrial dysfunction in AD, the ABAD/Aβ 
complex could be a useful target for therapy in AD.  However as ABAD is 
essential for fatty acid metabolism it is important not to alter its normal catalytic 
activity.  Conversely the ABAD/Aβ complex requires ABAD catalytic activity to 
mediate the Aβ toxicity.   A compound that could inhibit the complex forming 
without affecting normal ABAD function may add to the therapeutic strategies to 
alleviate AD. 
 
Fragment based screening is a very efficient method for drug discovery (Erlanson 
et al., 2004a).  It provides multiple small lead compounds that are then linked or 
expanded to produce a larger therapeutic end product.  An in-house library of 
1000 compounds has been developed, based on the commercially available 
Maybridge fragment library.  Some initial screens were carried out with ABAD 
and ABAD with NAD+, its cofactor. Several compounds were identified that 
bound to ABAD or ABAD with NAD+ making it more stable. This screen used 
approximately 100 compounds and has led the way for further screening including 
ABAD in the presence of the Aβ peptide. The complete library has now been 
screened (data unpublished). It is important that any hits from the thermal shift 
screening are confirmed by other biophysical methods such as NMR and SPR, as 
these preliminary screening methods can produce false positive hits. Ultimately, 
X-ray crystallography will allow a definitive view of the binding of any of these 
fragments to confirm that they are structurally relevant for chemical elaboration. 
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These future studies will require close collaboration with synthetic chemists to 
develop a novel compound suitable to prevent the toxic effects of the ABAD/Aβ 
complex.  
 
This thesis has studied a novel protein-Aβ complex that has subsequently been 
shown to be involved in mitochondrial dysfunction in AD.  Expansion of the 
techniques and methods used may contribute towards a better understanding of 
the pathogenesis and therapeutic treatment of AD. 
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